fluttershy的个人主页 - 老虎社区

fluttershy

fluttershy

暂无个人介绍

IP属地：未知

5关注

23粉丝

0主题

0勋章

2021-12-29

Like

S&P 500 Ends Lower after Four-Day Rally to Record High

2021-12-28

Like

7 of the Best EV Stocks to Buy Now for 2022 Gains

2021-12-27

Like

Santa Claus Rally watch: What to know this week

2021-12-26

Like

Can This Top Blue Chip Stock Handle Soaring Inflation?

2021-12-25

Like

What are MKM Partners 'Black Swan' Internet predictions for 2022?

2021-12-24

Like

S&P 500 hits record close as Omicron fears ebb

2021-12-21

Like

Microsoft's $16 billion Nuance bid gets EU antitrust approval

2021-12-20

Like

Sea Stock: Down 43% From Its High, is a Buy Now?

2021-12-18

Like

Wall Street ends down after mostly negative week

2021-12-17

Like

3 Cheap Energy Stocks to Buy Right Now

2021-12-16

Like

46 Biggest Movers From Yesterday

2021-12-15

Like

Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation

2021-12-14

Like

Wall Street ends down; investors eye Omicron and Fed meeting

2021-12-13

Like

Rivian,Adobe,FedEx,Lennar,Campbell Soup,and Other Stocks to Watch This Week

2021-12-12

Like

At Its Highest Price in a Decade, Can Bank of America Go Higher in 2022?

2021-12-11

Like

抱歉，原内容已删除

2021-12-10

Like

Wall St closes lower ahead of inflation data, Fed meeting

2021-12-08

Like

SentinelOne stock plunged 11% in premarket trading

2021-12-07

Like

Wall Street regains some ground with help from easing virus fears

2021-12-06

Like

Game Stop, Toll Brothers, Costco, CVS, and Other Stocks to Watch This Week

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3584399073835367","uuid":"3584399073835367","gmtCreate":1621305988100,"gmtModify":1622210993450,"name":"fluttershy","pinyin":"fluttershy","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":23,"headSize":5,"tweetSize":164,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":696546723,"gmtCreate":1640740644669,"gmtModify":1640740644987,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/696546723","repostId":"1186633322","repostType":4,"repost":{"id":"1186633322","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640732718,"share":"https://www.laohu8.com/m/news/1186633322?lang=&edition=full","pubTime":"2021-12-29 07:05","market":"us","language":"en","title":"S&P 500 Ends Lower after Four-Day Rally to Record High","url":"https://stock-news.laohu8.com/highlight/detail?id=1186633322","media":"Reuters","summary":"Dec 28  - The S&P 500closed slightly lower after hitting a record intraday high on Tuesday, as a four-day rally lost steam in thin trading and investors weighed Omicron-driven travel disruptions and store closures.The Centers for Disease Control and Prevention  on Monday shortened the recommended isolation time for Americans with asymptomatic cases of COVID-19 to five days from the previous guidance of 10 days.The update follows approvals for new pills and more vaccines to fight COVID-19. It hel","content":"<p>Dec 28 (Reuters) - The S&amp;P 500(.SPX)closed slightly lower after hitting a record intraday high on Tuesday, as a four-day rally lost steam in thin trading and investors weighed Omicron-driven travel disruptions and store closures.</p>\n<p>The Centers for Disease Control and Prevention (CDC) on Monday shortened the recommended isolation time for Americans with asymptomatic cases of COVID-19 to five days from the previous guidance of 10 days.</p>\n<p>The update follows approvals for new pills and more vaccines to fight COVID-19. It helped investors shrug off concerns over thousands of flight cancellations and <a href=\"https://laohu8.com/S/AAPL\">Apple</a> Inc(AAPL.O)shutting its <a href=\"https://laohu8.com/S/NWY\">New York</a> stores due to surging cases, and put U.S. stocks on pace for monthly gains.</p>\n<p>\"This is a holiday-shortened week. So daily movements will likely be exaggerated because of a low relative volume,\" said Sam Stovall, chief investment strategist at CFRA Research in <a href=\"https://laohu8.com/S/NYRT\">New York</a>.</p>\n<p>Seven&nbsp;of the 11 major S&amp;P 500 sector indexes rose on Tuesday. Technology(.SPLRCT)and <a href=\"https://laohu8.com/S/JCS\">Communications</a> Services(.SPLRCL)led declines.</p>\n<p>The Dow Jones Industrial Average(.DJI)rose 95.83 points, or 0.26%, to 36,398.21; the S&amp;P 500(.SPX)lost 4.84 points, or 0.10%, to 4,786.35 and the <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> Composite(.IXIC)dropped 89.54 points, or 0.56%, to 15,781.72.</p>\n<p>In company news, <a href=\"https://laohu8.com/S/BA\">Boeing</a> Co(BA.N)rose 1.46% as Indonesia lifted a ban on its 737 MAX, three years after the crash of <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the aircraft and loss of all 189 people on board.</p>\n<p>Markets are in the seasonal Santa Claus rally, with CFRA Research data showing the S&amp;P 500 has on average risen 1.3% in the last five trading days of the year, and first two days of the new year since 1969.</p>\n<p>\"<a href=\"https://laohu8.com/S/ISBC\">Investors</a> are digesting the gains from the last three days, ... but there are concerns such as how will the Omicron variant affect the market? Would that end up undoing the Santa Claus rally? What about the Fed raising interest rates, could that cause challenges for the year ahead?\" Stovall said.</p>\n<p>The Federal Reserve signaled earlier this month three quarter-percentage-point interest rate hikes by the end of 2022 as the economy nears full employment and the U.S. central bank copes with an inflation surge. L1N2SZ1G5</p>\n<p>Volume on U.S. exchanges was 7.55 billion shares, compared with the 11.56 billion average for the full session over the last 20 trading days.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.04-to-1 ratio; on Nasdaq, a 1.88-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 81 new 52-week highs and no new lows; the Nasdaq Composite recorded 105 new highs and 264 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 Ends Lower after Four-Day Rally to Record High</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 Ends Lower after Four-Day Rally to Record High\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-29 07:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 28 (Reuters) - The S&amp;P 500(.SPX)closed slightly lower after hitting a record intraday high on Tuesday, as a four-day rally lost steam in thin trading and investors weighed Omicron-driven travel disruptions and store closures.</p>\n<p>The Centers for Disease Control and Prevention (CDC) on Monday shortened the recommended isolation time for Americans with asymptomatic cases of COVID-19 to five days from the previous guidance of 10 days.</p>\n<p>The update follows approvals for new pills and more vaccines to fight COVID-19. It helped investors shrug off concerns over thousands of flight cancellations and <a href=\"https://laohu8.com/S/AAPL\">Apple</a> Inc(AAPL.O)shutting its <a href=\"https://laohu8.com/S/NWY\">New York</a> stores due to surging cases, and put U.S. stocks on pace for monthly gains.</p>\n<p>\"This is a holiday-shortened week. So daily movements will likely be exaggerated because of a low relative volume,\" said Sam Stovall, chief investment strategist at CFRA Research in <a href=\"https://laohu8.com/S/NYRT\">New York</a>.</p>\n<p>Seven&nbsp;of the 11 major S&amp;P 500 sector indexes rose on Tuesday. Technology(.SPLRCT)and <a href=\"https://laohu8.com/S/JCS\">Communications</a> Services(.SPLRCL)led declines.</p>\n<p>The Dow Jones Industrial Average(.DJI)rose 95.83 points, or 0.26%, to 36,398.21; the S&amp;P 500(.SPX)lost 4.84 points, or 0.10%, to 4,786.35 and the <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> Composite(.IXIC)dropped 89.54 points, or 0.56%, to 15,781.72.</p>\n<p>In company news, <a href=\"https://laohu8.com/S/BA\">Boeing</a> Co(BA.N)rose 1.46% as Indonesia lifted a ban on its 737 MAX, three years after the crash of <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the aircraft and loss of all 189 people on board.</p>\n<p>Markets are in the seasonal Santa Claus rally, with CFRA Research data showing the S&amp;P 500 has on average risen 1.3% in the last five trading days of the year, and first two days of the new year since 1969.</p>\n<p>\"<a href=\"https://laohu8.com/S/ISBC\">Investors</a> are digesting the gains from the last three days, ... but there are concerns such as how will the Omicron variant affect the market? Would that end up undoing the Santa Claus rally? What about the Fed raising interest rates, could that cause challenges for the year ahead?\" Stovall said.</p>\n<p>The Federal Reserve signaled earlier this month three quarter-percentage-point interest rate hikes by the end of 2022 as the economy nears full employment and the U.S. central bank copes with an inflation surge. L1N2SZ1G5</p>\n<p>Volume on U.S. exchanges was 7.55 billion shares, compared with the 11.56 billion average for the full session over the last 20 trading days.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.04-to-1 ratio; on Nasdaq, a 1.88-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 81 new 52-week highs and no new lows; the Nasdaq Composite recorded 105 new highs and 264 new lows.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","BK4504":"桥水持仓","SSO":"两倍做多标普500ETF","BK4550":"红杉资本持仓","OEF":"标普100指数ETF-iShares","SH":"标普500反向ETF","BK4559":"巴菲特持仓","SPY":"标普500ETF","BK4534":"瑞士信贷持仓","IVV":"标普500指数ETF","OEX":"标普100",".SPX":"S&P 500 Index","SPXU":"三倍做空标普500ETF","SDS":"两倍做空标普500ETF","UPRO":"三倍做多标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186633322","content_text":"Dec 28 (Reuters) - The S&P 500(.SPX)closed slightly lower after hitting a record intraday high on Tuesday, as a four-day rally lost steam in thin trading and investors weighed Omicron-driven travel disruptions and store closures.\nThe Centers for Disease Control and Prevention (CDC) on Monday shortened the recommended isolation time for Americans with asymptomatic cases of COVID-19 to five days from the previous guidance of 10 days.\nThe update follows approvals for new pills and more vaccines to fight COVID-19. It helped investors shrug off concerns over thousands of flight cancellations and Apple Inc(AAPL.O)shutting its New York stores due to surging cases, and put U.S. stocks on pace for monthly gains.\n\"This is a holiday-shortened week. So daily movements will likely be exaggerated because of a low relative volume,\" said Sam Stovall, chief investment strategist at CFRA Research in New York.\nSeven of the 11 major S&P 500 sector indexes rose on Tuesday. Technology(.SPLRCT)and Communications Services(.SPLRCL)led declines.\nThe Dow Jones Industrial Average(.DJI)rose 95.83 points, or 0.26%, to 36,398.21; the S&P 500(.SPX)lost 4.84 points, or 0.10%, to 4,786.35 and the Nasdaq Composite(.IXIC)dropped 89.54 points, or 0.56%, to 15,781.72.\nIn company news, Boeing Co(BA.N)rose 1.46% as Indonesia lifted a ban on its 737 MAX, three years after the crash of one of the aircraft and loss of all 189 people on board.\nMarkets are in the seasonal Santa Claus rally, with CFRA Research data showing the S&P 500 has on average risen 1.3% in the last five trading days of the year, and first two days of the new year since 1969.\n\"Investors are digesting the gains from the last three days, ... but there are concerns such as how will the Omicron variant affect the market? Would that end up undoing the Santa Claus rally? What about the Fed raising interest rates, could that cause challenges for the year ahead?\" Stovall said.\nThe Federal Reserve signaled earlier this month three quarter-percentage-point interest rate hikes by the end of 2022 as the economy nears full employment and the U.S. central bank copes with an inflation surge. L1N2SZ1G5\nVolume on U.S. exchanges was 7.55 billion shares, compared with the 11.56 billion average for the full session over the last 20 trading days.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.04-to-1 ratio; on Nasdaq, a 1.88-to-1 ratio favored decliners.\nThe S&P 500 posted 81 new 52-week highs and no new lows; the Nasdaq Composite recorded 105 new highs and 264 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":734,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696643069,"gmtCreate":1640691221206,"gmtModify":1640691221510,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696643069","repostId":"1148680933","repostType":4,"repost":{"id":"1148680933","pubTimestamp":1640689821,"share":"https://www.laohu8.com/m/news/1148680933?lang=&edition=full","pubTime":"2021-12-28 19:10","market":"us","language":"en","title":"7 of the Best EV Stocks to Buy Now for 2022 Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1148680933","media":"InvestorPlace","summary":"These seven EV makers have a technological edge likely to provide a boost to market share in the com","content":"<p>These seven EV makers have a technological edge likely to provide a boost to market share in the coming year</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5999b76f711aa5716e8a9111eacfc50e\" tg-width=\"1024\" tg-height=\"768\" width=\"100%\" height=\"auto\"><span>Source: Heliographer / Shutterstock</span></p>\n<p>It’s been a mixed year for electric vehicle (EV) stocks. While&nbsp;<b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>) has delivered a healthy 51.2% return year to date and the&nbsp;<b>KraneShares Electric Vehicles &amp; Future Mobility Index ETF</b>(NYSEARCA:<b><u>KARS</u></b>) is up 23.8%, Chinese EV stocks have under-performed even as vehicle deliveries have proven strong. That’s evident in the near-28% YTD decline in the&nbsp;<b>Global X MSCI China Consumer Disc ETF</b>(NYSEARCA:<b><u>CHIQ</u></b>), which includes the stocks of a number of that country’s EV makers in its&nbsp;77-stock portfolio.</p>\n<p>The year 2021 has also been characterized by emergence of new players in the consumer and commercial EV segment. Overall, the electric vehicle sector is getting competitive. Traditional car-makers entry in the EV space has further intensified competition.</p>\n<p>However, there is ample headroom for value creation from the sector. EV companies with a technological edge — be it batteries-as-a-service or self-driving capabilities — are likely to gain or maintain market share. Further, as companies expand globally, there is a big addressable market.</p>\n<p>It’s also worth noting that various estimates suggest that the industry is poised for&nbsp;healthy growth through 2030.It’s therefore likely that EV stocks will be consistently among the attractive investment themes in the coming decade.</p>\n<p>However, the industry is likely to witness consolidation in the next few years. My focus is on EV companies that are likely to be leaders or acquirers.</p>\n<p>For 2022, let’s talk about seven EV stocks that a poised for a strong rally.</p>\n<ul>\n <li><b>Lucid Motors</b>(NASDAQ:<b><u>LCID</u></b>)</li>\n <li><b>Rivian Automotive</b>(NASDAQ:<b><u>RIVN</u></b>)</li>\n <li><b>Fisker</b>(NYSE:<b><u>FSR</u></b>)</li>\n <li><b>Ford</b>(NYSE:<b><u>F</u></b>)</li>\n <li><b>Li Auto</b>(NASDAQ:<b><u>LI</u></b>)</li>\n <li><b>Nio</b>(NYSE:<b><u>NIO</u></b>)</li>\n <li><b>XPeng</b>(NYSE:<b><u>XPEV</u></b>)</li>\n</ul>\n<p><b>Lucid Motors (LCID)</b></p>\n<p>Among the emerging names,U.S. EV maker Lucid Motors&nbsp;looks attractive for 2022. The company has already commenced delivery of its first model. The initial bookings have been encouraging and Lucid has a backlog of 17,000 vehicles as of November 2021. This would imply a revenue backlog of $1.3 billion.</p>\n<p>LCID stock surged over 100% after consolidation around $20 levels. However, there has been a correction in the recent past and it provides an attractive entry opportunity.</p>\n<p>A key catalyst for 2022 is continued growth in vehicle deliveries as Lucid expands to Canada and EMEA. Additionally, the company is pursuing the second phase of manufacturing expansion, which will boost&nbsp;annual deliveries capacity to 90,000 vehicles.</p>\n<p>Lucid also has plans to enter China in 2023. In the same year, the company will be launching its second model, a SUV. This will help in further accelerating growth.</p>\n<p>LCID stock is among the top EV stocks to consider with the company’s focus on innovation and technology. Lucid Air, as an example, is the longest-range car rated by the EPA, at 520 miles in a single charge. (Speaking of a single charge, be sure to check out Luke Lango’s latest,<i>The EV Charging Revolution Is in Full Swing</i>.)</p>\n<p>Overall, Lucid is positioned to capture market share in a fast-growing EV market. I would not be surprised if LCID stock doubles in the next 12-18 months.</p>\n<p><b>Rivian Automotive (RIVN)</b></p>\n<p>After surging to highs of $180,RIVN stock has cooled-off&nbsp;and currently trades at $96. I believe that current levels are attractive for some exposure.</p>\n<p>The company’s R1S SUV mass delivery will commence in 2022 and there is a healthy pre-order pipeline of 71,000 vehicles. It’s also worth noting that Rivian EDV van has an&nbsp;order backlog of 100,000 vehicles&nbsp;from&nbsp;<b>Amazon</b>(NASDAQ:<b><u>AMZN</u></b>). During the last quarter, Rivian completed the certification process for the sale of electric delivery van.</p>\n<p>In terms of manufacturing capacity, the Normal, Illinois plant has planned annual capacity of 200,000 vehicles. Rivian is also looking at expansion with its Georgia facility likely to have an annual capacity of 400,000 vehicles.</p>\n<p>From a financial perspective, Rivian mopped-up $13.7 billion from the recent initial public offering. The proceeds will support manufacturing capacity expansion in both locations.</p>\n<p>An important point to note is that the company reported negative free cash flow of $1.1 billion for third quarter 2021. This would imply an annualized cash outflow of $4.4 billion. Cash burn is likely to sustain and Rivian will need additional liquidity infusion in 2023 or 2024.</p>\n<p>However, that’s unlikely to be a reason for the stock remaining depressed. Once vehicle deliveries accelerate, RIVN stock is likely to trend higher.</p>\n<p><b>Fisker (FSR)</b></p>\n<p>FSR stock is&nbsp;another interesting name&nbsp;among EV stocks that seems positioned for a big 2022. In the last 12 months, Fisker shares have trended higher by 7%. After an extended period of consolidation, the stock seems positioned for a break-out.</p>\n<p>The company’s first product, Fisker Ocean, is expected to launch in Q4 2022. The vehicle has already received 62,500 indications of interest. With marketing campaign initiated in the U.S. and Europe, Fisker Ocean is likely to have a healthy launch.</p>\n<p>It’s also worth noting that Fisker plans to launch four vehicles through 2025. In this timeframe, Fisker is&nbsp;targeting annual volumes of 200,000 to 250,000 vehicles. With ambitious long-term plans, FSR stock looks attractive.</p>\n<p>Recently, Fisker announced a partnership with&nbsp;<b>Bridgestone</b>&nbsp;to provide&nbsp;total after-sales services&nbsp;for Fisker customers in France and Germany. Collaborations are likely to help in accelerating expansion outside the United States. China is also a target market for Fisker Ocean and Project Pear.</p>\n<p>Currently,FSR stock has short interest&nbsp;of over 20%. I believe that the stock is likely to witness a short-squeeze rally in 2022. Further, swelling of pre-orders is likely to be another catalyst for upside.</p>\n<p><b>Ford (F)</b></p>\n<p>Ford is among the traditional carmakers that’s&nbsp;making big investments&nbsp;in the electric vehicle segment. F stock has surged by over 100% in the last 12 months. Yet, at a forward price-to-earnings-ratio of 10.3, the stock remains attractive.</p>\n<p>Ford CEO Jim Farley recently estimated that the company is likely to&nbsp;increase EV production to 600,000 vehicles by 2023. This will make the company the second-largest U.S. producer of electric vehicles.</p>\n<p>With the Mustang Mach-E, F-150 Lightning and E-Transit electric vehicles in the pipeline, Ford is well positioned to make inroads in the EV segment.</p>\n<p>Ford and South Korea’s&nbsp;<b>SK Innovation</b>&nbsp;plan to invest $11.4 billion&nbsp;in production of a new EV plant and three battery manufacturing facilities. The advanced lithium-ion battery production will commence in 2025.</p>\n<p>A key point to note is that Ford reported&nbsp;adjusted free cash flow of $7.7 billion&nbsp;for Q3 2021. The company has annualized cash flow potential of $30 billion. This provides ample financial flexibility for big investment in the electric vehicle segment.</p>\n<p>Ford also has ambitious plans for several new EV models in China. This will help in accelerating the sales transformation from conventional to EV.</p>\n<p>Overall, F stock looks attractive and is positioned for further rally in 2022 with EV developments being the catalyst. It is the&nbsp;third-largest holding in the KARS&nbsp;exchange-traded fund, mentioned above. It has a 5.31% weighting of the assets in the 71-stock portfolio.</p>\n<p><b>Li Auto (LI)</b></p>\n<p>Chinese EV stocks have under-performed in the last 12 months. I believe that LI stock is attractive at current levels and&nbsp;poised for a rallyrelatively soon.</p>\n<p>For Q3 2021, Li Auto reported vehicle deliveries of 25,116. On a year-on-year basis, deliveries surged by 190%. For the same period, revenue increased by 199.7% to $1.15 billion.</p>\n<p>Besides the headline numbers and the strong growth, there are two important reasons to like Li stock.</p>\n<p>First and foremost, the company’s vehicle deliveries growth has been driven by just one model, Li ONE. With a more diversified portfolio in the next few years, deliveries are likely to remain robust.</p>\n<p>Furthermore, the company&nbsp;reported free cash flow of $180.8 million&nbsp;for Q3 2021. This would imply an annualized FCF of nearly $800 million. Even at an early growth stage, Li Auto has been delivering healthy operating and free cash flow. With robust financial flexibility, the company is positioned to make big investments in innovation and expansion. As of Q3 2021, the company reported cash and equivalents of $7.6 billion.</p>\n<p>Li Auto also made research and development expense of $137.9 million for the most recent quarter. On a y-o-y basis, R&amp;D expense increased by 165.6%. These investments will translate into innovation driven growth.</p>\n<p><b>Nio (NIO)</b></p>\n<p>Nio stock has been on a steady decline. For year-to-date 2021, the stock is lower by 38%. However, I believe that the stock is oversold at current levels. A sharp rally in 2022 seems very likely.</p>\n<p>One reason to be bullish on Nio for 2022 is thelaunch of new models.The electric vehicle maker&nbsp;plans three new models&nbsp;on its Nio Technology Platform 2.0. This is likely to ensure healthy growth in vehicle deliveries over the next 24-months.</p>\n<p>Global expansion is another catalyst for growth. Nio plans to enter&nbsp;Germany, Netherlands, Sweden and Denmark in 2022. The company has already established presence in Norway. Europe is another big market for EV, which is at a tipping point.</p>\n<p>Nio is well positioned for aggressive international expansion from a financial perspective. As of Q3 2021, the company reported cash and equivalents of $7.3 billion. An at-the-market offering in November 2021 helped Nio raise $2.0 billion.</p>\n<p>The company therefore seems fully financed for the next 12-24 months. With growth in vehicle deliveries coupled with vehicle margin expansion, Nio stock is likely to trend higher. NIO stock, at 5.72% of assets, is the largest EV maker holding in the CHIQ exchange-traded fund.</p>\n<p><b>XPeng (XPEV)</b></p>\n<p>Among Chinese EV stocks, XPEV stock has been the best performer in the last 12 months. Returns have been marginally positive during this period. With strong growth in deliveries and new product pipeline,XPeng is likely to break-out&nbsp;to the upside.</p>\n<p>In November 2021, XPeng unveiled a new model that’s&nbsp;targeted toward international markets. The G9 SUV will be launched in China in Q3 2022. This launch will support deliveries growth in 2023. It’s worth noting that G9 will feature&nbsp;<b>Nvidia</b>(NASDAQ:<b><u>NVDA</u></b>) chips, lidar technology and semi-autonomous driving system. The car is likely to be “tech-heavy” and will attract global attention.</p>\n<p>It’s also worth noting that the company launched XPeng P5 smart family sedan in October 2021. This is the third production model for the company. Growth in P5 deliveries will have a positive impact on revenue through 2022.</p>\n<p>XPeng has witnessed a healthy&nbsp;increase in vehicle margin&nbsp;to 13.6% for Q3 2021 as compared to 3.2% for Q3 2020. With sustained growth in deliveries, it’s likely that margin expansion will continue.</p>\n<p>Like other Chinese EV companies, XPeng has also strengthened its balance sheet for aggressive growth. At the end of September 2021, the company reported $7.0 billion in cash and equivalents.</p>\n<p>Overall, XPEV stock is among the best EV stocks to consider for 2022. With product launch, global expansion and margin improvement, there are ample catalysts. It is among the top 10 holdings in both the KARS (2.8%) and the CHIQ (3.08%) exchange-traded funds.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 of the Best EV Stocks to Buy Now for 2022 Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 of the Best EV Stocks to Buy Now for 2022 Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-28 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/7-of-the-best-ev-stocks-fsr-xpev-li-nio-f-lcid-rivn-for-2022-to-buy-now/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These seven EV makers have a technological edge likely to provide a boost to market share in the coming year\nSource: Heliographer / Shutterstock\nIt’s been a mixed year for electric vehicle (EV) stocks...</p>\n\n<a href=\"https://investorplace.com/2021/12/7-of-the-best-ev-stocks-fsr-xpev-li-nio-f-lcid-rivn-for-2022-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc","NIO":"蔚来","FSR":"菲斯克","LI":"理想汽车","XPEV":"小鹏汽车","RIVN":"Rivian Automotive, Inc.","F":"福特汽车"},"source_url":"https://investorplace.com/2021/12/7-of-the-best-ev-stocks-fsr-xpev-li-nio-f-lcid-rivn-for-2022-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148680933","content_text":"These seven EV makers have a technological edge likely to provide a boost to market share in the coming year\nSource: Heliographer / Shutterstock\nIt’s been a mixed year for electric vehicle (EV) stocks. While Tesla(NASDAQ:TSLA) has delivered a healthy 51.2% return year to date and the KraneShares Electric Vehicles & Future Mobility Index ETF(NYSEARCA:KARS) is up 23.8%, Chinese EV stocks have under-performed even as vehicle deliveries have proven strong. That’s evident in the near-28% YTD decline in the Global X MSCI China Consumer Disc ETF(NYSEARCA:CHIQ), which includes the stocks of a number of that country’s EV makers in its 77-stock portfolio.\nThe year 2021 has also been characterized by emergence of new players in the consumer and commercial EV segment. Overall, the electric vehicle sector is getting competitive. Traditional car-makers entry in the EV space has further intensified competition.\nHowever, there is ample headroom for value creation from the sector. EV companies with a technological edge — be it batteries-as-a-service or self-driving capabilities — are likely to gain or maintain market share. Further, as companies expand globally, there is a big addressable market.\nIt’s also worth noting that various estimates suggest that the industry is poised for healthy growth through 2030.It’s therefore likely that EV stocks will be consistently among the attractive investment themes in the coming decade.\nHowever, the industry is likely to witness consolidation in the next few years. My focus is on EV companies that are likely to be leaders or acquirers.\nFor 2022, let’s talk about seven EV stocks that a poised for a strong rally.\n\nLucid Motors(NASDAQ:LCID)\nRivian Automotive(NASDAQ:RIVN)\nFisker(NYSE:FSR)\nFord(NYSE:F)\nLi Auto(NASDAQ:LI)\nNio(NYSE:NIO)\nXPeng(NYSE:XPEV)\n\nLucid Motors (LCID)\nAmong the emerging names,U.S. EV maker Lucid Motors looks attractive for 2022. The company has already commenced delivery of its first model. The initial bookings have been encouraging and Lucid has a backlog of 17,000 vehicles as of November 2021. This would imply a revenue backlog of $1.3 billion.\nLCID stock surged over 100% after consolidation around $20 levels. However, there has been a correction in the recent past and it provides an attractive entry opportunity.\nA key catalyst for 2022 is continued growth in vehicle deliveries as Lucid expands to Canada and EMEA. Additionally, the company is pursuing the second phase of manufacturing expansion, which will boost annual deliveries capacity to 90,000 vehicles.\nLucid also has plans to enter China in 2023. In the same year, the company will be launching its second model, a SUV. This will help in further accelerating growth.\nLCID stock is among the top EV stocks to consider with the company’s focus on innovation and technology. Lucid Air, as an example, is the longest-range car rated by the EPA, at 520 miles in a single charge. (Speaking of a single charge, be sure to check out Luke Lango’s latest,The EV Charging Revolution Is in Full Swing.)\nOverall, Lucid is positioned to capture market share in a fast-growing EV market. I would not be surprised if LCID stock doubles in the next 12-18 months.\nRivian Automotive (RIVN)\nAfter surging to highs of $180,RIVN stock has cooled-off and currently trades at $96. I believe that current levels are attractive for some exposure.\nThe company’s R1S SUV mass delivery will commence in 2022 and there is a healthy pre-order pipeline of 71,000 vehicles. It’s also worth noting that Rivian EDV van has an order backlog of 100,000 vehicles from Amazon(NASDAQ:AMZN). During the last quarter, Rivian completed the certification process for the sale of electric delivery van.\nIn terms of manufacturing capacity, the Normal, Illinois plant has planned annual capacity of 200,000 vehicles. Rivian is also looking at expansion with its Georgia facility likely to have an annual capacity of 400,000 vehicles.\nFrom a financial perspective, Rivian mopped-up $13.7 billion from the recent initial public offering. The proceeds will support manufacturing capacity expansion in both locations.\nAn important point to note is that the company reported negative free cash flow of $1.1 billion for third quarter 2021. This would imply an annualized cash outflow of $4.4 billion. Cash burn is likely to sustain and Rivian will need additional liquidity infusion in 2023 or 2024.\nHowever, that’s unlikely to be a reason for the stock remaining depressed. Once vehicle deliveries accelerate, RIVN stock is likely to trend higher.\nFisker (FSR)\nFSR stock is another interesting name among EV stocks that seems positioned for a big 2022. In the last 12 months, Fisker shares have trended higher by 7%. After an extended period of consolidation, the stock seems positioned for a break-out.\nThe company’s first product, Fisker Ocean, is expected to launch in Q4 2022. The vehicle has already received 62,500 indications of interest. With marketing campaign initiated in the U.S. and Europe, Fisker Ocean is likely to have a healthy launch.\nIt’s also worth noting that Fisker plans to launch four vehicles through 2025. In this timeframe, Fisker is targeting annual volumes of 200,000 to 250,000 vehicles. With ambitious long-term plans, FSR stock looks attractive.\nRecently, Fisker announced a partnership with Bridgestone to provide total after-sales services for Fisker customers in France and Germany. Collaborations are likely to help in accelerating expansion outside the United States. China is also a target market for Fisker Ocean and Project Pear.\nCurrently,FSR stock has short interest of over 20%. I believe that the stock is likely to witness a short-squeeze rally in 2022. Further, swelling of pre-orders is likely to be another catalyst for upside.\nFord (F)\nFord is among the traditional carmakers that’s making big investments in the electric vehicle segment. F stock has surged by over 100% in the last 12 months. Yet, at a forward price-to-earnings-ratio of 10.3, the stock remains attractive.\nFord CEO Jim Farley recently estimated that the company is likely to increase EV production to 600,000 vehicles by 2023. This will make the company the second-largest U.S. producer of electric vehicles.\nWith the Mustang Mach-E, F-150 Lightning and E-Transit electric vehicles in the pipeline, Ford is well positioned to make inroads in the EV segment.\nFord and South Korea’s SK Innovation plan to invest $11.4 billion in production of a new EV plant and three battery manufacturing facilities. The advanced lithium-ion battery production will commence in 2025.\nA key point to note is that Ford reported adjusted free cash flow of $7.7 billion for Q3 2021. The company has annualized cash flow potential of $30 billion. This provides ample financial flexibility for big investment in the electric vehicle segment.\nFord also has ambitious plans for several new EV models in China. This will help in accelerating the sales transformation from conventional to EV.\nOverall, F stock looks attractive and is positioned for further rally in 2022 with EV developments being the catalyst. It is the third-largest holding in the KARS exchange-traded fund, mentioned above. It has a 5.31% weighting of the assets in the 71-stock portfolio.\nLi Auto (LI)\nChinese EV stocks have under-performed in the last 12 months. I believe that LI stock is attractive at current levels and poised for a rallyrelatively soon.\nFor Q3 2021, Li Auto reported vehicle deliveries of 25,116. On a year-on-year basis, deliveries surged by 190%. For the same period, revenue increased by 199.7% to $1.15 billion.\nBesides the headline numbers and the strong growth, there are two important reasons to like Li stock.\nFirst and foremost, the company’s vehicle deliveries growth has been driven by just one model, Li ONE. With a more diversified portfolio in the next few years, deliveries are likely to remain robust.\nFurthermore, the company reported free cash flow of $180.8 million for Q3 2021. This would imply an annualized FCF of nearly $800 million. Even at an early growth stage, Li Auto has been delivering healthy operating and free cash flow. With robust financial flexibility, the company is positioned to make big investments in innovation and expansion. As of Q3 2021, the company reported cash and equivalents of $7.6 billion.\nLi Auto also made research and development expense of $137.9 million for the most recent quarter. On a y-o-y basis, R&D expense increased by 165.6%. These investments will translate into innovation driven growth.\nNio (NIO)\nNio stock has been on a steady decline. For year-to-date 2021, the stock is lower by 38%. However, I believe that the stock is oversold at current levels. A sharp rally in 2022 seems very likely.\nOne reason to be bullish on Nio for 2022 is thelaunch of new models.The electric vehicle maker plans three new models on its Nio Technology Platform 2.0. This is likely to ensure healthy growth in vehicle deliveries over the next 24-months.\nGlobal expansion is another catalyst for growth. Nio plans to enter Germany, Netherlands, Sweden and Denmark in 2022. The company has already established presence in Norway. Europe is another big market for EV, which is at a tipping point.\nNio is well positioned for aggressive international expansion from a financial perspective. As of Q3 2021, the company reported cash and equivalents of $7.3 billion. An at-the-market offering in November 2021 helped Nio raise $2.0 billion.\nThe company therefore seems fully financed for the next 12-24 months. With growth in vehicle deliveries coupled with vehicle margin expansion, Nio stock is likely to trend higher. NIO stock, at 5.72% of assets, is the largest EV maker holding in the CHIQ exchange-traded fund.\nXPeng (XPEV)\nAmong Chinese EV stocks, XPEV stock has been the best performer in the last 12 months. Returns have been marginally positive during this period. With strong growth in deliveries and new product pipeline,XPeng is likely to break-out to the upside.\nIn November 2021, XPeng unveiled a new model that’s targeted toward international markets. The G9 SUV will be launched in China in Q3 2022. This launch will support deliveries growth in 2023. It’s worth noting that G9 will feature Nvidia(NASDAQ:NVDA) chips, lidar technology and semi-autonomous driving system. The car is likely to be “tech-heavy” and will attract global attention.\nIt’s also worth noting that the company launched XPeng P5 smart family sedan in October 2021. This is the third production model for the company. Growth in P5 deliveries will have a positive impact on revenue through 2022.\nXPeng has witnessed a healthy increase in vehicle margin to 13.6% for Q3 2021 as compared to 3.2% for Q3 2020. With sustained growth in deliveries, it’s likely that margin expansion will continue.\nLike other Chinese EV companies, XPeng has also strengthened its balance sheet for aggressive growth. At the end of September 2021, the company reported $7.0 billion in cash and equivalents.\nOverall, XPEV stock is among the best EV stocks to consider for 2022. With product launch, global expansion and margin improvement, there are ample catalysts. It is among the top 10 holdings in both the KARS (2.8%) and the CHIQ (3.08%) exchange-traded funds.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1026,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696918191,"gmtCreate":1640596660413,"gmtModify":1640596660744,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/696918191","repostId":"2194177239","repostType":4,"repost":{"id":"2194177239","pubTimestamp":1640559609,"share":"https://www.laohu8.com/m/news/2194177239?lang=&edition=full","pubTime":"2021-12-27 07:00","market":"us","language":"en","title":"Santa Claus Rally watch: What to know this week","url":"https://stock-news.laohu8.com/highlight/detail?id=2194177239","media":"Yahoo Finance","summary":"As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for the coming days.The S&P 500  is entering the period known for ushering in the so-called Santa Claus Rally, or seasonally strong timeframe for stocks at the end of each year.According to data from LPL Financial, the Santa Claus Rally period encapsulates the seven days most likely to be higher in any ","content":"<p>As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for the coming days.</p>\n<p>The S&amp;P 500 (^GSPC) is entering the period known for ushering in the so-called Santa Claus Rally, or seasonally strong timeframe for stocks at the end of each year.</p>\n<p>The term, coined by Stock Trader's Almanac in the 1970s, encompasses the final five trading days of the year and first two sessions of the new year. This year, that Santa Claus Rally window is set to start on Monday, Dec. 27 — or the latest a Santa Claus rally has started in 11 years, due to the timing of the holidays this year.</p>\n<p>According to data from LPL Financial, the Santa Claus Rally period encapsulates the seven days most likely to be higher in any given year. Since 1950, the Santa Claus Rally period has produced a positive return for the S&amp;P 500 78.9% of the time, with an average return of 1.33%.</p>\n<p>“Why are these seven days so strong?” wrote Ryan Detrick, LPL Financial chief market strategist, in a note. “Whether optimism over a coming new year, holiday spending, traders on vacation, institutions squaring up their books — or the holiday spirit — the bottom line is that bulls tend to believe in Santa.”</p>\n<p>And if history is any indication, the absence of a Santa Claus Rally has also typically served as a harbinger of lower near-term returns.</p>\n<p>\"Going back to the mid-1990s, there have been only six times Santa failed to show in December. January was lower five of those six times, and the full year had a solid gain only once (in 2016, but a mini-bear market early in the year),\" Detrick added.</p>\n<p>“Considering the bear markets of 2000 and 2008 both took place after <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the rare instances that Santa failed to show makes believers out of us,\" he said. A bear market typically refers to when stocks drop at least 20% from recent record highs. \"Should this seasonally strong period miss the mark, it could be a warning sign.\"</p>\n<p>And this year, investors do have considerable additional concerns to mull heading into the new year. Though stocks closed out Thursday's session at fresh record highs before the long holiday weekend, December still marked a volatile month to start, with renewed concerns over the Omicron variant and the potential for tighter monetary policy from the Federal Reserve weighing on risk assets. Plus, prospects for more near-term fiscal support via the Biden administration's Build Back Better bill have dwindled, and inflation concerns spiked further. Last week, the Bureau of Economic Analysis reported core personal consumption expenditures (PCE) — the Fed's preferred inflation gauge — rose at a 4.7% year-over-year clip, or the fastest since 1983.</p>\n<p>\"If the U.S. was not battling the Omicron variant, U.S. stocks would be dancing higher as the Santa Claus Rally would have kept the climb going into uncharted territory,\" Edward Moya, chief market strategist at OANDA, wrote in a note last week. \"It is too early to say for sure if we will get a Santa Claus Rally, but given all the short-term risks of Fed tightening, Chinese weakness, fiscal support uncertainty and COVID, Wall Street is not complaining.\"</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1279eeacff5d764e6ff5b3e8f7a24f49\" tg-width=\"4000\" tg-height=\"2667\" referrerpolicy=\"no-referrer\"><span>A man in a Santa Claus costume gestures on the floor at the closing bell of the Dow Industrial Average at the New York Stock Exchange on December 5, 2019 in New York. (Photo by Bryan R. Smith / AFP) (Photo by BRYAN R. SMITH/AFP via Getty Images)BRYAN R. SMITH via Getty Images</span></p>\n<h2>Economic calendar</h2>\n<ul>\n <li><p><b>Monday: </b>Dallas Federal Reserve Manufacturing Activity Index, Dec. (13.0 expected, 11.8 in November)</p></li>\n <li><p><b>Tuesday: </b>FHFA House Price Index, month-over-month, October (0.9% in September); S&amp;P <a href=\"https://laohu8.com/S/CLGX\">CoreLogic</a> Case-Shiller 20 City Composite Index, month-over-month, October (0.9% expected, 0.96% in September); S&amp;P CoreLogic Case-Shiller 20 City Composite Index, year-over-year, October (18.6%. expected, 19.05% in September); S&amp;P CoreLogic Case-Shiller Home Price Index, year-over-year, November (19.51% in October); Richmond Fed Manufacturing Index, December (11 expected,11 in November)</p></li>\n <li><p><b>Wednesday: </b>Wholesale Inventories, month-over-month, November preliminary (1.7% expected, 2.3% in October); Advance Goods Trade Balance, November (-$89.0 billion expected, -$82.9 billion in October); Retail Inventories, month-over-month, November (0.5% expected, 0.1% in October); Pending Home Sales, month-over-month, November (0.5% expected, 7.5% in October)</p></li>\n <li><p><b>Thursday: </b>Initial jobless claims, week ended Dec. 25. (205,000 during prior week); Continuing claims, week ended Dec. 18 (1.859 million during prior week); MNI Chicago PMI, December (62.2 expected, 61.8 in November)</p></li>\n <li><p><b>Friday: </b><i>No notable reports scheduled for release</i></p></li>\n</ul>\n<h2>Earnings calendar</h2>\n<ul>\n <li><p><b>Monday: </b><i>No notable reports scheduled for release</i></p></li>\n <li><p><b>Tuesday: </b><i>No notable reports scheduled for release</i></p></li>\n <li><p><b>Wednesday: </b>FuelCell Energy Inc. (FCEL) before market open</p></li>\n <li><p><b>Thursday: </b><i>No notable reports scheduled for release</i></p></li>\n <li><p><b>Friday: </b><i>No notable reports scheduled for release</i></p></li>\n</ul>","source":"yahoofinance_au","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Santa Claus Rally watch: What to know this week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanta Claus Rally watch: What to know this week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 07:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/santa-claus-rally-watch-what-to-know-this-week-142909627.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for ...</p>\n\n<a href=\"https://finance.yahoo.com/news/santa-claus-rally-watch-what-to-know-this-week-142909627.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FCEL":"燃料电池能源","BK4541":"氢能源","BK4096":"电气部件与设备","SPY.AU":"SPDR® S&P 500® ETF Trust"},"source_url":"https://finance.yahoo.com/news/santa-claus-rally-watch-what-to-know-this-week-142909627.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2194177239","content_text":"As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for the coming days.\nThe S&P 500 (^GSPC) is entering the period known for ushering in the so-called Santa Claus Rally, or seasonally strong timeframe for stocks at the end of each year.\nThe term, coined by Stock Trader's Almanac in the 1970s, encompasses the final five trading days of the year and first two sessions of the new year. This year, that Santa Claus Rally window is set to start on Monday, Dec. 27 — or the latest a Santa Claus rally has started in 11 years, due to the timing of the holidays this year.\nAccording to data from LPL Financial, the Santa Claus Rally period encapsulates the seven days most likely to be higher in any given year. Since 1950, the Santa Claus Rally period has produced a positive return for the S&P 500 78.9% of the time, with an average return of 1.33%.\n“Why are these seven days so strong?” wrote Ryan Detrick, LPL Financial chief market strategist, in a note. “Whether optimism over a coming new year, holiday spending, traders on vacation, institutions squaring up their books — or the holiday spirit — the bottom line is that bulls tend to believe in Santa.”\nAnd if history is any indication, the absence of a Santa Claus Rally has also typically served as a harbinger of lower near-term returns.\n\"Going back to the mid-1990s, there have been only six times Santa failed to show in December. January was lower five of those six times, and the full year had a solid gain only once (in 2016, but a mini-bear market early in the year),\" Detrick added.\n“Considering the bear markets of 2000 and 2008 both took place after one of the rare instances that Santa failed to show makes believers out of us,\" he said. A bear market typically refers to when stocks drop at least 20% from recent record highs. \"Should this seasonally strong period miss the mark, it could be a warning sign.\"\nAnd this year, investors do have considerable additional concerns to mull heading into the new year. Though stocks closed out Thursday's session at fresh record highs before the long holiday weekend, December still marked a volatile month to start, with renewed concerns over the Omicron variant and the potential for tighter monetary policy from the Federal Reserve weighing on risk assets. Plus, prospects for more near-term fiscal support via the Biden administration's Build Back Better bill have dwindled, and inflation concerns spiked further. Last week, the Bureau of Economic Analysis reported core personal consumption expenditures (PCE) — the Fed's preferred inflation gauge — rose at a 4.7% year-over-year clip, or the fastest since 1983.\n\"If the U.S. was not battling the Omicron variant, U.S. stocks would be dancing higher as the Santa Claus Rally would have kept the climb going into uncharted territory,\" Edward Moya, chief market strategist at OANDA, wrote in a note last week. \"It is too early to say for sure if we will get a Santa Claus Rally, but given all the short-term risks of Fed tightening, Chinese weakness, fiscal support uncertainty and COVID, Wall Street is not complaining.\"\nA man in a Santa Claus costume gestures on the floor at the closing bell of the Dow Industrial Average at the New York Stock Exchange on December 5, 2019 in New York. (Photo by Bryan R. Smith / AFP) (Photo by BRYAN R. SMITH/AFP via Getty Images)BRYAN R. SMITH via Getty Images\nEconomic calendar\n\nMonday: Dallas Federal Reserve Manufacturing Activity Index, Dec. (13.0 expected, 11.8 in November)\nTuesday: FHFA House Price Index, month-over-month, October (0.9% in September); S&P CoreLogic Case-Shiller 20 City Composite Index, month-over-month, October (0.9% expected, 0.96% in September); S&P CoreLogic Case-Shiller 20 City Composite Index, year-over-year, October (18.6%. expected, 19.05% in September); S&P CoreLogic Case-Shiller Home Price Index, year-over-year, November (19.51% in October); Richmond Fed Manufacturing Index, December (11 expected,11 in November)\nWednesday: Wholesale Inventories, month-over-month, November preliminary (1.7% expected, 2.3% in October); Advance Goods Trade Balance, November (-$89.0 billion expected, -$82.9 billion in October); Retail Inventories, month-over-month, November (0.5% expected, 0.1% in October); Pending Home Sales, month-over-month, November (0.5% expected, 7.5% in October)\nThursday: Initial jobless claims, week ended Dec. 25. (205,000 during prior week); Continuing claims, week ended Dec. 18 (1.859 million during prior week); MNI Chicago PMI, December (62.2 expected, 61.8 in November)\nFriday: No notable reports scheduled for release\n\nEarnings calendar\n\nMonday: No notable reports scheduled for release\nTuesday: No notable reports scheduled for release\nWednesday: FuelCell Energy Inc. (FCEL) before market open\nThursday: No notable reports scheduled for release\nFriday: No notable reports scheduled for release","news_type":1},"isVote":1,"tweetType":1,"viewCount":1256,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698548525,"gmtCreate":1640479849002,"gmtModify":1640479849281,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698548525","repostId":"2193317305","repostType":4,"repost":{"id":"2193317305","pubTimestamp":1640399660,"share":"https://www.laohu8.com/m/news/2193317305?lang=&edition=full","pubTime":"2021-12-25 10:34","market":"us","language":"en","title":"Can This Top Blue Chip Stock Handle Soaring Inflation?","url":"https://stock-news.laohu8.com/highlight/detail?id=2193317305","media":"Motley Fool","summary":"We are in strange times right now, so how companies navigate the current environment is vital to their success.","content":"<p>In the month of November, the Consumer Price Index, a widely used measure of inflation, jumped 6.8% from a year ago. Sparked by supply-chain disruptions and labor shortages across the economy, it was the highest increase in almost 40 years.&nbsp;</p>\n<p>For a company like&nbsp;<b>Home Depot</b>&nbsp;(NYSE:HD) that has done extremely well during the pandemic, the threat of rising costs is a real challenge heading into the new year, having possibly negative implications ahead of what is traditionally a busy spring and summer for the&nbsp;business.&nbsp;</p>\n<p>Continue reading to find out how this&nbsp;blue chip stock&nbsp;is dealing with the current situation.&nbsp;</p>\n<h2>Lumber prices are going back up&nbsp;</h2>\n<p>A major commodity that has a meaningful&nbsp;impact&nbsp;on Home Depot's&nbsp;business&nbsp;is lumber. From April 2020 to May 2021,&nbsp;lumber prices skyrocketed&nbsp;to nearly $1,700 per thousand board feet, an all-time record. Prices came down over the following few months, but they shot up again from mid-November to mid-December, settling at just over $1,000 per thousand board feet today. This is still extremely high from a historical perspective.&nbsp;</p>\n<p>\"Lumber is a driver of projects throughout the business, and that certainly carries on,\" Chief Executive Officer Craig Menear highlighted on the company's third-quarter earnings call. During Home Depot's fiscal second quarter that ended Aug. 1 (when lumber prices were sky-high), the company posted record quarterly sales of $41.1 billion. The gross margin of 33.2%, while down slightly from previous quarters, was still very healthy and in line with past results.&nbsp;</p>\n<p>This is a positive indicator of Home Depot's ability to handle the unpredictable price swings with a core commodity like lumber. As prices soared, unit sales fell. Even so, the business reported a historic quarter. Now, as lumber prices rise, especially ahead of the busy home-building and remodeling season in the spring and summer, don't be surprised if lumber unit sales start to drop again.&nbsp;</p>\n<p>Nonetheless, other product categories like outdoor garden, appliances, and kitchen and bath should be strong. And thanks to a robust housing market, characterized by low interest rates, consumers are increasingly looking to undertake renovation projects to boost the value of their existing homes. This underlying trend supports demand for the products and services Home Depot offers.&nbsp;</p>\n<p>\"We have effectively managed inflationary environments in the past, and we feel good about our ability to continue managing through the current environment,\" said President and Chief Operating Officer Ted Decker on the latest conference call with Wall Street analysts.</p>\n<h2>Home Depot's success is&nbsp;undeniable&nbsp;</h2>\n<p>One of Home Depot's overarching objectives is to be the low-cost provider in the home improvement industry. This means that the business wants to lag competitors when raising prices and lead when reducing prices. Obviously, this negatively impacts profitability in the near term as the company is hesitant to pass higher costs on to consumers.&nbsp;</p>\n<p>But if we look at Home Depot's historical performance, we see that this is definitely the right strategy to take. Over the past several years, while revenue has grown in the mid-single digits on a yearly basis, net income has soared as a result of expanding margins. In fiscal 2015, profit totaled $7 billion. Over the trailing-12-month period, it was almost $16 billion.&nbsp;</p>\n<p>And the business is popular among contractors and other professionals, who account for roughly 45% of sales. Instead of immediately passing on higher input costs, which could alienate these high-value customers and push them to competitors, Home Depot understands that building long-term relationships with them is crucial to the success of the company. Sacrificing margin in unusual times like today to keep customers loyal is the right move.&nbsp;</p>\n<p>The current economic environment is full of uncertainties with issues like the omicron coronavirus variant and tightening monetary policy receiving the bulk of investors' attention. When it comes to inflation in particular, I have no reason to believe that Home Depot won't be able to step up to whatever challenges 2022 brings. &nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can This Top Blue Chip Stock Handle Soaring Inflation?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan This Top Blue Chip Stock Handle Soaring Inflation?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-25 10:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/can-top-blue-chip-stock-handle-soaring-inflation/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the month of November, the Consumer Price Index, a widely used measure of inflation, jumped 6.8% from a year ago. Sparked by supply-chain disruptions and labor shortages across the economy, it was ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/can-top-blue-chip-stock-handle-soaring-inflation/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4504":"桥水持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","HD":"家得宝","BK4566":"资本集团","BK4083":"家庭装潢零售"},"source_url":"https://www.fool.com/investing/2021/12/24/can-top-blue-chip-stock-handle-soaring-inflation/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193317305","content_text":"In the month of November, the Consumer Price Index, a widely used measure of inflation, jumped 6.8% from a year ago. Sparked by supply-chain disruptions and labor shortages across the economy, it was the highest increase in almost 40 years. \nFor a company like Home Depot (NYSE:HD) that has done extremely well during the pandemic, the threat of rising costs is a real challenge heading into the new year, having possibly negative implications ahead of what is traditionally a busy spring and summer for the business. \nContinue reading to find out how this blue chip stock is dealing with the current situation. \nLumber prices are going back up \nA major commodity that has a meaningful impact on Home Depot's business is lumber. From April 2020 to May 2021, lumber prices skyrocketed to nearly $1,700 per thousand board feet, an all-time record. Prices came down over the following few months, but they shot up again from mid-November to mid-December, settling at just over $1,000 per thousand board feet today. This is still extremely high from a historical perspective. \n\"Lumber is a driver of projects throughout the business, and that certainly carries on,\" Chief Executive Officer Craig Menear highlighted on the company's third-quarter earnings call. During Home Depot's fiscal second quarter that ended Aug. 1 (when lumber prices were sky-high), the company posted record quarterly sales of $41.1 billion. The gross margin of 33.2%, while down slightly from previous quarters, was still very healthy and in line with past results. \nThis is a positive indicator of Home Depot's ability to handle the unpredictable price swings with a core commodity like lumber. As prices soared, unit sales fell. Even so, the business reported a historic quarter. Now, as lumber prices rise, especially ahead of the busy home-building and remodeling season in the spring and summer, don't be surprised if lumber unit sales start to drop again. \nNonetheless, other product categories like outdoor garden, appliances, and kitchen and bath should be strong. And thanks to a robust housing market, characterized by low interest rates, consumers are increasingly looking to undertake renovation projects to boost the value of their existing homes. This underlying trend supports demand for the products and services Home Depot offers. \n\"We have effectively managed inflationary environments in the past, and we feel good about our ability to continue managing through the current environment,\" said President and Chief Operating Officer Ted Decker on the latest conference call with Wall Street analysts.\nHome Depot's success is undeniable \nOne of Home Depot's overarching objectives is to be the low-cost provider in the home improvement industry. This means that the business wants to lag competitors when raising prices and lead when reducing prices. Obviously, this negatively impacts profitability in the near term as the company is hesitant to pass higher costs on to consumers. \nBut if we look at Home Depot's historical performance, we see that this is definitely the right strategy to take. Over the past several years, while revenue has grown in the mid-single digits on a yearly basis, net income has soared as a result of expanding margins. In fiscal 2015, profit totaled $7 billion. Over the trailing-12-month period, it was almost $16 billion. \nAnd the business is popular among contractors and other professionals, who account for roughly 45% of sales. Instead of immediately passing on higher input costs, which could alienate these high-value customers and push them to competitors, Home Depot understands that building long-term relationships with them is crucial to the success of the company. Sacrificing margin in unusual times like today to keep customers loyal is the right move. \nThe current economic environment is full of uncertainties with issues like the omicron coronavirus variant and tightening monetary policy receiving the bulk of investors' attention. When it comes to inflation in particular, I have no reason to believe that Home Depot won't be able to step up to whatever challenges 2022 brings.","news_type":1},"isVote":1,"tweetType":1,"viewCount":773,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698597423,"gmtCreate":1640439763197,"gmtModify":1640439763466,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698597423","repostId":"1156159690","repostType":4,"repost":{"id":"1156159690","pubTimestamp":1640335867,"share":"https://www.laohu8.com/m/news/1156159690?lang=&edition=full","pubTime":"2021-12-24 16:51","market":"us","language":"en","title":"What are MKM Partners 'Black Swan' Internet predictions for 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=1156159690","media":"seekingalpha","summary":"As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.So, it should come as no surprise that, like many analysts, MKM Partners managing director Rohit Kulkarni came out with a list of 10 things that could shape the Internet industry next year. However, instead of diving into matters such as revenue growth rates and price-to-earnings ratios, Kulkarni released a slate of \"Bla","content":"<p>As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.</p>\n<p>So, it should come as no surprise that, like many analysts, MKM Partners managing director Rohit Kulkarni came out with a list of 10 things that could shape the Internet industry next year. However, instead of diving into matters such as revenue growth rates and price-to-earnings ratios, Kulkarni released a slate of \"Black Swan\"--or, High-Impact-Low-Probability [HILP]--predictions for 2022. Kulkarni said these ideas \"have a very low likelihood of occurrence, but we wouldn't assign a zero probability\" chance of then happening.</p>\n<p>The \"HILP\" predictions Kulkarni has for 2022 include \"consumers [will] return to brick and mortar stores and millennials and Gen Z start watching TV.\" Kulkarni said this could result from Covid-19 vaccinations reaching mass-population levels and reaching an end to the pandemic.</p>\n<p>Kulkarni said Facebook's(NASDAQ:FB)<a href=\"https://laohu8.com/S/CASH\">Meta</a> could launch its own cryptocurrency that could start displacing several traditional fiat currencies, and that mega cap tech companies will manage to not pay any fines to U.S. or European regulators regarding legal cases currently in the works.</p>\n<p>\"We have stopped counting the number of lawsuits facing Big Tech,\" Kulkarni said. \"However, there is fairly limited consensus in the ideas or bills presented to date, and Congress has been focused on the pandemic and infrastructure bill for 2021.</p>\n<ul>\n <li>Kulkarni's other Black Swan predictions are:</li>\n <li>SPAC IPOs will outperform traditional IPOs and direct stock listings.</li>\n <li><a href=\"https://laohu8.com/S/UBER\">Uber</a>(NYSE:UBER)launches its own robotaxi service in several U.S. cities.</li>\n <li><a href=\"https://laohu8.com/S/TWTR\">Twitter</a>(NYSE:TWTR)and Pinterest(NYSE:PINS)are acquired and are no longer independent public companies.</li>\n <li>DoorDash(NYSE:DASH)acquires Instacart for between $40B-50B and spurs a new round of grocery delivery wars.</li>\n <li><a href=\"https://laohu8.com/S/AAPL\">Apple</a>(NASDAQ:AAPL)reaches $10B in annual revenue run rate from advertising due to changes in its iOS ad policies.</li>\n <li>Google's(NASDAQ:GOOG)YouTube get in position to go public.</li>\n <li>Snap(NYSE:SNAP)and TikTok (BDNCE) look to capitalize on their younger audiences by acquiring movie or gaming studios so they can boost their original video content offerings.</li>\n <li>As a \"bonus\" prediction, Kulkarni forecasts that as the pandemic ends, more people will go back to working out at gyms and neighborhood parks, and this will result in difficulty in forecasting sales for the likes of Peloton(NASDAQ:PTON). The home-exercise technology company also had its sails trimmed on Thursday when analysts at Citi cut their price target on Peloton's (PTON) stock to $38 a share on expectations of higher expenses and&nbsp;falling demand for Peloton (PTON) products next year.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What are MKM Partners 'Black Swan' Internet predictions for 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat are MKM Partners 'Black Swan' Internet predictions for 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 16:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3783065-mkm-black-swan-look-at-internet-stocks><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.\nSo, it should come as...</p>\n\n<a href=\"https://seekingalpha.com/news/3783065-mkm-black-swan-look-at-internet-stocks\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","PTON":"Peloton Interactive, Inc.","PINS":"Pinterest, Inc.","TWTR":"Twitter","GOOG":"谷歌","SNAP":"Snap Inc","DASH":"DoorDash, Inc."},"source_url":"https://seekingalpha.com/news/3783065-mkm-black-swan-look-at-internet-stocks","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1156159690","content_text":"As the year comes to a close, Wall Street analysts are practically falling over themselves with almost daily serious predictions aboutwhat to expect from the tech sector in 2022.\nSo, it should come as no surprise that, like many analysts, MKM Partners managing director Rohit Kulkarni came out with a list of 10 things that could shape the Internet industry next year. However, instead of diving into matters such as revenue growth rates and price-to-earnings ratios, Kulkarni released a slate of \"Black Swan\"--or, High-Impact-Low-Probability [HILP]--predictions for 2022. Kulkarni said these ideas \"have a very low likelihood of occurrence, but we wouldn't assign a zero probability\" chance of then happening.\nThe \"HILP\" predictions Kulkarni has for 2022 include \"consumers [will] return to brick and mortar stores and millennials and Gen Z start watching TV.\" Kulkarni said this could result from Covid-19 vaccinations reaching mass-population levels and reaching an end to the pandemic.\nKulkarni said Facebook's(NASDAQ:FB)Meta could launch its own cryptocurrency that could start displacing several traditional fiat currencies, and that mega cap tech companies will manage to not pay any fines to U.S. or European regulators regarding legal cases currently in the works.\n\"We have stopped counting the number of lawsuits facing Big Tech,\" Kulkarni said. \"However, there is fairly limited consensus in the ideas or bills presented to date, and Congress has been focused on the pandemic and infrastructure bill for 2021.\n\nKulkarni's other Black Swan predictions are:\nSPAC IPOs will outperform traditional IPOs and direct stock listings.\nUber(NYSE:UBER)launches its own robotaxi service in several U.S. cities.\nTwitter(NYSE:TWTR)and Pinterest(NYSE:PINS)are acquired and are no longer independent public companies.\nDoorDash(NYSE:DASH)acquires Instacart for between $40B-50B and spurs a new round of grocery delivery wars.\nApple(NASDAQ:AAPL)reaches $10B in annual revenue run rate from advertising due to changes in its iOS ad policies.\nGoogle's(NASDAQ:GOOG)YouTube get in position to go public.\nSnap(NYSE:SNAP)and TikTok (BDNCE) look to capitalize on their younger audiences by acquiring movie or gaming studios so they can boost their original video content offerings.\nAs a \"bonus\" prediction, Kulkarni forecasts that as the pandemic ends, more people will go back to working out at gyms and neighborhood parks, and this will result in difficulty in forecasting sales for the likes of Peloton(NASDAQ:PTON). The home-exercise technology company also had its sails trimmed on Thursday when analysts at Citi cut their price target on Peloton's (PTON) stock to $38 a share on expectations of higher expenses and falling demand for Peloton (PTON) products next year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":994,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698892256,"gmtCreate":1640331968167,"gmtModify":1640331968486,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698892256","repostId":"2193078140","repostType":4,"repost":{"id":"2193078140","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640299360,"share":"https://www.laohu8.com/m/news/2193078140?lang=&edition=full","pubTime":"2021-12-24 06:42","market":"us","language":"en","title":"S&P 500 hits record close as Omicron fears ebb","url":"https://stock-news.laohu8.com/highlight/detail?id=2193078140","media":"Reuters","summary":"* Major indexes climb for 3rd straight session\n* Merck's at-home COVID-19 pill gets U.S. approval\n* ","content":"<p>* Major indexes climb for 3rd straight session</p>\n<p>* Merck's at-home COVID-19 pill gets U.S. approval</p>\n<p>* Weekly jobless claims unchanged at 205,000</p>\n<p>* Consumer spending increases 0.6% in November</p>\n<p>* Indexes up: Dow 0.55%, S&amp;P 0.62%, Nasdaq 0.85%</p>\n<p>Dec 23 (Reuters) - Wall Street's main indexes posted solid gains for a third straight session on Thursday, with the S&amp;P 500 marking a record-high close, as encouraging developments gave investors more ease about the economic impact of the Omicron coronavirus variant.</p>\n<p>Stocks ended the holiday-shortened week on a positive note, lifting sentiment heading into Christmas. Gains were broad among S&amp;P 500 sectors, led by consumer discretionary&nbsp;and industrials, which both rose about 1.2%.</p>\n<p>Vaccine makers <a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a>&nbsp;and Novavax Inc&nbsp;said their shots protected against Omicron as UK data suggested it may cause proportionally fewer hospital cases than the Delta variant, though public health experts warned the battle against COVID-19 was far from over.</p>\n<p>The arrival of Omicron has helped ratchet up market volatility for much of the last month of 2021, which has been a strong year for equities.</p>\n<p>“There was a lot of negative sentiment coming into the final part of the year, and investors have likely continued to see pretty strong economic growth and pretty positive developments as it relates to healthcare innovation around COVID and that is putting in a bit of a bid into equities and causing investors to look to allocate capital as they close out the year,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 196.67 points, or 0.55%, to 35,950.56, the S&amp;P 500&nbsp;gained 29.23 points, or 0.62%, to 4,725.79 and the Nasdaq Composite&nbsp;added 131.48 points, or 0.85%, to 15,653.37.</p>\n<p>Defensive sectors, which have mostly outperformed in December, generally lagged on Thursday. The real estate sector&nbsp;fell 0.4%.</p>\n<p>The S&amp;P 500 has gained for three days, after falling in the three prior sessions.</p>\n<p>“People are seeing the strength on Tuesday and Wednesday and all of a sudden everybody is more optimistic again,” said Robert Pavlik, senior portfolio manager at Dakota Wealth Management.</p>\n<p>For the week, the S&amp;P 500 rose 2.3%, the Dow gained about 1.7% and the Nasdaq climbed 3.2%.</p>\n<p>Trading volumes were expected to be thinner than usual ahead of the Christmas and New Year holidays. The stock market will be closed on Friday in observance of the Christmas holiday.</p>\n<p>In another medical development against the pandemic, the United States authorized Merck &amp; Co's&nbsp;antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment from Pfizer Inc. Merck shares fell 0.6%, while Pfizer dropped 1.4%.</p>\n<p>The number of Americans filing new claims for unemployment benefits held below pre-pandemic levels last week as the labor market tightens, while consumer spending increased solidly, putting the economy on track for a strong finish to 2021.</p>\n<p>Tesla Inc&nbsp;shares rose 5.8%, gaining sharply for a second day after Chief Executive Elon Musk said on Wednesday he was \"almost done\" with his stock sales after selling over $15 billion worth since early November.</p>\n<p>The S&amp;P 500 is up about 26% so far this year. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.40-to-1 ratio; on Nasdaq, a 2.22-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 35 new 52-week highs and no new lows; the Nasdaq Composite recorded 62 new highs and 80 new lows.</p>\n<p>About 8 billion shares changed hands in U.S. exchanges, compared with the 11.8 billion daily average over the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 hits record close as Omicron fears ebb</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 hits record close as Omicron fears ebb\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-24 06:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Major indexes climb for 3rd straight session</p>\n<p>* Merck's at-home COVID-19 pill gets U.S. approval</p>\n<p>* Weekly jobless claims unchanged at 205,000</p>\n<p>* Consumer spending increases 0.6% in November</p>\n<p>* Indexes up: Dow 0.55%, S&amp;P 0.62%, Nasdaq 0.85%</p>\n<p>Dec 23 (Reuters) - Wall Street's main indexes posted solid gains for a third straight session on Thursday, with the S&amp;P 500 marking a record-high close, as encouraging developments gave investors more ease about the economic impact of the Omicron coronavirus variant.</p>\n<p>Stocks ended the holiday-shortened week on a positive note, lifting sentiment heading into Christmas. Gains were broad among S&amp;P 500 sectors, led by consumer discretionary&nbsp;and industrials, which both rose about 1.2%.</p>\n<p>Vaccine makers <a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a>&nbsp;and Novavax Inc&nbsp;said their shots protected against Omicron as UK data suggested it may cause proportionally fewer hospital cases than the Delta variant, though public health experts warned the battle against COVID-19 was far from over.</p>\n<p>The arrival of Omicron has helped ratchet up market volatility for much of the last month of 2021, which has been a strong year for equities.</p>\n<p>“There was a lot of negative sentiment coming into the final part of the year, and investors have likely continued to see pretty strong economic growth and pretty positive developments as it relates to healthcare innovation around COVID and that is putting in a bit of a bid into equities and causing investors to look to allocate capital as they close out the year,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 196.67 points, or 0.55%, to 35,950.56, the S&amp;P 500&nbsp;gained 29.23 points, or 0.62%, to 4,725.79 and the Nasdaq Composite&nbsp;added 131.48 points, or 0.85%, to 15,653.37.</p>\n<p>Defensive sectors, which have mostly outperformed in December, generally lagged on Thursday. The real estate sector&nbsp;fell 0.4%.</p>\n<p>The S&amp;P 500 has gained for three days, after falling in the three prior sessions.</p>\n<p>“People are seeing the strength on Tuesday and Wednesday and all of a sudden everybody is more optimistic again,” said Robert Pavlik, senior portfolio manager at Dakota Wealth Management.</p>\n<p>For the week, the S&amp;P 500 rose 2.3%, the Dow gained about 1.7% and the Nasdaq climbed 3.2%.</p>\n<p>Trading volumes were expected to be thinner than usual ahead of the Christmas and New Year holidays. The stock market will be closed on Friday in observance of the Christmas holiday.</p>\n<p>In another medical development against the pandemic, the United States authorized Merck &amp; Co's&nbsp;antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment from Pfizer Inc. Merck shares fell 0.6%, while Pfizer dropped 1.4%.</p>\n<p>The number of Americans filing new claims for unemployment benefits held below pre-pandemic levels last week as the labor market tightens, while consumer spending increased solidly, putting the economy on track for a strong finish to 2021.</p>\n<p>Tesla Inc&nbsp;shares rose 5.8%, gaining sharply for a second day after Chief Executive Elon Musk said on Wednesday he was \"almost done\" with his stock sales after selling over $15 billion worth since early November.</p>\n<p>The S&amp;P 500 is up about 26% so far this year. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.40-to-1 ratio; on Nasdaq, a 2.22-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 35 new 52-week highs and no new lows; the Nasdaq Composite recorded 62 new highs and 80 new lows.</p>\n<p>About 8 billion shares changed hands in U.S. exchanges, compared with the 11.8 billion daily average over the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SPY":"标普500ETF","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","OEF":"标普100指数ETF-iShares",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","OEX":"标普100",".SPX":"S&P 500 Index","SDS":"两倍做空标普500ETF","UPRO":"三倍做多标普500ETF","BK4504":"桥水持仓","IVV":"标普500指数ETF","SSO":"两倍做多标普500ETF","SH":"标普500反向ETF","SPXU":"三倍做空标普500ETF","BK4534":"瑞士信贷持仓"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193078140","content_text":"* Major indexes climb for 3rd straight session\n* Merck's at-home COVID-19 pill gets U.S. approval\n* Weekly jobless claims unchanged at 205,000\n* Consumer spending increases 0.6% in November\n* Indexes up: Dow 0.55%, S&P 0.62%, Nasdaq 0.85%\nDec 23 (Reuters) - Wall Street's main indexes posted solid gains for a third straight session on Thursday, with the S&P 500 marking a record-high close, as encouraging developments gave investors more ease about the economic impact of the Omicron coronavirus variant.\nStocks ended the holiday-shortened week on a positive note, lifting sentiment heading into Christmas. Gains were broad among S&P 500 sectors, led by consumer discretionary and industrials, which both rose about 1.2%.\nVaccine makers AstraZeneca Plc and Novavax Inc said their shots protected against Omicron as UK data suggested it may cause proportionally fewer hospital cases than the Delta variant, though public health experts warned the battle against COVID-19 was far from over.\nThe arrival of Omicron has helped ratchet up market volatility for much of the last month of 2021, which has been a strong year for equities.\n“There was a lot of negative sentiment coming into the final part of the year, and investors have likely continued to see pretty strong economic growth and pretty positive developments as it relates to healthcare innovation around COVID and that is putting in a bit of a bid into equities and causing investors to look to allocate capital as they close out the year,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.\nThe Dow Jones Industrial Average rose 196.67 points, or 0.55%, to 35,950.56, the S&P 500 gained 29.23 points, or 0.62%, to 4,725.79 and the Nasdaq Composite added 131.48 points, or 0.85%, to 15,653.37.\nDefensive sectors, which have mostly outperformed in December, generally lagged on Thursday. The real estate sector fell 0.4%.\nThe S&P 500 has gained for three days, after falling in the three prior sessions.\n“People are seeing the strength on Tuesday and Wednesday and all of a sudden everybody is more optimistic again,” said Robert Pavlik, senior portfolio manager at Dakota Wealth Management.\nFor the week, the S&P 500 rose 2.3%, the Dow gained about 1.7% and the Nasdaq climbed 3.2%.\nTrading volumes were expected to be thinner than usual ahead of the Christmas and New Year holidays. The stock market will be closed on Friday in observance of the Christmas holiday.\nIn another medical development against the pandemic, the United States authorized Merck & Co's antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment from Pfizer Inc. Merck shares fell 0.6%, while Pfizer dropped 1.4%.\nThe number of Americans filing new claims for unemployment benefits held below pre-pandemic levels last week as the labor market tightens, while consumer spending increased solidly, putting the economy on track for a strong finish to 2021.\nTesla Inc shares rose 5.8%, gaining sharply for a second day after Chief Executive Elon Musk said on Wednesday he was \"almost done\" with his stock sales after selling over $15 billion worth since early November.\nThe S&P 500 is up about 26% so far this year. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.40-to-1 ratio; on Nasdaq, a 2.22-to-1 ratio favored advancers.\nThe S&P 500 posted 35 new 52-week highs and no new lows; the Nasdaq Composite recorded 62 new highs and 80 new lows.\nAbout 8 billion shares changed hands in U.S. exchanges, compared with the 11.8 billion daily average over the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691058903,"gmtCreate":1640100935431,"gmtModify":1640100935722,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691058903","repostId":"1131687838","repostType":4,"repost":{"id":"1131687838","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640100532,"share":"https://www.laohu8.com/m/news/1131687838?lang=&edition=full","pubTime":"2021-12-21 23:28","market":"us","language":"en","title":"Microsoft's $16 billion Nuance bid gets EU antitrust approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1131687838","media":"Reuters","summary":"BRUSSELS, Dec 21 (Reuters) - The European Commission on Tuesday granted Microsoft(MSFT.O)uncondition","content":"<p>BRUSSELS, Dec 21 (Reuters) - The European Commission on Tuesday granted Microsoft(MSFT.O)unconditional antitrust approval for its $16 billion bid for artificial intelligence and speech technology company Nuance Communications(NUAN.O).</p>\n<p>The deal is Microsoft's second biggest after its $26.2 billion LinkedIn purchase in 2016, and would boost its presence in cloud services for healthcare.</p>\n<p>It has already regulatory approval in the United States and Australia, and Reuters reported earlier this month it was set to receive EU approval.</p>\n<p>The Commission said its investigation into the deal had concluded that it would not significantly reduce competition in markets for transcription software, cloud services, enterprise communication services, PC operating systems and other products.</p>\n<p>\"The proposed transaction would raise no competition concerns on any of the markets examined in the European Economic Area,\" the Commission said.</p>\n<p>U.S.-based Nuance serves 77% of U.S. hospitals and helped launch Apple's(AAPL.O)Siri virtual assistant.</p>\n<p>The Commission said it had examined issues including the overlap between Microsoft and Nuance's transcription software activities, and found that they offered \"very different products\" that, when combined, would continue to face strong competition from other players.</p>\n<p>Tech companies have ramped up acquisitions of AI-focused firms as more integrate this technology into their products and services.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft's $16 billion Nuance bid gets EU antitrust approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft's $16 billion Nuance bid gets EU antitrust approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-21 23:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BRUSSELS, Dec 21 (Reuters) - The European Commission on Tuesday granted Microsoft(MSFT.O)unconditional antitrust approval for its $16 billion bid for artificial intelligence and speech technology company Nuance Communications(NUAN.O).</p>\n<p>The deal is Microsoft's second biggest after its $26.2 billion LinkedIn purchase in 2016, and would boost its presence in cloud services for healthcare.</p>\n<p>It has already regulatory approval in the United States and Australia, and Reuters reported earlier this month it was set to receive EU approval.</p>\n<p>The Commission said its investigation into the deal had concluded that it would not significantly reduce competition in markets for transcription software, cloud services, enterprise communication services, PC operating systems and other products.</p>\n<p>\"The proposed transaction would raise no competition concerns on any of the markets examined in the European Economic Area,\" the Commission said.</p>\n<p>U.S.-based Nuance serves 77% of U.S. hospitals and helped launch Apple's(AAPL.O)Siri virtual assistant.</p>\n<p>The Commission said it had examined issues including the overlap between Microsoft and Nuance's transcription software activities, and found that they offered \"very different products\" that, when combined, would continue to face strong competition from other players.</p>\n<p>Tech companies have ramped up acquisitions of AI-focused firms as more integrate this technology into their products and services.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131687838","content_text":"BRUSSELS, Dec 21 (Reuters) - The European Commission on Tuesday granted Microsoft(MSFT.O)unconditional antitrust approval for its $16 billion bid for artificial intelligence and speech technology company Nuance Communications(NUAN.O).\nThe deal is Microsoft's second biggest after its $26.2 billion LinkedIn purchase in 2016, and would boost its presence in cloud services for healthcare.\nIt has already regulatory approval in the United States and Australia, and Reuters reported earlier this month it was set to receive EU approval.\nThe Commission said its investigation into the deal had concluded that it would not significantly reduce competition in markets for transcription software, cloud services, enterprise communication services, PC operating systems and other products.\n\"The proposed transaction would raise no competition concerns on any of the markets examined in the European Economic Area,\" the Commission said.\nU.S.-based Nuance serves 77% of U.S. hospitals and helped launch Apple's(AAPL.O)Siri virtual assistant.\nThe Commission said it had examined issues including the overlap between Microsoft and Nuance's transcription software activities, and found that they offered \"very different products\" that, when combined, would continue to face strong competition from other players.\nTech companies have ramped up acquisitions of AI-focused firms as more integrate this technology into their products and services.","news_type":1},"isVote":1,"tweetType":1,"viewCount":825,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693169847,"gmtCreate":1639986888092,"gmtModify":1639986888371,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693169847","repostId":"1109541249","repostType":4,"repost":{"id":"1109541249","pubTimestamp":1639972523,"share":"https://www.laohu8.com/m/news/1109541249?lang=&edition=full","pubTime":"2021-12-20 11:55","market":"us","language":"en","title":"Sea Stock: Down 43% From Its High, is a Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=1109541249","media":"Seeking Alpha","summary":"Summary\n\nSea Limited stock has been battered recently as growth stocks sold off massively in the mar","content":"<p><b>Summary</b></p>\n<ul>\n <li>Sea Limited stock has been battered recently as growth stocks sold off massively in the market.</li>\n <li>However, we believe that the fundamental thesis on its rapid growth remains robust.</li>\n <li>We discuss why investors should capitalize on its recent significant correction to add exposure.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/aa5cbe0a30acc723a2c6f62300024002\" tg-width=\"1536\" tg-height=\"1024\" referrerpolicy=\"no-referrer\"><span>kokkai/iStock Unreleased via Getty Images</span></p>\n<p><b>Investment Thesis</b></p>\n<p>Sea Limited(NYSE:SE)&nbsp;stock is one of our highest conviction growth stocks that has been severely battered over the last month. Since its recent all-time high (ATH) in October, its price has dropped by a dramatic 43%. Many reasons have been presented on why the stock has fallen. We exhort investors not to read too much into them. We believe nothing material has changed from its fundamental thesis. The stock has had a remarkable run in 2021 relative to its gaming peers or e-tailer peers. Therefore, profit-taking of this extent should not be surprising as fear struck growth stocks.</p>\n<p>Moreover, the recent significant correction in growth stocks across the market has also hit SE stock hard. But, we are not concerned. Significant volatility will always be a factor influencing the performance of growth stocks like SE in the short term.</p>\n<p>Notably, we observed that the consensus target price on SE stock had been revised upwards since its FQ3 report card. Moreover, the gap between its price target and its current stock price has been greater than its last significant correction in April/May.</p>\n<p>Our internal DCF valuation model also points to a stock that is now significantly undervalued. Thanks to the market's myopia, we have been presented with another fantastic opportunity since April/May to add SE stock with great fervor again.</p>\n<p>We discuss why we think investors should not miss this incredible opportunity to add exposure to an outstanding growth stock.</p>\n<p><b>SE Stock YTD Performance</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6c191d1f0f6a10e392845cdbda1264aa\" tg-width=\"640\" tg-height=\"331\" referrerpolicy=\"no-referrer\"><span>SE stock YTD performance (as of 17 December'21).</span></p>\n<p>As a result of the significant correction recently, SE stock's YTD return has dropped to 6.9%, thus underperforming the market. Notably, its YTD gain was as high as 80% in October/early November. Despite that, the stock is still outperforming its e-tailer and gaming peers, as shown above.</p>\n<p><b>Sea Stock Estimates Have Consistently Been Revised Upwards</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8555128e2a30e924dd6c2dd162a27eea\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Sea Limited revised revenue mean consensus estimates. Data source: S&amp;P Capital IQ, Seeking Alpha</span></p>\n<p>Readers can quickly observe that the company's revenue consensus estimates for FY21-23 have consistently been revised upwards over the last five months. These revisions lend credence to the robust growth prospects of the company over the next two years. Notably, Sea Limited's revenue is estimated to increase at a phenomenal CAGR of 42.8% through FY23.</p>\n<p>There were concerns over the growth rates of its Garena gaming arm in its FQ3 report card.We also explained in our previous article&nbsp;that Sea Limited has clearly explained that investors should expect normalization in Garena's growth after two spectacular years. However, its monetization capability continues to dazzle. Therefore, we are confident that Garena can continue its robust monetization strategies moving forward.</p>\n<p>Moreover, data from Sensor Tower's recent gaming statistics continue to point to sturdy performance from its Free Fire game. It continues to be ranked among the&nbsp;top ten mobile games in terms of overall gaming revenue&nbsp;in November. Moreover, it's also ranked#2 in overall downloadsacross both the App Store and Google Play. Notably, it's also among&nbsp;eight games globally whose annual revenue crossed $1B&nbsp;as of 14 December. Therefore, we think the sentiments and chatter about Free Fire's \"one-shot wonder\" have been overblown.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/51247ba1efd7fa6d333b482446e94c9a\" tg-width=\"515\" tg-height=\"380\" referrerpolicy=\"no-referrer\"><span>Global games market forecast. Source: Google, Newzoo</span></p>\n<p>In addition, the global gaming market is estimated to experience a slight decline to $175.8B after last year's massive 23% growth to $177.8B. However, given Garena's impressive growth in FY21 despite the decline in the global market, we believe it validates its business model and prospects. Notably, the gaming market is expected to reverse its decline moving forward. Therefore, Garena's leadership in mobile gaming could continue to propel its growth underpinned by the recovery in the global gaming market.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0a0612da9a19f7b7198d43213b4f4470\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Shopee adjusted EBITDA per order. Data source: Company filings</span></p>\n<p>But, some investors may have been spooked by Shopee's (Sea Limited's e-commerce arm) continued expansion into new geographical markets. Notably, Shopee continues to report adjusted EBITDA loss per order, as shown above. Therefore, some investors might have been concerned about whether the company's plate is getting too much to handle. Over the last three months, the company has entered into new markets such as India, France, Spain, and Poland. They are in addition to its battle with MercadoLibre (MELI) in Latin America, particularly Brazil. As a result, there are concerns on whether Sea Limited could continue its adroit execution in these markets while still making losses. We believe such concerns are valid. However, Sea Limited has shown its tremendous capability in penetrating the most important markets where the incumbents have strong leadership. It includes Lazada (BABA) in Southeast Asia, MercadoLibre in Brazil, and Tokopedia in Indonesia. Shopee was never the first-mover. But, it took advantage as the \"late-comer\" as it sought to compete with the incumbents. It's important to note that Sea Limited is not averse to competition. It has thrived against the incumbents and has made the e-commerce space in these geographical regions much more competitive.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/80938433e2d55307ca40000eeea2a26f\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Sea Limited revised adjusted EPS mean consensus estimates. Data source: S&amp;P Capital IQ, Seeking Alpha</span></p>\n<p>Nevertheless, the road towards profitability might be stretched further due to its e-commerce expansion. Readers can quickly glance over the chart above, where its adjusted EPS estimates have been revised downwards through FY23 over the last five months. However, we believe that if you are a long-term investor with a five-year horizon at least, it's not a cause for concern. Earlier investors in Sea Limited can keenly recall the company's massive adjusted EBITDA per order losses, as seen in the previous chart. Shopee has scaled tremendously over the last five years and has improved its operating leverage further. But, it's important to note that it takes time to scale up. Therefore, earlier losses in new geographical markets are expected. But, management has demonstrated its execution capability over the last three years. Considering its much reduced adjusted EBITDA losses over the previous few years, we believe that Shopee is even better positioned than before to navigate its expansion.</p>\n<p><b>So, is SE Stock a Buy Now?</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3dbc835e49ded8a7a0e5f4fcc9e10649\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\"><span>SE stock EV/NTM Revenue 4Y mean.</span></p>\n<p>SE stock is trading at an EV/NTM Revenue of 8.3x. Therefore, it has brought it back to its 4Y NTM revenue multiple mean of 8.6x. We believe there's a fantastic opportunity right now as the market has undoubtedly overreacted. As demonstrated clearly, SE is still expected to generate massive revenue growth moving ahead, even though it means the road to profitability gets further extended.</p>\n<p>Considering its FY23 revenue estimate, SE stock is trading at just 5.8x FY23 revenue. No one can accurately predict where the stock will be headed over the next few months. But, we think it represents a tremendous opportunity right now.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3bea18a0bdfd970ea640308dc35e099c\" tg-width=\"635\" tg-height=\"362\" referrerpolicy=\"no-referrer\"><span>SE stock price target Vs. actual price trend. Source: Seeking Alpha</span></p>\n<p>Moreover, readers can observe that the valuation gap between SE stock's consensus price target (PT) of $405.87 and its current price has never been more significant in a while. It's even more pronounced than its last significant correction in April/May. Notably, the consensus price target has been revised upwards despite the so-called \"gaming headwinds.\" And, if you look at the price chart, SE stock price has followed the revised PT trend very consistently over time. Therefore, the current price could be one of the most significant discounts you could observe in a long time.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/939a544ab94c9e2a2b8a6db943703b39\" tg-width=\"910\" tg-height=\"602\" referrerpolicy=\"no-referrer\"><span>SE stock DCF valuation model. Data source: S&amp;P Capital IQ, company filings, author</span></p>\n<p>Our DCF model also shows that SE stock is now significantly undervalued with an implied fair value of $371.46. We have also used reasonable estimates in our model. Moreover, we believe that SE will continue to gain significant operating leverage as it scales in the new markets. We estimate that its adjusted EBITDA margins could reach 15% by FY25.</p>\n<p>Lastly, the stock is also testing a critical support level that has strongly underpinned the stock's advance since early 2021. Therefore, there are sufficient reasons to believe that the current entry point to add exposure to SE stock seems very attractive now.</p>\n<p>Consequently,<i>we revise our rating on SE stock to Strong Buy</i>.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea Stock: Down 43% From Its High, is a Buy Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea Stock: Down 43% From Its High, is a Buy Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-20 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4475931-sea-se-down-significantly-stock-strong-buy><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nSea Limited stock has been battered recently as growth stocks sold off massively in the market.\nHowever, we believe that the fundamental thesis on its rapid growth remains robust.\nWe discuss ...</p>\n\n<a href=\"https://seekingalpha.com/article/4475931-sea-se-down-significantly-stock-strong-buy\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"source_url":"https://seekingalpha.com/article/4475931-sea-se-down-significantly-stock-strong-buy","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109541249","content_text":"Summary\n\nSea Limited stock has been battered recently as growth stocks sold off massively in the market.\nHowever, we believe that the fundamental thesis on its rapid growth remains robust.\nWe discuss why investors should capitalize on its recent significant correction to add exposure.\n\nkokkai/iStock Unreleased via Getty Images\nInvestment Thesis\nSea Limited(NYSE:SE) stock is one of our highest conviction growth stocks that has been severely battered over the last month. Since its recent all-time high (ATH) in October, its price has dropped by a dramatic 43%. Many reasons have been presented on why the stock has fallen. We exhort investors not to read too much into them. We believe nothing material has changed from its fundamental thesis. The stock has had a remarkable run in 2021 relative to its gaming peers or e-tailer peers. Therefore, profit-taking of this extent should not be surprising as fear struck growth stocks.\nMoreover, the recent significant correction in growth stocks across the market has also hit SE stock hard. But, we are not concerned. Significant volatility will always be a factor influencing the performance of growth stocks like SE in the short term.\nNotably, we observed that the consensus target price on SE stock had been revised upwards since its FQ3 report card. Moreover, the gap between its price target and its current stock price has been greater than its last significant correction in April/May.\nOur internal DCF valuation model also points to a stock that is now significantly undervalued. Thanks to the market's myopia, we have been presented with another fantastic opportunity since April/May to add SE stock with great fervor again.\nWe discuss why we think investors should not miss this incredible opportunity to add exposure to an outstanding growth stock.\nSE Stock YTD Performance\nSE stock YTD performance (as of 17 December'21).\nAs a result of the significant correction recently, SE stock's YTD return has dropped to 6.9%, thus underperforming the market. Notably, its YTD gain was as high as 80% in October/early November. Despite that, the stock is still outperforming its e-tailer and gaming peers, as shown above.\nSea Stock Estimates Have Consistently Been Revised Upwards\nSea Limited revised revenue mean consensus estimates. Data source: S&P Capital IQ, Seeking Alpha\nReaders can quickly observe that the company's revenue consensus estimates for FY21-23 have consistently been revised upwards over the last five months. These revisions lend credence to the robust growth prospects of the company over the next two years. Notably, Sea Limited's revenue is estimated to increase at a phenomenal CAGR of 42.8% through FY23.\nThere were concerns over the growth rates of its Garena gaming arm in its FQ3 report card.We also explained in our previous article that Sea Limited has clearly explained that investors should expect normalization in Garena's growth after two spectacular years. However, its monetization capability continues to dazzle. Therefore, we are confident that Garena can continue its robust monetization strategies moving forward.\nMoreover, data from Sensor Tower's recent gaming statistics continue to point to sturdy performance from its Free Fire game. It continues to be ranked among the top ten mobile games in terms of overall gaming revenue in November. Moreover, it's also ranked#2 in overall downloadsacross both the App Store and Google Play. Notably, it's also among eight games globally whose annual revenue crossed $1B as of 14 December. Therefore, we think the sentiments and chatter about Free Fire's \"one-shot wonder\" have been overblown.\nGlobal games market forecast. Source: Google, Newzoo\nIn addition, the global gaming market is estimated to experience a slight decline to $175.8B after last year's massive 23% growth to $177.8B. However, given Garena's impressive growth in FY21 despite the decline in the global market, we believe it validates its business model and prospects. Notably, the gaming market is expected to reverse its decline moving forward. Therefore, Garena's leadership in mobile gaming could continue to propel its growth underpinned by the recovery in the global gaming market.\nShopee adjusted EBITDA per order. Data source: Company filings\nBut, some investors may have been spooked by Shopee's (Sea Limited's e-commerce arm) continued expansion into new geographical markets. Notably, Shopee continues to report adjusted EBITDA loss per order, as shown above. Therefore, some investors might have been concerned about whether the company's plate is getting too much to handle. Over the last three months, the company has entered into new markets such as India, France, Spain, and Poland. They are in addition to its battle with MercadoLibre (MELI) in Latin America, particularly Brazil. As a result, there are concerns on whether Sea Limited could continue its adroit execution in these markets while still making losses. We believe such concerns are valid. However, Sea Limited has shown its tremendous capability in penetrating the most important markets where the incumbents have strong leadership. It includes Lazada (BABA) in Southeast Asia, MercadoLibre in Brazil, and Tokopedia in Indonesia. Shopee was never the first-mover. But, it took advantage as the \"late-comer\" as it sought to compete with the incumbents. It's important to note that Sea Limited is not averse to competition. It has thrived against the incumbents and has made the e-commerce space in these geographical regions much more competitive.\nSea Limited revised adjusted EPS mean consensus estimates. Data source: S&P Capital IQ, Seeking Alpha\nNevertheless, the road towards profitability might be stretched further due to its e-commerce expansion. Readers can quickly glance over the chart above, where its adjusted EPS estimates have been revised downwards through FY23 over the last five months. However, we believe that if you are a long-term investor with a five-year horizon at least, it's not a cause for concern. Earlier investors in Sea Limited can keenly recall the company's massive adjusted EBITDA per order losses, as seen in the previous chart. Shopee has scaled tremendously over the last five years and has improved its operating leverage further. But, it's important to note that it takes time to scale up. Therefore, earlier losses in new geographical markets are expected. But, management has demonstrated its execution capability over the last three years. Considering its much reduced adjusted EBITDA losses over the previous few years, we believe that Shopee is even better positioned than before to navigate its expansion.\nSo, is SE Stock a Buy Now?\nSE stock EV/NTM Revenue 4Y mean.\nSE stock is trading at an EV/NTM Revenue of 8.3x. Therefore, it has brought it back to its 4Y NTM revenue multiple mean of 8.6x. We believe there's a fantastic opportunity right now as the market has undoubtedly overreacted. As demonstrated clearly, SE is still expected to generate massive revenue growth moving ahead, even though it means the road to profitability gets further extended.\nConsidering its FY23 revenue estimate, SE stock is trading at just 5.8x FY23 revenue. No one can accurately predict where the stock will be headed over the next few months. But, we think it represents a tremendous opportunity right now.\nSE stock price target Vs. actual price trend. Source: Seeking Alpha\nMoreover, readers can observe that the valuation gap between SE stock's consensus price target (PT) of $405.87 and its current price has never been more significant in a while. It's even more pronounced than its last significant correction in April/May. Notably, the consensus price target has been revised upwards despite the so-called \"gaming headwinds.\" And, if you look at the price chart, SE stock price has followed the revised PT trend very consistently over time. Therefore, the current price could be one of the most significant discounts you could observe in a long time.\nSE stock DCF valuation model. Data source: S&P Capital IQ, company filings, author\nOur DCF model also shows that SE stock is now significantly undervalued with an implied fair value of $371.46. We have also used reasonable estimates in our model. Moreover, we believe that SE will continue to gain significant operating leverage as it scales in the new markets. We estimate that its adjusted EBITDA margins could reach 15% by FY25.\nLastly, the stock is also testing a critical support level that has strongly underpinned the stock's advance since early 2021. Therefore, there are sufficient reasons to believe that the current entry point to add exposure to SE stock seems very attractive now.\nConsequently,we revise our rating on SE stock to Strong Buy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1085,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699274681,"gmtCreate":1639826937362,"gmtModify":1639826937669,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699274681","repostId":"1116106959","repostType":4,"repost":{"id":"1116106959","pubTimestamp":1639785552,"share":"https://www.laohu8.com/m/news/1116106959?lang=&edition=full","pubTime":"2021-12-18 07:59","market":"us","language":"en","title":"Wall Street ends down after mostly negative week","url":"https://stock-news.laohu8.com/highlight/detail?id=1116106959","media":"Reuters","summary":" - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.The S","content":"<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.</p>\n<p>All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.</p>\n<p>Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&amp;P 500 and Nasdaq.</p>\n<p>The S&amp;P 500 growth index lost 0.7% and the value index declined 1.4%.</p>\n<p>All of the 11 major S&amp;P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.</p>\n<p>Adding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.</p>\n<p>Traders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.</p>\n<p>\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"</p>\n<p>Heavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&amp;P 500 index gained around 23% in the same period.</p>\n<p>In Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&amp;P 500 lost 1.03% to 4,620.64.</p>\n<p>The Nasdaq Composite dropped 0.07% to 15,169.68.</p>\n<p>On a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.</p>\n<p>With options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.</p>\n<p>For the week, the S&amp;P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.</p>\n<p>In Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.</p>\n<p>FedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends down after mostly negative week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends down after mostly negative week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 07:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116106959","content_text":"(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.\nAll three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.\nNvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.\nThe S&P 500 growth index lost 0.7% and the value index declined 1.4%.\nAll of the 11 major S&P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.\nAdding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.\nTraders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.\n\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"\nHeavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&P 500 index gained around 23% in the same period.\nIn Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&P 500 lost 1.03% to 4,620.64.\nThe Nasdaq Composite dropped 0.07% to 15,169.68.\nOn a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.\nWith options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.\nFor the week, the S&P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.\nIn Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.\nFedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.\nThe S&P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":787,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690563169,"gmtCreate":1639693839768,"gmtModify":1639693840047,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690563169","repostId":"2191453039","repostType":4,"repost":{"id":"2191453039","pubTimestamp":1639667741,"share":"https://www.laohu8.com/m/news/2191453039?lang=&edition=full","pubTime":"2021-12-16 23:15","market":"us","language":"en","title":"3 Cheap Energy Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2191453039","media":"Motley Fool","summary":"There's one area of the energy sector that isn't getting any respect. And you can collect fat yields if you act today.","content":"<p>The broader energy sector has been a bit volatile of late, with oil prices driven higher and lower by the latest coronavirus news. However, overall, oil prices and oil stocks have staged a material rebound since the drilling industry's pandemic downturn in 2020. One niche in the energy space that's still not feeling much investor love, however, is the midstream space. And investors looking for solid companies with big yields would do well to dig into <b>Enterprise Products Partners</b> (NYSE:EPD), <b>Magellan Midstream Partners</b> (NYSE:MMP), and <b>Enbridge</b> (NYSE:ENB).</p>\n<h2>1. The bellwether</h2>\n<p>One of the first names that comes to mind when investors think of midstream investments is usually Enterprise Products Partners, a $46 billion market cap North American master limited partnership (MLP). Its collection of pipelines, storage, transportation, and processing assets would be virtually impossible to replace. And, like the other two names here, it largely gets paid for the use of its assets, so commodity volatility isn't a huge deal. And with demand for oil and natural gas likely to remain strong for decades to come, thanks to growing global demand for energy, there's no reason to expect Enterprise's systems to suddenly run on empty. That fact remains true even as clean energy investment ramps up, since it will take many years for these options to displace oil and natural gas.</p>\n<p>Enterprise currently yields a historically high 8.4% backed by a distribution that has been increased annually for 23 consecutive years. The MLP covered its distribution with distributable cash flow by 1.7 times in the third quarter as well, so there's ample leeway for adversity before the payment would be at risk. That said, with clean energy investment on the upswing, growth is a big question mark. Historically, ground-up construction of oil &amp; gas infrastructure has played a big role, but now that's less certain. So look for Enterprise to be more acquisitive and for distribution growth to be a bit on the low side (think low single digits at best). However, with a huge yield, that probably won't upset income-oriented investors looking for a broadly diversified, and cheap, energy investment.</p>\n<h2>2. Focused on oil</h2>\n<p>Magellan Midstream Partners is another MLP, but is much smaller with a market cap that's just under $10 billion. Unlike Enterprise, Magellan has a fairly concentrated business focused on transporting and storing oil (about 30% of operating margin) and refined products (70%) like gasoline. Its fortunes are tied far more tightly to the ups and downs of the economy because of that, given that demand for refined products tends to ebb and flow with economic activity. While it largely fee-based business still avoids the ups and downs of commodity prices, the economic shutdowns related to the pandemic in 2020 depressed demand for its midstream assets because demand for refined products fell. That left investors worried about the partnership's ability to support its distribution. In fact, as it started 2021, the company was projecting distribution coverage of just 1.1 times, which is cutting it pretty tight compared with the coverage levels at Enterprise. However, thanks to the economic reopenings, coverage is now expected to be a touch over 1.2 times. That's the MLP's long-term target.</p>\n<p>What's interesting about Magellan is that its distribution yield is a huge 9.1%, easily at the high end of its historical range and even higher than what you'll get from Enterprise. And that distribution has been increased annually every year since Magellan's initial public offering in 2001. Indeed, despite the headwinds it faced in 2020, it has continued to prioritize distribution growth. One of the key reasons it was able to do this is that Magellan has long focused on maintaining a strong balance sheet, noting that its financial debt to earnings before interest, taxes, depreciation, and amortization (EBITDA) ratio is usually at the low end of the industry. Don't look for massive distribution growth here (though the MLP did recently initiate a large share buyback as a way to return value to investors), but so long as refined products are in demand, Magellan's business should remain resilient.</p>\n<p><img src=\"https://static.tigerbbs.com/b8cff6902538ef473ac8295b95e0c893\" tg-width=\"720\" tg-height=\"483\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>MMP Dividend Yield data by YCharts</p>\n<h2>3. Expanding its reach</h2>\n<p>The last name up is Canada's Enbridge, with a $76 billion market cap and a historically high 7.1% dividend yield. Like Enterprise, it is one of the largest midstream names in North America, with a massive portfolio of fee-driven assets. However, it's not exactly a pure play. Roughly 14% of EBITDA comes from a natural gas distribution business, which is a utility operation, and 3% comes from contract-based renewable power assets. The natural gas distribution operation is benefiting from the switch to the cleaner-burning fuel, which is often cheaper and more convenient for customers, from dirtier alternatives like heating oil.&nbsp;And the company's renewable power investments give it a toehold in the area that could, eventually, displace demand for its midstream services.</p>\n<p>What's interesting here is that Enbridge is generating a huge amount of cash today, expecting to have around $2 billion in excess cash flow in 2022 above its current investment plans. That's money that can be used to grow the business (potentially including more clean energy investment), strengthen the balance sheet, or be returned to investors via dividend growth and stock buybacks. Given the high yield today, dividend growth is likely to be modest since investors aren't rewarding the company for its fat payout. However, Enbridge is in Dividend Aristocrat territory with 26 years of annual dividend increases under its belt and no sign that this trend is going to change. So, if the yield were to come back down toward more historical levels, it wouldn't be shocking to see Enbridge shift distribution growth higher again. For investors looking to hedge their energy bets against a clean energy future, Enbridge is a good, cash-rich option.</p>\n<h2>The unloved niche</h2>\n<p>In the grand scheme of the energy sector, midstream assets are pretty boring. That's actually part of their allure for dividend investors, however, because they are highly reliable businesses. Right now, Wall Street is more focused on clean energy than reliable oil-tied businesses, even though there are likely to be decades of demand ahead for midstream companies. If you can think past the groupthink that often drives stock prices, Enterprise, Magellan, and Enbridge are all high-yield energy options that look very cheap today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Cheap Energy Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Cheap Energy Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/16/3-cheap-energy-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The broader energy sector has been a bit volatile of late, with oil prices driven higher and lower by the latest coronavirus news. However, overall, oil prices and oil stocks have staged a material ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/16/3-cheap-energy-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4144":"石油与天然气的储存和运输","MLP":"毛伊岛菠萝食品","BK4024":"房地产开发","BK4561":"索罗斯持仓","EPD":"Enterprise Products Partners L.P","ENB":"安桥"},"source_url":"https://www.fool.com/investing/2021/12/16/3-cheap-energy-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191453039","content_text":"The broader energy sector has been a bit volatile of late, with oil prices driven higher and lower by the latest coronavirus news. However, overall, oil prices and oil stocks have staged a material rebound since the drilling industry's pandemic downturn in 2020. One niche in the energy space that's still not feeling much investor love, however, is the midstream space. And investors looking for solid companies with big yields would do well to dig into Enterprise Products Partners (NYSE:EPD), Magellan Midstream Partners (NYSE:MMP), and Enbridge (NYSE:ENB).\n1. The bellwether\nOne of the first names that comes to mind when investors think of midstream investments is usually Enterprise Products Partners, a $46 billion market cap North American master limited partnership (MLP). Its collection of pipelines, storage, transportation, and processing assets would be virtually impossible to replace. And, like the other two names here, it largely gets paid for the use of its assets, so commodity volatility isn't a huge deal. And with demand for oil and natural gas likely to remain strong for decades to come, thanks to growing global demand for energy, there's no reason to expect Enterprise's systems to suddenly run on empty. That fact remains true even as clean energy investment ramps up, since it will take many years for these options to displace oil and natural gas.\nEnterprise currently yields a historically high 8.4% backed by a distribution that has been increased annually for 23 consecutive years. The MLP covered its distribution with distributable cash flow by 1.7 times in the third quarter as well, so there's ample leeway for adversity before the payment would be at risk. That said, with clean energy investment on the upswing, growth is a big question mark. Historically, ground-up construction of oil & gas infrastructure has played a big role, but now that's less certain. So look for Enterprise to be more acquisitive and for distribution growth to be a bit on the low side (think low single digits at best). However, with a huge yield, that probably won't upset income-oriented investors looking for a broadly diversified, and cheap, energy investment.\n2. Focused on oil\nMagellan Midstream Partners is another MLP, but is much smaller with a market cap that's just under $10 billion. Unlike Enterprise, Magellan has a fairly concentrated business focused on transporting and storing oil (about 30% of operating margin) and refined products (70%) like gasoline. Its fortunes are tied far more tightly to the ups and downs of the economy because of that, given that demand for refined products tends to ebb and flow with economic activity. While it largely fee-based business still avoids the ups and downs of commodity prices, the economic shutdowns related to the pandemic in 2020 depressed demand for its midstream assets because demand for refined products fell. That left investors worried about the partnership's ability to support its distribution. In fact, as it started 2021, the company was projecting distribution coverage of just 1.1 times, which is cutting it pretty tight compared with the coverage levels at Enterprise. However, thanks to the economic reopenings, coverage is now expected to be a touch over 1.2 times. That's the MLP's long-term target.\nWhat's interesting about Magellan is that its distribution yield is a huge 9.1%, easily at the high end of its historical range and even higher than what you'll get from Enterprise. And that distribution has been increased annually every year since Magellan's initial public offering in 2001. Indeed, despite the headwinds it faced in 2020, it has continued to prioritize distribution growth. One of the key reasons it was able to do this is that Magellan has long focused on maintaining a strong balance sheet, noting that its financial debt to earnings before interest, taxes, depreciation, and amortization (EBITDA) ratio is usually at the low end of the industry. Don't look for massive distribution growth here (though the MLP did recently initiate a large share buyback as a way to return value to investors), but so long as refined products are in demand, Magellan's business should remain resilient.\n\nMMP Dividend Yield data by YCharts\n3. Expanding its reach\nThe last name up is Canada's Enbridge, with a $76 billion market cap and a historically high 7.1% dividend yield. Like Enterprise, it is one of the largest midstream names in North America, with a massive portfolio of fee-driven assets. However, it's not exactly a pure play. Roughly 14% of EBITDA comes from a natural gas distribution business, which is a utility operation, and 3% comes from contract-based renewable power assets. The natural gas distribution operation is benefiting from the switch to the cleaner-burning fuel, which is often cheaper and more convenient for customers, from dirtier alternatives like heating oil. And the company's renewable power investments give it a toehold in the area that could, eventually, displace demand for its midstream services.\nWhat's interesting here is that Enbridge is generating a huge amount of cash today, expecting to have around $2 billion in excess cash flow in 2022 above its current investment plans. That's money that can be used to grow the business (potentially including more clean energy investment), strengthen the balance sheet, or be returned to investors via dividend growth and stock buybacks. Given the high yield today, dividend growth is likely to be modest since investors aren't rewarding the company for its fat payout. However, Enbridge is in Dividend Aristocrat territory with 26 years of annual dividend increases under its belt and no sign that this trend is going to change. So, if the yield were to come back down toward more historical levels, it wouldn't be shocking to see Enbridge shift distribution growth higher again. For investors looking to hedge their energy bets against a clean energy future, Enbridge is a good, cash-rich option.\nThe unloved niche\nIn the grand scheme of the energy sector, midstream assets are pretty boring. That's actually part of their allure for dividend investors, however, because they are highly reliable businesses. Right now, Wall Street is more focused on clean energy than reliable oil-tied businesses, even though there are likely to be decades of demand ahead for midstream companies. If you can think past the groupthink that often drives stock prices, Enterprise, Magellan, and Enbridge are all high-yield energy options that look very cheap today.","news_type":1},"isVote":1,"tweetType":1,"viewCount":773,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690142006,"gmtCreate":1639649726021,"gmtModify":1639649726263,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690142006","repostId":"1171817404","repostType":4,"repost":{"id":"1171817404","pubTimestamp":1639648605,"share":"https://www.laohu8.com/m/news/1171817404?lang=&edition=full","pubTime":"2021-12-16 17:56","market":"us","language":"en","title":"46 Biggest Movers From Yesterday","url":"https://stock-news.laohu8.com/highlight/detail?id=1171817404","media":"Benzinga","summary":"Gainers\n\nTheseus Pharmaceuticals, Inc. gained 34.1% to settle at $12.58 on Wednesday.\nCMC Materials,","content":"<p><b>Gainers</b></p>\n<ul>\n <li><b>Theseus Pharmaceuticals, Inc.</b>&nbsp;gained 34.1% to settle at $12.58 on Wednesday.</li>\n <li><b>CMC Materials, Inc.</b>&nbsp;climbed 33.9% to close at $195.50 on Wednesday after the company announced it will be acquired by Entegris for $6.5 billion in cash and stock.</li>\n <li><b>Biofrontera Inc.</b>&nbsp;shares jumped 26.4% to settle at $6.95 on Wednesday after Benchmark initiated coverage on the stock with a Buy rating and announced a $11 price target.</li>\n <li><b>Regional Health Properties, Inc.</b>&nbsp;gained 23.8% to close at $6.70.Regional Health Props, last month, posted a Q3 loss of $1.25 per share.</li>\n <li><b>Gemini Therapeutics, Inc.</b>&nbsp;rose 23.1% to settle at $2.99 after HC Wainwright &amp; Co initiated coverage on the stock with a Buy rating and a $20 price target.</li>\n <li><b>CN Energy Group. Inc.</b>&nbsp;jumped 22.4% to close at $3.01.</li>\n <li><b>Mesoblast Limited</b>&nbsp;climbed 19.2% to settle at $4.97. Mesoblast shares dropped around 28% on Tuesday after the company was notified by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing.</li>\n <li><b>Broadstone Acquisition Corp.</b>&nbsp;gained 19.1% to close at $10.68.</li>\n <li><b>Cabaletta Bio, Inc.</b>&nbsp;jumped 18.2% to settle at $3.97.</li>\n <li><b>Ensysce Biosciences, Inc.</b>&nbsp;surged 17.4% to close at $4.11. Ensysce Biosciences said that the first patients have been enrolled in Phase 1 study of PF614-MPAR, its unique technology platform to provide opioid overdose protection.</li>\n <li><b>Trio-Tech International</b>&nbsp;gained 16.6% to close at $9.42.</li>\n <li><b>Aerovate Therapeutics, Inc.</b>&nbsp;jumped 16.3% to close at $12.34 after the company announced the initiation of its IMPAHCT Phase 2b/Phase 3 trial of AV-101 In Pulmonary Arterial Hypertension.</li>\n <li><b>Optical Cable Corporation</b>&nbsp;gained 16.2% to settle at $6.40.</li>\n <li><b>Conn's, Inc.</b>&nbsp;rose 16.1% to close at $20.81. Conn's Board of Directors authorized a repurchase program of $150 million of its outstanding stock.</li>\n <li><b>Design Therapeutics, Inc.</b>&nbsp;surged 16% to settle at $20.36.</li>\n <li><b>Bird Global, Inc.</b>&nbsp;gained 15.7% to close at $8.97.</li>\n <li><b>VerifyMe, Inc.</b>&nbsp;jumped 13.7% to close at $3.65.</li>\n <li><b>East Stone Acquisition Corporation</b>&nbsp;gained 12.9% to close at $15.24 after declining 26% on Tuesday.</li>\n <li><b>Vir Biotechnology, Inc.</b>&nbsp;gained 12.1% to close at $51.62 after the company announced new preclinical data demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant.</li>\n <li><b>SeaChange International, Inc.</b>&nbsp;rose 11.9% to close at $1.69 after the company reported better-than-expected Q3 results.</li>\n <li><b>Nxt-ID, Inc.</b>&nbsp;shares rose 11.7% to close at $2.78 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers.</li>\n <li><b>Tandem Diabetes Care, Inc.</b>&nbsp;climbed 10.5% to close at $144.34.</li>\n <li><b>Eli Lilly and Company</b>&nbsp;climbed 10.4% to close at $275.28 after the company issued FY21 EPS guidance above analyst estimates.</li>\n <li><b>Borr Drilling Limited</b>&nbsp;gained 9.2% to close at $1.67 after declining over 4% on Tuesday..</li>\n <li><b>Galera Therapeutics, Inc.</b>&nbsp;gained 7.4% to close at $2.90 after BTIG upgraded the stock from Neutral to Buy and announced a $15 price target. Galera Therapeutics shares jumped around 96% on Tuesday after the company announced the primary endpoint met statistical significance in corrected topline efficacy data of Phase 3 ROMAN trial of avasopasem.</li>\n</ul>\n<p><b>Losers</b></p>\n<ul>\n <li><b>Atai Life Sciences N.V.</b>&nbsp;dropped 31.9% to close at $6.82 on Wednesday.</li>\n <li><b>China Xiangtai Food Co., Ltd.</b>&nbsp;fell 28.2% to settle at $1.81. The company earlier announced the completion of its first purchase of spot Bitcoin miners worth $7 million.</li>\n <li><b>Aspen Group, Inc.</b>&nbsp;shares declined 27.2% to close at $1.90 on Wednesday after the company reported worse-than-expected Q2 results and cut FY22 guidance.</li>\n <li><b>REV Group, Inc.</b>&nbsp;fell 25.5% to close at $11.87 after the company reported worse-than-expected Q4 EPS and sales results and issued FY22 sales guidance below estimates.</li>\n <li><b>Idera Pharmaceuticals, Inc.</b>&nbsp;shares dipped 25.3% to close at $0.6501 on Wednesday after the company announced tilsotolimod updates. The company said no further enrollment in ILLUMINATE-206 trial is planned at this point.</li>\n <li><b>LianBio</b>&nbsp;fell 21.3% to close at $7.68. LianBio reported a Q3 loss of $0.63 per share.</li>\n <li><b>The Oncology Institute, Inc.</b>&nbsp;fell 17.9% to close at $6.25.</li>\n <li><b>Alzamend Neuro, Inc.</b>&nbsp;fell 15.9% to close at $2.59 after jumping 28% on Tuesday.</li>\n <li><b>LogicBio Therapeutics, Inc</b>&nbsp;dropped 15.5% to close at $2.45. Barclays maintained LogicBio Therapeutics with an Overweight and lowered the price target from $24 to $8.</li>\n <li><b>Legend Biotech Corporation</b>&nbsp;shares fell 15.3% to close at $41.14 after the company reported an offering of $300 million in ADSs.</li>\n <li><b>Huadi International Group Co., Ltd.</b>&nbsp;fell 15% to close at $27.62.</li>\n <li><b>iSpecimen Inc.</b>&nbsp;fell 13.3% to close at $10.87.</li>\n <li><b>MIND Technology, Inc.</b>&nbsp;shares fell 12.9% to close at $1.55. MIND Technology shares gained 30% on Tuesday after the company reported it entered into a Cooperative Research and Development Agreement with the United States Navy's Naval Surface Warfare Center, Panama City Division.</li>\n <li><b>Adagio Therapeutics, Inc.</b>&nbsp;fell 12.5% to close at $6.35 after Stifel downgraded the stock from Buy to Hold and lowered the price target from $50 to $9. Adagio Therapeutics shares dipped 79% on Tuesday after the company said based on the in vitro findings related to Omicron, it plans to pause patient recruitment in its Phase 2/3 COVID-19 treatment trial at clinical sites in South Africa.</li>\n <li><b>Zai Lab Limited</b>&nbsp;fell 12.4% to close at $54.90.</li>\n <li><b>Cerence Inc.</b>&nbsp;dropped 11.4% to close at $69.20. Cerence’s board promoted Dr. Stefan Ortmanns to Chief Executive Officer and Director.</li>\n <li><b>ABM Industries Incorporated</b>&nbsp;fell 11% to close at $40.88 as the company reported fourth-quarter revenue growth of 14.2% year-over-year to $1.69 billion, comprised of 7.4% organic growth and 6.8% from acquisition.</li>\n <li><b>BeiGene, Ltd.</b>&nbsp;fell 10.7% to close at $248.56. BeiGene reported authorisation of BRUKINSA (zanubrutinib) from the UK’s MHRA for the treatment of adults with Waldenström’s Macroglobulinemia in Great Britain.</li>\n <li><b>Cooper-Standard Holdings Inc.</b>&nbsp;fell 7.1% to close at $19.71.</li>\n <li><b>Nisun International Enterprise Development Group Co., Ltd</b>&nbsp;fell 6.9% to close at $3.50.</li>\n <li><b>I-Mab</b>&nbsp;fell 5% to close at $46.97. I-Mab received IND approval for Phase 1 clinical trial of bispecific antibody TJ-CD4B in solid tumors in China.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>46 Biggest Movers From Yesterday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n46 Biggest Movers From Yesterday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 17:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/12/24638543/46-biggest-movers-from-yesterday><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gainers\n\nTheseus Pharmaceuticals, Inc. gained 34.1% to settle at $12.58 on Wednesday.\nCMC Materials, Inc. climbed 33.9% to close at $195.50 on Wednesday after the company announced it will be acquired...</p>\n\n<a href=\"https://www.benzinga.com/news/21/12/24638543/46-biggest-movers-from-yesterday\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","BGNE":"百济神州"},"source_url":"https://www.benzinga.com/news/21/12/24638543/46-biggest-movers-from-yesterday","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171817404","content_text":"Gainers\n\nTheseus Pharmaceuticals, Inc. gained 34.1% to settle at $12.58 on Wednesday.\nCMC Materials, Inc. climbed 33.9% to close at $195.50 on Wednesday after the company announced it will be acquired by Entegris for $6.5 billion in cash and stock.\nBiofrontera Inc. shares jumped 26.4% to settle at $6.95 on Wednesday after Benchmark initiated coverage on the stock with a Buy rating and announced a $11 price target.\nRegional Health Properties, Inc. gained 23.8% to close at $6.70.Regional Health Props, last month, posted a Q3 loss of $1.25 per share.\nGemini Therapeutics, Inc. rose 23.1% to settle at $2.99 after HC Wainwright & Co initiated coverage on the stock with a Buy rating and a $20 price target.\nCN Energy Group. Inc. jumped 22.4% to close at $3.01.\nMesoblast Limited climbed 19.2% to settle at $4.97. Mesoblast shares dropped around 28% on Tuesday after the company was notified by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing.\nBroadstone Acquisition Corp. gained 19.1% to close at $10.68.\nCabaletta Bio, Inc. jumped 18.2% to settle at $3.97.\nEnsysce Biosciences, Inc. surged 17.4% to close at $4.11. Ensysce Biosciences said that the first patients have been enrolled in Phase 1 study of PF614-MPAR, its unique technology platform to provide opioid overdose protection.\nTrio-Tech International gained 16.6% to close at $9.42.\nAerovate Therapeutics, Inc. jumped 16.3% to close at $12.34 after the company announced the initiation of its IMPAHCT Phase 2b/Phase 3 trial of AV-101 In Pulmonary Arterial Hypertension.\nOptical Cable Corporation gained 16.2% to settle at $6.40.\nConn's, Inc. rose 16.1% to close at $20.81. Conn's Board of Directors authorized a repurchase program of $150 million of its outstanding stock.\nDesign Therapeutics, Inc. surged 16% to settle at $20.36.\nBird Global, Inc. gained 15.7% to close at $8.97.\nVerifyMe, Inc. jumped 13.7% to close at $3.65.\nEast Stone Acquisition Corporation gained 12.9% to close at $15.24 after declining 26% on Tuesday.\nVir Biotechnology, Inc. gained 12.1% to close at $51.62 after the company announced new preclinical data demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant.\nSeaChange International, Inc. rose 11.9% to close at $1.69 after the company reported better-than-expected Q3 results.\nNxt-ID, Inc. shares rose 11.7% to close at $2.78 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers.\nTandem Diabetes Care, Inc. climbed 10.5% to close at $144.34.\nEli Lilly and Company climbed 10.4% to close at $275.28 after the company issued FY21 EPS guidance above analyst estimates.\nBorr Drilling Limited gained 9.2% to close at $1.67 after declining over 4% on Tuesday..\nGalera Therapeutics, Inc. gained 7.4% to close at $2.90 after BTIG upgraded the stock from Neutral to Buy and announced a $15 price target. Galera Therapeutics shares jumped around 96% on Tuesday after the company announced the primary endpoint met statistical significance in corrected topline efficacy data of Phase 3 ROMAN trial of avasopasem.\n\nLosers\n\nAtai Life Sciences N.V. dropped 31.9% to close at $6.82 on Wednesday.\nChina Xiangtai Food Co., Ltd. fell 28.2% to settle at $1.81. The company earlier announced the completion of its first purchase of spot Bitcoin miners worth $7 million.\nAspen Group, Inc. shares declined 27.2% to close at $1.90 on Wednesday after the company reported worse-than-expected Q2 results and cut FY22 guidance.\nREV Group, Inc. fell 25.5% to close at $11.87 after the company reported worse-than-expected Q4 EPS and sales results and issued FY22 sales guidance below estimates.\nIdera Pharmaceuticals, Inc. shares dipped 25.3% to close at $0.6501 on Wednesday after the company announced tilsotolimod updates. The company said no further enrollment in ILLUMINATE-206 trial is planned at this point.\nLianBio fell 21.3% to close at $7.68. LianBio reported a Q3 loss of $0.63 per share.\nThe Oncology Institute, Inc. fell 17.9% to close at $6.25.\nAlzamend Neuro, Inc. fell 15.9% to close at $2.59 after jumping 28% on Tuesday.\nLogicBio Therapeutics, Inc dropped 15.5% to close at $2.45. Barclays maintained LogicBio Therapeutics with an Overweight and lowered the price target from $24 to $8.\nLegend Biotech Corporation shares fell 15.3% to close at $41.14 after the company reported an offering of $300 million in ADSs.\nHuadi International Group Co., Ltd. fell 15% to close at $27.62.\niSpecimen Inc. fell 13.3% to close at $10.87.\nMIND Technology, Inc. shares fell 12.9% to close at $1.55. MIND Technology shares gained 30% on Tuesday after the company reported it entered into a Cooperative Research and Development Agreement with the United States Navy's Naval Surface Warfare Center, Panama City Division.\nAdagio Therapeutics, Inc. fell 12.5% to close at $6.35 after Stifel downgraded the stock from Buy to Hold and lowered the price target from $50 to $9. Adagio Therapeutics shares dipped 79% on Tuesday after the company said based on the in vitro findings related to Omicron, it plans to pause patient recruitment in its Phase 2/3 COVID-19 treatment trial at clinical sites in South Africa.\nZai Lab Limited fell 12.4% to close at $54.90.\nCerence Inc. dropped 11.4% to close at $69.20. Cerence’s board promoted Dr. Stefan Ortmanns to Chief Executive Officer and Director.\nABM Industries Incorporated fell 11% to close at $40.88 as the company reported fourth-quarter revenue growth of 14.2% year-over-year to $1.69 billion, comprised of 7.4% organic growth and 6.8% from acquisition.\nBeiGene, Ltd. fell 10.7% to close at $248.56. BeiGene reported authorisation of BRUKINSA (zanubrutinib) from the UK’s MHRA for the treatment of adults with Waldenström’s Macroglobulinemia in Great Britain.\nCooper-Standard Holdings Inc. fell 7.1% to close at $19.71.\nNisun International Enterprise Development Group Co., Ltd fell 6.9% to close at $3.50.\nI-Mab fell 5% to close at $46.97. I-Mab received IND approval for Phase 1 clinical trial of bispecific antibody TJ-CD4B in solid tumors in China.","news_type":1},"isVote":1,"tweetType":1,"viewCount":307,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607593319,"gmtCreate":1639557284217,"gmtModify":1639557284489,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/607593319","repostId":"1107549050","repostType":4,"repost":{"id":"1107549050","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639552499,"share":"https://www.laohu8.com/m/news/1107549050?lang=&edition=full","pubTime":"2021-12-15 15:14","market":"us","language":"en","title":"Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=1107549050","media":"Tiger Newspress","summary":"Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and c","content":"<p><b>Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation</b></p>\n<ul>\n <li>Positive booster data show that neutralizing antibodies increased across all primary vaccines received (mRNA or adenovirus) in a 9- to 43-fold range and for all age groups tested, with a good safety and tolerability profile</li>\n <li>Phase 3 trial continues to accrue number of events needed for analysis as populations around the world are increasingly exposed to COVID-19 variants; results expected in Q1, 2022</li>\n <li>Companies intend to file booster data with regulatory authorities following the Phase 3 results</li>\n</ul>\n<p>Sanofi and GSK announced today that a single booster dose of their recombinant adjuvanted COVID-19 vaccine candidate delivered consistently strong immune responses. Preliminary results from the VAT0002 clinical trial investigating the safety and immunogenicity of the booster showed neutralizing antibodies increased 9- to 43-fold regardless of the primary vaccine received (AstraZeneca, Johnson &amp; Johnson, Moderna, Pfizer/BioNTech) and for all age groups tested. The booster was well tolerated, with a safety profile similar to currently approved COVID-19 vaccines. This is the most comprehensive booster trial to date to explore boosting across different vaccine technologies used for primary vaccination.</p>\n<p>The ongoing global Phase 3 trial, VAT0008, includes regular reviews by an independent Data Safety Monitoring Board (DSMB). During its last review, the DSMB identified no safety concerns and recommended the trial to continue into early 2022 to accrue more data.</p>\n<p>Regulatory authorities require Phase 3 efficacy to be demonstrated in “naive” populations, i.e. participants who have never been infected by the COVID-19 virus (seronegative). The Phase 3 trial recruited most participants in Q3 2021, coinciding with a significant increase in the number of people infected by the COVID-19 virus globally due to the Delta variant. To provide the necessary data to regulatory authorities for the booster vaccine submission, the trial will continue to accrue the number of events needed for analysis, with results expected in Q1, 2022.</p>\n<p><i>“These preliminary data show we have a strong booster candidate, whatever primary vaccine you have received.”</i>said Thomas Triomphe, Executive Vice President, Sanofi Pasteur.<i>“This is consistent with our efforts to provide relevantresponses to evolving public health needs. While pursuing a phase 3 trial is a challenge in a quickly shifting pandemic environment, we look forward to seeing the results to support submissions of our booster vaccine as quickly as possible.”</i></p>\n<p>Roger Connor, President of GSK Vaccines, added<i>: “As the pandemic threat continues with the current dominant Delta variant and Omicron rapidly gaining ground, booster vaccines will continue to be needed to help protect people over time. The initial booster data are promising, and we await the phase III results to determine the next steps on making protein-based adjuvanted COVID-19 vaccines available.\"</i></p>\n<p>In parallel, Sanofi continues its contribution to global public health needs with the manufacturing of up to half a billion doses from BioNTech/Pfizer, Moderna, and Johnson &amp; Johnson vaccines.</p>\n<p><b>About the booster trial (VAT0002)</b></p>\n<p>The VAT0002 extension trial is the most comprehensive heterologous booster trial conducted to date. In the first cohort of this trial, the four most-widely approved COVID-19 primary vaccines using mRNA and adenovirus vector technologies were boosted with the Sanofi/GSK protein-based adjuvanted vaccine candidate after full primary vaccination to assess its safety profile and immunogenicity.</p>\n<p>Participants in the first cohort (n=521) had previously been vaccinated with the approved dosing schedule of an authorized COVID-19 mRNA vaccine (Moderna, Pfizer/BioNTech,) or adenovirus vector vaccine (AstraZeneca, Johnson &amp; Johnson,). This preliminary analysis includes data from trial participants who received one 5µg booster dose of the adjuvanted recombinant protein vaccine targeting the D614 parent virus, between four and ten months after a complete primary vaccination schedule.</p>\n<p>The trial is ongoing across sites in multiple countries, including the U.S., France, and the UK. To address the emergence of COVID-19 variants of concern, additional trial cohorts are assessing the boosting potential of monovalent and bivalent vaccine formulations also containing the Beta (B.1.351) variant. More data from this trial are expected during the first half of 2022. The Omicron variant was not circulating during the trial. Using sera from booster trial participants, testing is underway to establish the ability of the vaccine candidate to cross-neutralize against Omicron.</p>\n<p><b>About the Phase 3 efficacy trial (VAT0008)</b></p>\n<p>The primary endpoint of this ongoing Phase 3, randomized, double-blind, placebo-controlled trial is the prevention of symptomatic COVID-19 in SARS-CoV-2 naïve adults, with secondary endpoints of preventing severe COVID-19 disease and infection. Stage one of the trial is assessing the efficacy of a vaccine formulation containing the spike protein against the original D614 (parent) virus in more than 10,000 participants &gt;18 years of age, randomized to receive two doses of 10µg vaccine or placebo at day 1 and day 22 across sites in the US, Asia, Africa and Latin America. A second stage in the trial is evaluating a second bivalent formulation, adding the spike protein of the B.1.351 (Beta) variant.</p>\n<p>These efforts are supported by federal funds from the Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services in collaboration with the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense under Contract # W15QKN-16-9-1002.</p>\n<p><b>About the Sanofi and GSK collaboration</b></p>\n<p>In the collaboration between the two companies, Sanofi provides its recombinant antigen and GSK contributes its pandemic adjuvant, both established vaccine platforms that have proven successful against influenza.</p>\n<p><b>About GSK</b></p>\n<p>GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GSK is the leading manufacturer of vaccines globally.</p>\n<p><b>About Sanofi</b></p>\n<p>Sanofi is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. It prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. It stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.</p>\n<p>With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-15 15:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation</b></p>\n<ul>\n <li>Positive booster data show that neutralizing antibodies increased across all primary vaccines received (mRNA or adenovirus) in a 9- to 43-fold range and for all age groups tested, with a good safety and tolerability profile</li>\n <li>Phase 3 trial continues to accrue number of events needed for analysis as populations around the world are increasingly exposed to COVID-19 variants; results expected in Q1, 2022</li>\n <li>Companies intend to file booster data with regulatory authorities following the Phase 3 results</li>\n</ul>\n<p>Sanofi and GSK announced today that a single booster dose of their recombinant adjuvanted COVID-19 vaccine candidate delivered consistently strong immune responses. Preliminary results from the VAT0002 clinical trial investigating the safety and immunogenicity of the booster showed neutralizing antibodies increased 9- to 43-fold regardless of the primary vaccine received (AstraZeneca, Johnson &amp; Johnson, Moderna, Pfizer/BioNTech) and for all age groups tested. The booster was well tolerated, with a safety profile similar to currently approved COVID-19 vaccines. This is the most comprehensive booster trial to date to explore boosting across different vaccine technologies used for primary vaccination.</p>\n<p>The ongoing global Phase 3 trial, VAT0008, includes regular reviews by an independent Data Safety Monitoring Board (DSMB). During its last review, the DSMB identified no safety concerns and recommended the trial to continue into early 2022 to accrue more data.</p>\n<p>Regulatory authorities require Phase 3 efficacy to be demonstrated in “naive” populations, i.e. participants who have never been infected by the COVID-19 virus (seronegative). The Phase 3 trial recruited most participants in Q3 2021, coinciding with a significant increase in the number of people infected by the COVID-19 virus globally due to the Delta variant. To provide the necessary data to regulatory authorities for the booster vaccine submission, the trial will continue to accrue the number of events needed for analysis, with results expected in Q1, 2022.</p>\n<p><i>“These preliminary data show we have a strong booster candidate, whatever primary vaccine you have received.”</i>said Thomas Triomphe, Executive Vice President, Sanofi Pasteur.<i>“This is consistent with our efforts to provide relevantresponses to evolving public health needs. While pursuing a phase 3 trial is a challenge in a quickly shifting pandemic environment, we look forward to seeing the results to support submissions of our booster vaccine as quickly as possible.”</i></p>\n<p>Roger Connor, President of GSK Vaccines, added<i>: “As the pandemic threat continues with the current dominant Delta variant and Omicron rapidly gaining ground, booster vaccines will continue to be needed to help protect people over time. The initial booster data are promising, and we await the phase III results to determine the next steps on making protein-based adjuvanted COVID-19 vaccines available.\"</i></p>\n<p>In parallel, Sanofi continues its contribution to global public health needs with the manufacturing of up to half a billion doses from BioNTech/Pfizer, Moderna, and Johnson &amp; Johnson vaccines.</p>\n<p><b>About the booster trial (VAT0002)</b></p>\n<p>The VAT0002 extension trial is the most comprehensive heterologous booster trial conducted to date. In the first cohort of this trial, the four most-widely approved COVID-19 primary vaccines using mRNA and adenovirus vector technologies were boosted with the Sanofi/GSK protein-based adjuvanted vaccine candidate after full primary vaccination to assess its safety profile and immunogenicity.</p>\n<p>Participants in the first cohort (n=521) had previously been vaccinated with the approved dosing schedule of an authorized COVID-19 mRNA vaccine (Moderna, Pfizer/BioNTech,) or adenovirus vector vaccine (AstraZeneca, Johnson &amp; Johnson,). This preliminary analysis includes data from trial participants who received one 5µg booster dose of the adjuvanted recombinant protein vaccine targeting the D614 parent virus, between four and ten months after a complete primary vaccination schedule.</p>\n<p>The trial is ongoing across sites in multiple countries, including the U.S., France, and the UK. To address the emergence of COVID-19 variants of concern, additional trial cohorts are assessing the boosting potential of monovalent and bivalent vaccine formulations also containing the Beta (B.1.351) variant. More data from this trial are expected during the first half of 2022. The Omicron variant was not circulating during the trial. Using sera from booster trial participants, testing is underway to establish the ability of the vaccine candidate to cross-neutralize against Omicron.</p>\n<p><b>About the Phase 3 efficacy trial (VAT0008)</b></p>\n<p>The primary endpoint of this ongoing Phase 3, randomized, double-blind, placebo-controlled trial is the prevention of symptomatic COVID-19 in SARS-CoV-2 naïve adults, with secondary endpoints of preventing severe COVID-19 disease and infection. Stage one of the trial is assessing the efficacy of a vaccine formulation containing the spike protein against the original D614 (parent) virus in more than 10,000 participants &gt;18 years of age, randomized to receive two doses of 10µg vaccine or placebo at day 1 and day 22 across sites in the US, Asia, Africa and Latin America. A second stage in the trial is evaluating a second bivalent formulation, adding the spike protein of the B.1.351 (Beta) variant.</p>\n<p>These efforts are supported by federal funds from the Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services in collaboration with the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense under Contract # W15QKN-16-9-1002.</p>\n<p><b>About the Sanofi and GSK collaboration</b></p>\n<p>In the collaboration between the two companies, Sanofi provides its recombinant antigen and GSK contributes its pandemic adjuvant, both established vaccine platforms that have proven successful against influenza.</p>\n<p><b>About GSK</b></p>\n<p>GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GSK is the leading manufacturer of vaccines globally.</p>\n<p><b>About Sanofi</b></p>\n<p>Sanofi is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. It prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. It stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.</p>\n<p>With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNY":"赛诺菲安万特","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107549050","content_text":"Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation\n\nPositive booster data show that neutralizing antibodies increased across all primary vaccines received (mRNA or adenovirus) in a 9- to 43-fold range and for all age groups tested, with a good safety and tolerability profile\nPhase 3 trial continues to accrue number of events needed for analysis as populations around the world are increasingly exposed to COVID-19 variants; results expected in Q1, 2022\nCompanies intend to file booster data with regulatory authorities following the Phase 3 results\n\nSanofi and GSK announced today that a single booster dose of their recombinant adjuvanted COVID-19 vaccine candidate delivered consistently strong immune responses. Preliminary results from the VAT0002 clinical trial investigating the safety and immunogenicity of the booster showed neutralizing antibodies increased 9- to 43-fold regardless of the primary vaccine received (AstraZeneca, Johnson & Johnson, Moderna, Pfizer/BioNTech) and for all age groups tested. The booster was well tolerated, with a safety profile similar to currently approved COVID-19 vaccines. This is the most comprehensive booster trial to date to explore boosting across different vaccine technologies used for primary vaccination.\nThe ongoing global Phase 3 trial, VAT0008, includes regular reviews by an independent Data Safety Monitoring Board (DSMB). During its last review, the DSMB identified no safety concerns and recommended the trial to continue into early 2022 to accrue more data.\nRegulatory authorities require Phase 3 efficacy to be demonstrated in “naive” populations, i.e. participants who have never been infected by the COVID-19 virus (seronegative). The Phase 3 trial recruited most participants in Q3 2021, coinciding with a significant increase in the number of people infected by the COVID-19 virus globally due to the Delta variant. To provide the necessary data to regulatory authorities for the booster vaccine submission, the trial will continue to accrue the number of events needed for analysis, with results expected in Q1, 2022.\n“These preliminary data show we have a strong booster candidate, whatever primary vaccine you have received.”said Thomas Triomphe, Executive Vice President, Sanofi Pasteur.“This is consistent with our efforts to provide relevantresponses to evolving public health needs. While pursuing a phase 3 trial is a challenge in a quickly shifting pandemic environment, we look forward to seeing the results to support submissions of our booster vaccine as quickly as possible.”\nRoger Connor, President of GSK Vaccines, added: “As the pandemic threat continues with the current dominant Delta variant and Omicron rapidly gaining ground, booster vaccines will continue to be needed to help protect people over time. The initial booster data are promising, and we await the phase III results to determine the next steps on making protein-based adjuvanted COVID-19 vaccines available.\"\nIn parallel, Sanofi continues its contribution to global public health needs with the manufacturing of up to half a billion doses from BioNTech/Pfizer, Moderna, and Johnson & Johnson vaccines.\nAbout the booster trial (VAT0002)\nThe VAT0002 extension trial is the most comprehensive heterologous booster trial conducted to date. In the first cohort of this trial, the four most-widely approved COVID-19 primary vaccines using mRNA and adenovirus vector technologies were boosted with the Sanofi/GSK protein-based adjuvanted vaccine candidate after full primary vaccination to assess its safety profile and immunogenicity.\nParticipants in the first cohort (n=521) had previously been vaccinated with the approved dosing schedule of an authorized COVID-19 mRNA vaccine (Moderna, Pfizer/BioNTech,) or adenovirus vector vaccine (AstraZeneca, Johnson & Johnson,). This preliminary analysis includes data from trial participants who received one 5µg booster dose of the adjuvanted recombinant protein vaccine targeting the D614 parent virus, between four and ten months after a complete primary vaccination schedule.\nThe trial is ongoing across sites in multiple countries, including the U.S., France, and the UK. To address the emergence of COVID-19 variants of concern, additional trial cohorts are assessing the boosting potential of monovalent and bivalent vaccine formulations also containing the Beta (B.1.351) variant. More data from this trial are expected during the first half of 2022. The Omicron variant was not circulating during the trial. Using sera from booster trial participants, testing is underway to establish the ability of the vaccine candidate to cross-neutralize against Omicron.\nAbout the Phase 3 efficacy trial (VAT0008)\nThe primary endpoint of this ongoing Phase 3, randomized, double-blind, placebo-controlled trial is the prevention of symptomatic COVID-19 in SARS-CoV-2 naïve adults, with secondary endpoints of preventing severe COVID-19 disease and infection. Stage one of the trial is assessing the efficacy of a vaccine formulation containing the spike protein against the original D614 (parent) virus in more than 10,000 participants >18 years of age, randomized to receive two doses of 10µg vaccine or placebo at day 1 and day 22 across sites in the US, Asia, Africa and Latin America. A second stage in the trial is evaluating a second bivalent formulation, adding the spike protein of the B.1.351 (Beta) variant.\nThese efforts are supported by federal funds from the Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services in collaboration with the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense under Contract # W15QKN-16-9-1002.\nAbout the Sanofi and GSK collaboration\nIn the collaboration between the two companies, Sanofi provides its recombinant antigen and GSK contributes its pandemic adjuvant, both established vaccine platforms that have proven successful against influenza.\nAbout GSK\nGSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GSK is the leading manufacturer of vaccines globally.\nAbout Sanofi\nSanofi is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. It prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. It stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.\nWith more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.","news_type":1},"isVote":1,"tweetType":1,"viewCount":371,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604715891,"gmtCreate":1639446003056,"gmtModify":1639446003328,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604715891","repostId":"2191984334","repostType":4,"repost":{"id":"2191984334","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639435732,"share":"https://www.laohu8.com/m/news/2191984334?lang=&edition=full","pubTime":"2021-12-14 06:48","market":"us","language":"en","title":"Wall Street ends down; investors eye Omicron and Fed meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2191984334","media":"Reuters","summary":"* Pfizer to buy Arena Pharma, shares of both companies rise\n* Meme stocks GameStop, AMC slump to mul","content":"<p>* Pfizer to buy Arena Pharma, shares of both companies rise</p>\n<p>*&nbsp;Meme stocks GameStop, AMC slump to multi-month lows</p>\n<p>* Consumer discretionary, energy lead declines</p>\n<p>Dec 13 (Reuters) - Wall Street ended lower on Monday, with shares of Carnival Corp and several airlines tumbling as investors worried about the Omicron coronavirus variant ahead of a Federal Reserve meeting later this week.</p>\n<p>Travel-related stocks fell, with the fast-spreading variant accounting for around 40% of COVID-19 infections in London and at least one death in the United Kingdom.</p>\n<p>Norwegian Cruise Line Holdings, Carnival Corp&nbsp;and Royal Caribbean Cruises&nbsp;all slumped more than 4%, while the S&amp;P 1500 airlines index&nbsp;shed about 3%.</p>\n<p>\"It's transportation, restaurants, all the things that if it got bad enough that we started putting new restrictions on people, it would not be good for them,\" said Tom Martin, senior portfolio manager at Globalt Investments in Atlanta. \"They have all been bid over the past several months by the idea that we were going to get back to business as usual.\"</p>\n<p>Most of the 11 major S&amp;P 500 sector indexes fell, with only defensive sectors, including consumer staples, utilities&nbsp;and real estate&nbsp;gaining.</p>\n<p>The Dow Jones Industrial Average&nbsp;fell 0.89% to end at 35,650.95 points, while the S&amp;P 500&nbsp;lost 0.91% to 4,668.97.</p>\n<p>The Nasdaq Composite&nbsp;dropped 1.39% to 15,413.28.</p>\n<p>Following Monday's dip, the S&amp;P 500 remains up about 24% year to date.</p>\n<p>Apple Inc&nbsp;dipped 2.1%, even after J.P. Morgan raised its price target on the iPhone maker to the highest on Wall Street. The company is close to becoming the first in the world to hit $3 trillion in market value.</p>\n<p>Investors expect an increasingly hawkish tone out of the Federal Reserve's two-day meeting that wraps up on Wednesday. The U.S. central bank is expected to signal a faster wind-down of asset purchases, which could also usher closer a start to interest rate hikes.</p>\n<p>\"Everyone is focused on the Fed this week and what guidance we get in terms of bond purchases and interest rates. There's an expectation that there will be an acceleration of tapering, and there's a little anxiety leading up to that,\" said Ryan Jacob, chief portfolio manager at Jacob Internet Fund.</p>\n<p>A Reuters poll of economists sees the central bank hiking interest rates from near zero to 0.25%-0.50% in the third quarter of next year, followed by another in the fourth quarter.</p>\n<p>Positive updates about vaccines and antibody cocktails to combat the new COVID-19 variant, along with a recent reading on inflation that was in line with consensus, pushed the S&amp;P 500&nbsp;index to a record closing high on Friday.</p>\n<p>Pfizer Inc&nbsp;rose 4.6% after it agreed to acquire Arena Pharmaceuticals&nbsp;in a $6.7 billion all-cash deal. Arena's shares surged 80%.</p>\n<p>Shares of Gamestop&nbsp;and AMC Entertainment&nbsp;tumbled to multi-month lows on Monday as some investors appeared to sour on the names that had produced eye-watering gains earlier in the year.</p>\n<p>Video game retailer GameStop tumbled 13.9% at $136.88, briefly touching its lowest level since April, while movie theater operator AMC slumped 15.3% to $23.24, a level last seen in May.</p>\n<p>Volume on U.S. exchanges was 10.4 billion shares, compared with the 11.4 billion average over the last 20 trading days.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 2.30-to-1 ratio; on Nasdaq, a 2.53-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 52 new 52-week highs and 4 new lows; the Nasdaq Composite recorded 33 new highs and 302 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends down; investors eye Omicron and Fed meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends down; investors eye Omicron and Fed meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-14 06:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Pfizer to buy Arena Pharma, shares of both companies rise</p>\n<p>*&nbsp;Meme stocks GameStop, AMC slump to multi-month lows</p>\n<p>* Consumer discretionary, energy lead declines</p>\n<p>Dec 13 (Reuters) - Wall Street ended lower on Monday, with shares of Carnival Corp and several airlines tumbling as investors worried about the Omicron coronavirus variant ahead of a Federal Reserve meeting later this week.</p>\n<p>Travel-related stocks fell, with the fast-spreading variant accounting for around 40% of COVID-19 infections in London and at least one death in the United Kingdom.</p>\n<p>Norwegian Cruise Line Holdings, Carnival Corp&nbsp;and Royal Caribbean Cruises&nbsp;all slumped more than 4%, while the S&amp;P 1500 airlines index&nbsp;shed about 3%.</p>\n<p>\"It's transportation, restaurants, all the things that if it got bad enough that we started putting new restrictions on people, it would not be good for them,\" said Tom Martin, senior portfolio manager at Globalt Investments in Atlanta. \"They have all been bid over the past several months by the idea that we were going to get back to business as usual.\"</p>\n<p>Most of the 11 major S&amp;P 500 sector indexes fell, with only defensive sectors, including consumer staples, utilities&nbsp;and real estate&nbsp;gaining.</p>\n<p>The Dow Jones Industrial Average&nbsp;fell 0.89% to end at 35,650.95 points, while the S&amp;P 500&nbsp;lost 0.91% to 4,668.97.</p>\n<p>The Nasdaq Composite&nbsp;dropped 1.39% to 15,413.28.</p>\n<p>Following Monday's dip, the S&amp;P 500 remains up about 24% year to date.</p>\n<p>Apple Inc&nbsp;dipped 2.1%, even after J.P. Morgan raised its price target on the iPhone maker to the highest on Wall Street. The company is close to becoming the first in the world to hit $3 trillion in market value.</p>\n<p>Investors expect an increasingly hawkish tone out of the Federal Reserve's two-day meeting that wraps up on Wednesday. The U.S. central bank is expected to signal a faster wind-down of asset purchases, which could also usher closer a start to interest rate hikes.</p>\n<p>\"Everyone is focused on the Fed this week and what guidance we get in terms of bond purchases and interest rates. There's an expectation that there will be an acceleration of tapering, and there's a little anxiety leading up to that,\" said Ryan Jacob, chief portfolio manager at Jacob Internet Fund.</p>\n<p>A Reuters poll of economists sees the central bank hiking interest rates from near zero to 0.25%-0.50% in the third quarter of next year, followed by another in the fourth quarter.</p>\n<p>Positive updates about vaccines and antibody cocktails to combat the new COVID-19 variant, along with a recent reading on inflation that was in line with consensus, pushed the S&amp;P 500&nbsp;index to a record closing high on Friday.</p>\n<p>Pfizer Inc&nbsp;rose 4.6% after it agreed to acquire Arena Pharmaceuticals&nbsp;in a $6.7 billion all-cash deal. Arena's shares surged 80%.</p>\n<p>Shares of Gamestop&nbsp;and AMC Entertainment&nbsp;tumbled to multi-month lows on Monday as some investors appeared to sour on the names that had produced eye-watering gains earlier in the year.</p>\n<p>Video game retailer GameStop tumbled 13.9% at $136.88, briefly touching its lowest level since April, while movie theater operator AMC slumped 15.3% to $23.24, a level last seen in May.</p>\n<p>Volume on U.S. exchanges was 10.4 billion shares, compared with the 11.4 billion average over the last 20 trading days.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 2.30-to-1 ratio; on Nasdaq, a 2.53-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 52 new 52-week highs and 4 new lows; the Nasdaq Composite recorded 33 new highs and 302 new lows.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","SQQQ":"纳指三倍做空ETF","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","DOG":"道指反向ETF","NCLH":"挪威邮轮","BK4007":"制药","QLD":"纳指两倍做多ETF","PFE":"辉瑞","BK4568":"美国抗疫概念","TQQQ":"纳指三倍做多ETF","SDOW":"道指三倍做空ETF-ProShares","BK4517":"邮轮概念","PSQ":"纳指反向ETF","UDOW":"道指三倍做多ETF-ProShares","QQQ":"纳指100ETF","CCL":"嘉年华邮轮","RCL":"皇家加勒比邮轮","BK4142":"酒店、度假村与豪华游轮","DXD":"道指两倍做空ETF","DJX":"1/100道琼斯","QID":"纳指两倍做空ETF","DDM":"道指两倍做多ETF","ARNA":"阿里那"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191984334","content_text":"* Pfizer to buy Arena Pharma, shares of both companies rise\n* Meme stocks GameStop, AMC slump to multi-month lows\n* Consumer discretionary, energy lead declines\nDec 13 (Reuters) - Wall Street ended lower on Monday, with shares of Carnival Corp and several airlines tumbling as investors worried about the Omicron coronavirus variant ahead of a Federal Reserve meeting later this week.\nTravel-related stocks fell, with the fast-spreading variant accounting for around 40% of COVID-19 infections in London and at least one death in the United Kingdom.\nNorwegian Cruise Line Holdings, Carnival Corp and Royal Caribbean Cruises all slumped more than 4%, while the S&P 1500 airlines index shed about 3%.\n\"It's transportation, restaurants, all the things that if it got bad enough that we started putting new restrictions on people, it would not be good for them,\" said Tom Martin, senior portfolio manager at Globalt Investments in Atlanta. \"They have all been bid over the past several months by the idea that we were going to get back to business as usual.\"\nMost of the 11 major S&P 500 sector indexes fell, with only defensive sectors, including consumer staples, utilities and real estate gaining.\nThe Dow Jones Industrial Average fell 0.89% to end at 35,650.95 points, while the S&P 500 lost 0.91% to 4,668.97.\nThe Nasdaq Composite dropped 1.39% to 15,413.28.\nFollowing Monday's dip, the S&P 500 remains up about 24% year to date.\nApple Inc dipped 2.1%, even after J.P. Morgan raised its price target on the iPhone maker to the highest on Wall Street. The company is close to becoming the first in the world to hit $3 trillion in market value.\nInvestors expect an increasingly hawkish tone out of the Federal Reserve's two-day meeting that wraps up on Wednesday. The U.S. central bank is expected to signal a faster wind-down of asset purchases, which could also usher closer a start to interest rate hikes.\n\"Everyone is focused on the Fed this week and what guidance we get in terms of bond purchases and interest rates. There's an expectation that there will be an acceleration of tapering, and there's a little anxiety leading up to that,\" said Ryan Jacob, chief portfolio manager at Jacob Internet Fund.\nA Reuters poll of economists sees the central bank hiking interest rates from near zero to 0.25%-0.50% in the third quarter of next year, followed by another in the fourth quarter.\nPositive updates about vaccines and antibody cocktails to combat the new COVID-19 variant, along with a recent reading on inflation that was in line with consensus, pushed the S&P 500 index to a record closing high on Friday.\nPfizer Inc rose 4.6% after it agreed to acquire Arena Pharmaceuticals in a $6.7 billion all-cash deal. Arena's shares surged 80%.\nShares of Gamestop and AMC Entertainment tumbled to multi-month lows on Monday as some investors appeared to sour on the names that had produced eye-watering gains earlier in the year.\nVideo game retailer GameStop tumbled 13.9% at $136.88, briefly touching its lowest level since April, while movie theater operator AMC slumped 15.3% to $23.24, a level last seen in May.\nVolume on U.S. exchanges was 10.4 billion shares, compared with the 11.4 billion average over the last 20 trading days.\nDeclining issues outnumbered advancing ones on the NYSE by a 2.30-to-1 ratio; on Nasdaq, a 2.53-to-1 ratio favored decliners.\nThe S&P 500 posted 52 new 52-week highs and 4 new lows; the Nasdaq Composite recorded 33 new highs and 302 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604376669,"gmtCreate":1639355631085,"gmtModify":1639355631492,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604376669","repostId":"1171271872","repostType":4,"repost":{"id":"1171271872","pubTimestamp":1639348466,"share":"https://www.laohu8.com/m/news/1171271872?lang=&edition=full","pubTime":"2021-12-13 06:34","market":"us","language":"en","title":"Rivian,Adobe,FedEx,Lennar,Campbell Soup,and Other Stocks to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1171271872","media":"Barrons","summary":"The main event for investors this week will be the Federal Reserve’s rate-setting committee’s last meeting of 2021. Recent commentary from officials has leaned more hawkish, setting up a potential announcement of plans to accelerate monthly asset purchase tapering.The Federal Open Market Committee’s two-day meeting takes place on Tuesday and Wednesday.Earnings reports this week are few, but will include Campbell Soup on Tuesday;Lennar,Accenture,FedEx,Rivian Automotive, and Adobe on Thursday; and","content":"<p>The main event for investors this week will be the Federal Reserve’s rate-setting committee’s&nbsp;last meeting of 2021. Recent commentary from officials has leaned more hawkish, setting up a potential announcement of plans to accelerate monthly asset purchase tapering.</p>\n<p>The Federal Open Market Committee’s two-day meeting takes place on Tuesday and Wednesday.</p>\n<p>Earnings reports this week are few, but will include&nbsp;Campbell Soup&nbsp;on Tuesday;Lennar,Accenture,FedEx,Rivian&nbsp;Automotive, and&nbsp;Adobe&nbsp;on Thursday; and&nbsp;Darden Restaurants&nbsp;on Friday.</p>\n<p>Economic data coming out this week includes the Bureau of Labor Statistics’ producer price index for November on Tuesday. Economists expect a 0.55% month-over-month rise for the headline index and a 0.4% gain for the core PPI. Those would both roughly match October’s pace of producer inflation.</p>\n<p>Other data releases include the National Federation of Independent Businesses’ sentiment&nbsp;index on Tuesday, November retail-sales spending from the Census Bureau on Wednesday, and the November housing starts on Thursday.</p>\n<p><b>Monday 12/13</b></p>\n<p>J.Jill&nbsp;and&nbsp;PHX Minerals&nbsp;host earnings conference calls.</p>\n<p><b>Tuesday 12/14</b></p>\n<p>Campbell Soup, Barnes Group, and&nbsp;Avaya Holdings&nbsp;host investor days.</p>\n<p><b>The Bureau of Labor</b>&nbsp;Statistics releases the producer price index for November. Consensus estimate is for a 0.55% month-over-month rise, and for the core PPI, which excludes food and energy, to gain 0.4%. This compares with increases of 0.6% and 0.4%, respectively, in October.</p>\n<p><b>The National Federation</b>&nbsp;of Independent Businesses reports its index, which surveys about 5,000 small-business owners across the country, for November. Expectations call for a reading of 98.3, compared with 98.2 in October.</p>\n<p><b>Wednesday 12/15</b></p>\n<p><b>The Federal Open Market Committee</b> concludes its two-day meeting, when policy makers will discuss accelerating the timetable for tapering monthly securities purchases.</p>\n<p><b>The BLS reports</b> export and import price data for November. Expectations are for a 0.5% month-over-month rise in export prices, while import prices are seen increasing 0.5%. This compares with gains of 1.5% and 1.2%, respectively, in October.</p>\n<p><b>The National Association</b> of Home Builders releases its NAHB/Wells Fargo Housing Market Index for December. Consensus estimate is for an 84 reading, compared with an 83 reading in November. The index peaked at 90 late last year, and home builders remain bullish on the housing market.</p>\n<p><b>The Census Bureau</b> reports on retail-sales spending for November. Expectations are for a seasonally adjusted 0.7% month-over-month increase in retail sales, compared with a 1.7% rise in October. Excluding autos, spending is seen rising 0.8%, compared with 1.7% in the previous period.</p>\n<p><b>Thursday 12/16</b></p>\n<p>Heico,Lennar, Accenture, FedEx, Jabil, Adobe, Rivian Automotive, and Nordson are among companies hosting earnings conference calls.</p>\n<p><b>The Census Bureau</b>releases its New Residential Construction report for November. The seasonally adjusted annual rate of housing starts is expected to be 1.563 million units, compared with 1.52 million in October. A housing start is counted when excavation begins on a home. Permits issued for new-home construction are expected to be 1.655 million, compared with 1.653 million in October.</p>\n<p><b>The Bank of England</b> announces its interest-rate decision and publishes the minutes of the meeting.</p>\n<p><b>The Federal Reserve</b> releases industrial production data for November. Economists are looking for a 0.6% rise, after a 1.6% increase in October. Capacity utilization is expected at 76.8, roughly in line with October’s 76.4%.</p>\n<p><b>Friday 12/17</b></p>\n<p>Steelcase,Darden Restaurants, and&nbsp;Quanex Building Products&nbsp;host earnings conference calls.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rivian,Adobe,FedEx,Lennar,Campbell Soup,and Other Stocks to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRivian,Adobe,FedEx,Lennar,Campbell Soup,and Other Stocks to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 06:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stocks-to-watch-this-week-fedex-rivian-lennar-campbell-adobe-51639330550?mod=hp_LEAD_3><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The main event for investors this week will be the Federal Reserve’s rate-setting committee’s last meeting of 2021. Recent commentary from officials has leaned more hawkish, setting up a potential ...</p>\n\n<a href=\"https://www.barrons.com/articles/stocks-to-watch-this-week-fedex-rivian-lennar-campbell-adobe-51639330550?mod=hp_LEAD_3\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","ADBE":"Adobe","PHX":"潘汉德尔油气","RIVN":"Rivian Automotive, Inc.","FDX":"联邦快递","HEI":"海科航空","JILL":"J.Jill Inc.","LEN":"莱纳建筑公司","DRI":"达登饭店","ACN":"埃森哲","CPB":"金宝汤",".SPX":"S&P 500 Index","SCS":"Steelcase Inc.",".IXIC":"NASDAQ Composite"},"source_url":"https://www.barrons.com/articles/stocks-to-watch-this-week-fedex-rivian-lennar-campbell-adobe-51639330550?mod=hp_LEAD_3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171271872","content_text":"The main event for investors this week will be the Federal Reserve’s rate-setting committee’s last meeting of 2021. Recent commentary from officials has leaned more hawkish, setting up a potential announcement of plans to accelerate monthly asset purchase tapering.\nThe Federal Open Market Committee’s two-day meeting takes place on Tuesday and Wednesday.\nEarnings reports this week are few, but will include Campbell Soup on Tuesday;Lennar,Accenture,FedEx,Rivian Automotive, and Adobe on Thursday; and Darden Restaurants on Friday.\nEconomic data coming out this week includes the Bureau of Labor Statistics’ producer price index for November on Tuesday. Economists expect a 0.55% month-over-month rise for the headline index and a 0.4% gain for the core PPI. Those would both roughly match October’s pace of producer inflation.\nOther data releases include the National Federation of Independent Businesses’ sentiment index on Tuesday, November retail-sales spending from the Census Bureau on Wednesday, and the November housing starts on Thursday.\nMonday 12/13\nJ.Jill and PHX Minerals host earnings conference calls.\nTuesday 12/14\nCampbell Soup, Barnes Group, and Avaya Holdings host investor days.\nThe Bureau of Labor Statistics releases the producer price index for November. Consensus estimate is for a 0.55% month-over-month rise, and for the core PPI, which excludes food and energy, to gain 0.4%. This compares with increases of 0.6% and 0.4%, respectively, in October.\nThe National Federation of Independent Businesses reports its index, which surveys about 5,000 small-business owners across the country, for November. Expectations call for a reading of 98.3, compared with 98.2 in October.\nWednesday 12/15\nThe Federal Open Market Committee concludes its two-day meeting, when policy makers will discuss accelerating the timetable for tapering monthly securities purchases.\nThe BLS reports export and import price data for November. Expectations are for a 0.5% month-over-month rise in export prices, while import prices are seen increasing 0.5%. This compares with gains of 1.5% and 1.2%, respectively, in October.\nThe National Association of Home Builders releases its NAHB/Wells Fargo Housing Market Index for December. Consensus estimate is for an 84 reading, compared with an 83 reading in November. The index peaked at 90 late last year, and home builders remain bullish on the housing market.\nThe Census Bureau reports on retail-sales spending for November. Expectations are for a seasonally adjusted 0.7% month-over-month increase in retail sales, compared with a 1.7% rise in October. Excluding autos, spending is seen rising 0.8%, compared with 1.7% in the previous period.\nThursday 12/16\nHeico,Lennar, Accenture, FedEx, Jabil, Adobe, Rivian Automotive, and Nordson are among companies hosting earnings conference calls.\nThe Census Bureaureleases its New Residential Construction report for November. The seasonally adjusted annual rate of housing starts is expected to be 1.563 million units, compared with 1.52 million in October. A housing start is counted when excavation begins on a home. Permits issued for new-home construction are expected to be 1.655 million, compared with 1.653 million in October.\nThe Bank of England announces its interest-rate decision and publishes the minutes of the meeting.\nThe Federal Reserve releases industrial production data for November. Economists are looking for a 0.6% rise, after a 1.6% increase in October. Capacity utilization is expected at 76.8, roughly in line with October’s 76.4%.\nFriday 12/17\nSteelcase,Darden Restaurants, and Quanex Building Products host earnings conference calls.","news_type":1},"isVote":1,"tweetType":1,"viewCount":475,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604090190,"gmtCreate":1639275981351,"gmtModify":1639275981579,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/604090190","repostId":"2190967197","repostType":4,"repost":{"id":"2190967197","pubTimestamp":1639273902,"share":"https://www.laohu8.com/m/news/2190967197?lang=&edition=full","pubTime":"2021-12-12 09:51","market":"us","language":"en","title":"At Its Highest Price in a Decade, Can Bank of America Go Higher in 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=2190967197","media":"Motley Fool","summary":"The bank now trades at a strong valuation but also has a good outlook for 2022.","content":"<p>What a year it's been for&nbsp;<b>Bank of America</b> (NYSE:BAC). The stock price is up 47% this year and is more than double the lows it hit at the very beginning of the pandemic. At about $44 per share, the stock is at its highest level in more than a decade. Warren Buffett knew what he was doing when he plowed more than $2 billion into the stock in mid-2020. With a premium valuation, can America's second-largest bank by assets go higher in 2022? Let's take a look.</p>\n<h2>What to expect in 2022</h2>\n<p>This year's earnings at most banks were lumpy, with billions in reserves being released after previously being built up to manage loan losses that didn't materialize. Banks also generated record revenue for investment banking and sales and trading, but then saw slacking loan growth in the extremely low-rate environment.</p>\n<p><img src=\"https://static.tigerbbs.com/4362e920486edd2b13dc87efb01af483\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Bank of America.</p>\n<p>That's why analysts' consensus earnings per share (EPS) estimate for Bank of America in 2022 is $3.17, down from the $3.51 expected this year. But while EPS is estimated to shrink, Bank of America's revenue is projected by analysts to grow from just shy of $90 billion this year to more than $94 billion in 2022. The releasing of billions of dollars of reserves this year artificially juiced earnings after a tough year in 2020, so that will likely go away as loan balances start to tick up, which inevitably requires banks to stash away reserve capital for the normal course of losses expected over the life of a loan portfolio.</p>\n<p>However, with inflation now very real, Bank of America's research team sees the Federal Reserve hiking its federal funds rate three times in 2022. It's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most asset-sensitive banks in the country, meaning the yields on more of its interest-earning assets such as loans will reprice higher than yields on its interest-bearing deposits like liabilities.</p>\n<p>In its third-quarter presentation, Bank of America management noted that a 1% parallel move in short- and long-term yields would result in more than $7 billion of net interest income over the next year. Assuming three rate hikes, the bank will get a lot of that added net interest income. And who knows: If loan growth can pick up, that could boost net interest income more.</p>\n<p>The outlook for investment banking and sales and trading is also likely improving for 2022. After phenomenal performances in 2020 and early 2021, many thought these lines of business, which tend to thrive during periods of volatility, might settle down -- and fixed-income, currencies, and commodities trading has slowed from record levels seen earlier this year.</p>\n<p>But&nbsp;<b>JPMorgan Chase</b> analysts released a research note in October that said as inflation gets higher and bond yields creep up, that will likely create more volatility in the markets, which is when trading can pick up because there is less liquidity. With the Fed speeding up the tapering of its bond-buying program, this will also reduce the amount of liquidity in the market.</p>\n<p>Also, Bank of America is coming off a strong year in investment banking with lots of mergers and acquisitions activity. In multiple quarters this year, Bank of America generated more than $2 billion in investment banking fees, which was near record levels. CEO Brian Moynihan said at a recent conference that he thinks the team can get another quarter topping $2 billion in the future.</p>\n<p>With a bullish outlook in so many of Bank of America's business lines, and considering that the bank is currently buying back a lot of stock, I am optimistic that 2022 can be another strong year for earnings.</p>\n<h2>How to value the stock</h2>\n<p>Banks trade relative to their earnings and also to their tangible book value (TBV), which is what a bank would be worth if it were liquidated.</p>\n<p><img src=\"https://static.tigerbbs.com/0e7815935a2d177dc95dc4356740046f\" tg-width=\"720\" tg-height=\"449\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>BAC P/E ratio data by YCharts.</p>\n<p>Over the past five years or so, Bank of America has traded in a range of about 7 times earnings to close to 20 times earnings. Most large banks trade in the 11-to-14 window. Its price-to-tangible book has ranged from around 100% to 200%, and 200% is certainly a strong price-to-TBV ratio in this low-rate environment.</p>\n<p>But Bank of America, in my opinion, is in the strongest position it's ever been in. The bank has significantly enhanced its corporate and investment banking division, improved its deposit base, and continues to be a dominant commercial lender. Its digital capabilities are much better now as well, which will pay off as the pandemic has accelerated digital banking trends.</p>\n<p>Banks also solved a huge reputational issue during the pandemic that has dogged them since the Great Recession. They escaped a significant and rapid downturn with superb credit quality and were part of the solution this time around instead of the main issue behind the meltdown. Because banks looked so bad coming out of the Great Recession, I think investors have been very wary to return to them.</p>\n<p>For all of these reasons, it wouldn't be unreasonable for the bank to trade at an earnings multiple in the upper echelon of its previous range. While some of the benefits of rate hikes have been priced in, I think a large-cap bank stock like Bank of America could trade at 15 times earnings, which it traded around the last time rates rose in 2017 and 2018. With EPS estimated at $3.17 in 2022, that implies a share price of $47.55, which does not imply a ton of upside from the current stock price.</p>\n<p>Again, some of the benefits I've discussed from higher rates are likely priced in, but those earnings estimates from analysts for 2022 could certainly be conservative, so there could be further upside as well.</p>\n<p>Are there higher-growth opportunities elsewhere? Probably. But on a much longer-term basis, I have all the confidence in the world that Bank of America can keep delivering strong and consistent returns for investors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>At Its Highest Price in a Decade, Can Bank of America Go Higher in 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAt Its Highest Price in a Decade, Can Bank of America Go Higher in 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-12 09:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/11/trading-high-price-decade-bank-of-america-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What a year it's been for Bank of America (NYSE:BAC). The stock price is up 47% this year and is more than double the lows it hit at the very beginning of the pandemic. At about $44 per share, the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/11/trading-high-price-decade-bank-of-america-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","BAC":"美国银行","BK4207":"综合性银行","BK4553":"喜马拉雅资本持仓","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/11/trading-high-price-decade-bank-of-america-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190967197","content_text":"What a year it's been for Bank of America (NYSE:BAC). The stock price is up 47% this year and is more than double the lows it hit at the very beginning of the pandemic. At about $44 per share, the stock is at its highest level in more than a decade. Warren Buffett knew what he was doing when he plowed more than $2 billion into the stock in mid-2020. With a premium valuation, can America's second-largest bank by assets go higher in 2022? Let's take a look.\nWhat to expect in 2022\nThis year's earnings at most banks were lumpy, with billions in reserves being released after previously being built up to manage loan losses that didn't materialize. Banks also generated record revenue for investment banking and sales and trading, but then saw slacking loan growth in the extremely low-rate environment.\n\nImage source: Bank of America.\nThat's why analysts' consensus earnings per share (EPS) estimate for Bank of America in 2022 is $3.17, down from the $3.51 expected this year. But while EPS is estimated to shrink, Bank of America's revenue is projected by analysts to grow from just shy of $90 billion this year to more than $94 billion in 2022. The releasing of billions of dollars of reserves this year artificially juiced earnings after a tough year in 2020, so that will likely go away as loan balances start to tick up, which inevitably requires banks to stash away reserve capital for the normal course of losses expected over the life of a loan portfolio.\nHowever, with inflation now very real, Bank of America's research team sees the Federal Reserve hiking its federal funds rate three times in 2022. It's one of the most asset-sensitive banks in the country, meaning the yields on more of its interest-earning assets such as loans will reprice higher than yields on its interest-bearing deposits like liabilities.\nIn its third-quarter presentation, Bank of America management noted that a 1% parallel move in short- and long-term yields would result in more than $7 billion of net interest income over the next year. Assuming three rate hikes, the bank will get a lot of that added net interest income. And who knows: If loan growth can pick up, that could boost net interest income more.\nThe outlook for investment banking and sales and trading is also likely improving for 2022. After phenomenal performances in 2020 and early 2021, many thought these lines of business, which tend to thrive during periods of volatility, might settle down -- and fixed-income, currencies, and commodities trading has slowed from record levels seen earlier this year.\nBut JPMorgan Chase analysts released a research note in October that said as inflation gets higher and bond yields creep up, that will likely create more volatility in the markets, which is when trading can pick up because there is less liquidity. With the Fed speeding up the tapering of its bond-buying program, this will also reduce the amount of liquidity in the market.\nAlso, Bank of America is coming off a strong year in investment banking with lots of mergers and acquisitions activity. In multiple quarters this year, Bank of America generated more than $2 billion in investment banking fees, which was near record levels. CEO Brian Moynihan said at a recent conference that he thinks the team can get another quarter topping $2 billion in the future.\nWith a bullish outlook in so many of Bank of America's business lines, and considering that the bank is currently buying back a lot of stock, I am optimistic that 2022 can be another strong year for earnings.\nHow to value the stock\nBanks trade relative to their earnings and also to their tangible book value (TBV), which is what a bank would be worth if it were liquidated.\n\nBAC P/E ratio data by YCharts.\nOver the past five years or so, Bank of America has traded in a range of about 7 times earnings to close to 20 times earnings. Most large banks trade in the 11-to-14 window. Its price-to-tangible book has ranged from around 100% to 200%, and 200% is certainly a strong price-to-TBV ratio in this low-rate environment.\nBut Bank of America, in my opinion, is in the strongest position it's ever been in. The bank has significantly enhanced its corporate and investment banking division, improved its deposit base, and continues to be a dominant commercial lender. Its digital capabilities are much better now as well, which will pay off as the pandemic has accelerated digital banking trends.\nBanks also solved a huge reputational issue during the pandemic that has dogged them since the Great Recession. They escaped a significant and rapid downturn with superb credit quality and were part of the solution this time around instead of the main issue behind the meltdown. Because banks looked so bad coming out of the Great Recession, I think investors have been very wary to return to them.\nFor all of these reasons, it wouldn't be unreasonable for the bank to trade at an earnings multiple in the upper echelon of its previous range. While some of the benefits of rate hikes have been priced in, I think a large-cap bank stock like Bank of America could trade at 15 times earnings, which it traded around the last time rates rose in 2017 and 2018. With EPS estimated at $3.17 in 2022, that implies a share price of $47.55, which does not imply a ton of upside from the current stock price.\nAgain, some of the benefits I've discussed from higher rates are likely priced in, but those earnings estimates from analysts for 2022 could certainly be conservative, so there could be further upside as well.\nAre there higher-growth opportunities elsewhere? Probably. But on a much longer-term basis, I have all the confidence in the world that Bank of America can keep delivering strong and consistent returns for investors.","news_type":1},"isVote":1,"tweetType":1,"viewCount":475,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605518587,"gmtCreate":1639189739043,"gmtModify":1639190167967,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605518587","repostId":"2190767366","repostType":4,"isVote":1,"tweetType":1,"viewCount":369,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605345611,"gmtCreate":1639122001547,"gmtModify":1639122065526,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/605345611","repostId":"2190964556","repostType":4,"repost":{"id":"2190964556","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639090919,"share":"https://www.laohu8.com/m/news/2190964556?lang=&edition=full","pubTime":"2021-12-10 07:01","market":"us","language":"en","title":"Wall St closes lower ahead of inflation data, Fed meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2190964556","media":"Reuters","summary":"Wall Street closed lower on Thursday as investors banked some profits after three straight days of g","content":"<p>Wall Street closed lower on Thursday as investors banked some profits after three straight days of gains and turned their focus toward upcoming inflation data and how it might influence the Federal Reserve's meeting next week.</p>\n<p>The Nasdaq was down more sharply than the S&amp;P 500 while the Dow was virtually flat, ending down less than 1 point.</p>\n<p>Investors were in a waiting game ahead of U.S. consumer prices index inflation data due Friday morning. A higher-than-expected reading would strengthen the case for a policy tightening decision at the U.S. central bank's meeting.</p>\n<p>In the first three days of the week, the Nasdaq rallied 4.7%, the S&amp;P advanced 3.6% and the Dow gained 3.4% as fears abated about the latest coronavirus variant Omicron.</p>\n<p>\"We had a rip roaring rally. There's still nervous people out there,\" said Dennis Dick, head of markets structure, proprietary trader at Bright Trading LLC in Las Vegas.</p>\n<p>\"We'd a Omicron relief rally but the underlying problem still remains, that the Fed's taking the punchbowl away.\"</p>\n<p>Joe Quinlan, chief market strategist for the CIO office of Bank of America, said investors may be taking profits and pausing buying after the three days of gains.</p>\n<p>\"Also there may be a little risk-off trade ahead of the CPI number on Friday,\" he said. \"If it comes in hotter than expected it really shines the light and the focus on the Fed meeting. The pressure would build on the Fed for a faster tapering.\"</p>\n<p>Fed Chair Powell signaled last week that the meeting would include a discussion about a faster tapering of bond-buying.</p>\n<p>\"It would reaffirm in many people's minds that the Fed is behind the curve,\" said Quinlan.</p>\n<p>If the inflation number implies a need to hike rates faster, this \"would put pressure on technology and give a bid to cyclicals\" he said.</p>\n<p>\"You'd want to buy the companies that could pass on these higher costs to consumers. That undermines the growth story. You want to own more cyclicals and value than growth,\" said Quinlan.</p>\n<p>A Reuters poll of economists predicted the Fed would raise rates by 25 basis points to 0.25-0.50% in the third quarter of next year. However, most saw the risk that a hike comes even sooner.</p>\n<p>The Dow Jones Industrial Average fell 0.06 points to 35,754.69, the S&amp;P 500 lost 33.76 points, or 0.72%, to 4,667.45 and the Nasdaq Composite dropped 269.62 points, or 1.71%, to 15,517.37.</p>\n<p>Nine of the 11 major S&amp;P sectors declined, with consumer discretionary down 1.7%, losing the most and real estate , down 1.4%, and information technology&nbsp;falling 1%, showing the next biggest losses.</p>\n<p>The only sector gainers were healthcare up 0.2% and consumer staples which clung to a 0.06% advance.</p>\n<p>Healthcare was boosted by a CVS Health Corp share gain of 4.5% after the drugstore operator raised its 2021 profit forecast.</p>\n<p>In consumer staples, heavyweight electric car maker Tesla&nbsp;was the biggest percentage decliner, falling 6%.</p>\n<p>Markets have seesawed since late November when the Omicron variant was discovered. Investors worried it could upend a global recovery at a time of surging inflation with Fed commentary exacerbating volatility.</p>\n<p>Wall Street's main indexes were supported this week by an update showing Pfizer and BioNTech's vaccine offered some protection against the Omicron variant.</p>\n<p>Data showed initial claims for state unemployment benefits tumbled 43,000 last week to 184,000, the lowest level in more than 52 years.</p>\n<p>GameStop Corp fell 10% after the video game retailer popular among retail investors said it was issued a subpoena by the U.S. securities regulator back in August for documents on an investigation into its share trading activity.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 3.03-to-1 ratio; on Nasdaq, a 3.05-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 23 new 52-week highs and 1 new lows; the Nasdaq Composite recorded 34 new highs and 68 new lows.</p>\n<p>On U.S. exchanges 9.75 billion shares changed hands compared with the 11.41 billion average for the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St closes lower ahead of inflation data, Fed meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St closes lower ahead of inflation data, Fed meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-10 07:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Wall Street closed lower on Thursday as investors banked some profits after three straight days of gains and turned their focus toward upcoming inflation data and how it might influence the Federal Reserve's meeting next week.</p>\n<p>The Nasdaq was down more sharply than the S&amp;P 500 while the Dow was virtually flat, ending down less than 1 point.</p>\n<p>Investors were in a waiting game ahead of U.S. consumer prices index inflation data due Friday morning. A higher-than-expected reading would strengthen the case for a policy tightening decision at the U.S. central bank's meeting.</p>\n<p>In the first three days of the week, the Nasdaq rallied 4.7%, the S&amp;P advanced 3.6% and the Dow gained 3.4% as fears abated about the latest coronavirus variant Omicron.</p>\n<p>\"We had a rip roaring rally. There's still nervous people out there,\" said Dennis Dick, head of markets structure, proprietary trader at Bright Trading LLC in Las Vegas.</p>\n<p>\"We'd a Omicron relief rally but the underlying problem still remains, that the Fed's taking the punchbowl away.\"</p>\n<p>Joe Quinlan, chief market strategist for the CIO office of Bank of America, said investors may be taking profits and pausing buying after the three days of gains.</p>\n<p>\"Also there may be a little risk-off trade ahead of the CPI number on Friday,\" he said. \"If it comes in hotter than expected it really shines the light and the focus on the Fed meeting. The pressure would build on the Fed for a faster tapering.\"</p>\n<p>Fed Chair Powell signaled last week that the meeting would include a discussion about a faster tapering of bond-buying.</p>\n<p>\"It would reaffirm in many people's minds that the Fed is behind the curve,\" said Quinlan.</p>\n<p>If the inflation number implies a need to hike rates faster, this \"would put pressure on technology and give a bid to cyclicals\" he said.</p>\n<p>\"You'd want to buy the companies that could pass on these higher costs to consumers. That undermines the growth story. You want to own more cyclicals and value than growth,\" said Quinlan.</p>\n<p>A Reuters poll of economists predicted the Fed would raise rates by 25 basis points to 0.25-0.50% in the third quarter of next year. However, most saw the risk that a hike comes even sooner.</p>\n<p>The Dow Jones Industrial Average fell 0.06 points to 35,754.69, the S&amp;P 500 lost 33.76 points, or 0.72%, to 4,667.45 and the Nasdaq Composite dropped 269.62 points, or 1.71%, to 15,517.37.</p>\n<p>Nine of the 11 major S&amp;P sectors declined, with consumer discretionary down 1.7%, losing the most and real estate , down 1.4%, and information technology&nbsp;falling 1%, showing the next biggest losses.</p>\n<p>The only sector gainers were healthcare up 0.2% and consumer staples which clung to a 0.06% advance.</p>\n<p>Healthcare was boosted by a CVS Health Corp share gain of 4.5% after the drugstore operator raised its 2021 profit forecast.</p>\n<p>In consumer staples, heavyweight electric car maker Tesla&nbsp;was the biggest percentage decliner, falling 6%.</p>\n<p>Markets have seesawed since late November when the Omicron variant was discovered. Investors worried it could upend a global recovery at a time of surging inflation with Fed commentary exacerbating volatility.</p>\n<p>Wall Street's main indexes were supported this week by an update showing Pfizer and BioNTech's vaccine offered some protection against the Omicron variant.</p>\n<p>Data showed initial claims for state unemployment benefits tumbled 43,000 last week to 184,000, the lowest level in more than 52 years.</p>\n<p>GameStop Corp fell 10% after the video game retailer popular among retail investors said it was issued a subpoena by the U.S. securities regulator back in August for documents on an investigation into its share trading activity.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 3.03-to-1 ratio; on Nasdaq, a 3.05-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 23 new 52-week highs and 1 new lows; the Nasdaq Composite recorded 34 new highs and 68 new lows.</p>\n<p>On U.S. exchanges 9.75 billion shares changed hands compared with the 11.41 billion average for the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QLD":"纳指两倍做多ETF","BK4504":"桥水持仓","TQQQ":"纳指三倍做多ETF","BK4099":"汽车制造商","BK4548":"巴美列捷福持仓","SDOW":"道指三倍做空ETF-ProShares","DJX":"1/100道琼斯","PSQ":"纳指反向ETF","TSLA":"特斯拉","QQQ":"纳指100ETF","UDOW":"道指三倍做多ETF-ProShares","PFE":"辉瑞","DXD":"道指两倍做空ETF","BK4534":"瑞士信贷持仓","BK4555":"新能源车","CVS":"西维斯健康","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4196":"保健护理服务","QID":"纳指两倍做空ETF","DDM":"道指两倍做多ETF","CPI":"IQ Real Return ETF","BK4527":"明星科技股",".DJI":"道琼斯","BK4550":"红杉资本持仓","SQQQ":"纳指三倍做空ETF",".IXIC":"NASDAQ Composite","BK4076":"电脑与电子产品零售","GME":"游戏驿站","DOG":"道指反向ETF",".SPX":"S&P 500 Index","BK4551":"寇图资本持仓","BK4547":"WSB热门概念"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190964556","content_text":"Wall Street closed lower on Thursday as investors banked some profits after three straight days of gains and turned their focus toward upcoming inflation data and how it might influence the Federal Reserve's meeting next week.\nThe Nasdaq was down more sharply than the S&P 500 while the Dow was virtually flat, ending down less than 1 point.\nInvestors were in a waiting game ahead of U.S. consumer prices index inflation data due Friday morning. A higher-than-expected reading would strengthen the case for a policy tightening decision at the U.S. central bank's meeting.\nIn the first three days of the week, the Nasdaq rallied 4.7%, the S&P advanced 3.6% and the Dow gained 3.4% as fears abated about the latest coronavirus variant Omicron.\n\"We had a rip roaring rally. There's still nervous people out there,\" said Dennis Dick, head of markets structure, proprietary trader at Bright Trading LLC in Las Vegas.\n\"We'd a Omicron relief rally but the underlying problem still remains, that the Fed's taking the punchbowl away.\"\nJoe Quinlan, chief market strategist for the CIO office of Bank of America, said investors may be taking profits and pausing buying after the three days of gains.\n\"Also there may be a little risk-off trade ahead of the CPI number on Friday,\" he said. \"If it comes in hotter than expected it really shines the light and the focus on the Fed meeting. The pressure would build on the Fed for a faster tapering.\"\nFed Chair Powell signaled last week that the meeting would include a discussion about a faster tapering of bond-buying.\n\"It would reaffirm in many people's minds that the Fed is behind the curve,\" said Quinlan.\nIf the inflation number implies a need to hike rates faster, this \"would put pressure on technology and give a bid to cyclicals\" he said.\n\"You'd want to buy the companies that could pass on these higher costs to consumers. That undermines the growth story. You want to own more cyclicals and value than growth,\" said Quinlan.\nA Reuters poll of economists predicted the Fed would raise rates by 25 basis points to 0.25-0.50% in the third quarter of next year. However, most saw the risk that a hike comes even sooner.\nThe Dow Jones Industrial Average fell 0.06 points to 35,754.69, the S&P 500 lost 33.76 points, or 0.72%, to 4,667.45 and the Nasdaq Composite dropped 269.62 points, or 1.71%, to 15,517.37.\nNine of the 11 major S&P sectors declined, with consumer discretionary down 1.7%, losing the most and real estate , down 1.4%, and information technology falling 1%, showing the next biggest losses.\nThe only sector gainers were healthcare up 0.2% and consumer staples which clung to a 0.06% advance.\nHealthcare was boosted by a CVS Health Corp share gain of 4.5% after the drugstore operator raised its 2021 profit forecast.\nIn consumer staples, heavyweight electric car maker Tesla was the biggest percentage decliner, falling 6%.\nMarkets have seesawed since late November when the Omicron variant was discovered. Investors worried it could upend a global recovery at a time of surging inflation with Fed commentary exacerbating volatility.\nWall Street's main indexes were supported this week by an update showing Pfizer and BioNTech's vaccine offered some protection against the Omicron variant.\nData showed initial claims for state unemployment benefits tumbled 43,000 last week to 184,000, the lowest level in more than 52 years.\nGameStop Corp fell 10% after the video game retailer popular among retail investors said it was issued a subpoena by the U.S. securities regulator back in August for documents on an investigation into its share trading activity.\nDeclining issues outnumbered advancing ones on the NYSE by a 3.03-to-1 ratio; on Nasdaq, a 3.05-to-1 ratio favored decliners.\nThe S&P 500 posted 23 new 52-week highs and 1 new lows; the Nasdaq Composite recorded 34 new highs and 68 new lows.\nOn U.S. exchanges 9.75 billion shares changed hands compared with the 11.41 billion average for the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":578,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602948282,"gmtCreate":1638964138075,"gmtModify":1638964145087,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602948282","repostId":"1175313304","repostType":4,"repost":{"id":"1175313304","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638964005,"share":"https://www.laohu8.com/m/news/1175313304?lang=&edition=full","pubTime":"2021-12-08 19:46","market":"us","language":"en","title":"SentinelOne stock plunged 11% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1175313304","media":"Tiger Newspress","summary":"SentinelOne stock plunged 11% in premarket trading after soaring 13.4% yesterday.\n\nSentinelOne repor","content":"<p>SentinelOne stock plunged 11% in premarket trading&nbsp;after&nbsp;soaring&nbsp;13.4%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/c99dadc27cd626b6f052e60be655ae59\" tg-width=\"851\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>SentinelOne&nbsp;reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.18) by 44.44 percent. This is a 69.41 percent increase over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $56.02 million which beat the analyst consensus estimate of $49.57 million by 13.01 percent. This is a 128.11 percent increase over sales of $24.56 million the same period last year.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SentinelOne stock plunged 11% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSentinelOne stock plunged 11% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 19:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SentinelOne stock plunged 11% in premarket trading&nbsp;after&nbsp;soaring&nbsp;13.4%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/c99dadc27cd626b6f052e60be655ae59\" tg-width=\"851\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>SentinelOne&nbsp;reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.18) by 44.44 percent. This is a 69.41 percent increase over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $56.02 million which beat the analyst consensus estimate of $49.57 million by 13.01 percent. This is a 128.11 percent increase over sales of $24.56 million the same period last year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"S":"SentinelOne, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175313304","content_text":"SentinelOne stock plunged 11% in premarket trading after soaring 13.4% yesterday.\n\nSentinelOne reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.18) by 44.44 percent. This is a 69.41 percent increase over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $56.02 million which beat the analyst consensus estimate of $49.57 million by 13.01 percent. This is a 128.11 percent increase over sales of $24.56 million the same period last year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":657,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606897372,"gmtCreate":1638851793844,"gmtModify":1638851794052,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606897372","repostId":"2189686612","repostType":4,"repost":{"id":"2189686612","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1638826608,"share":"https://www.laohu8.com/m/news/2189686612?lang=&edition=full","pubTime":"2021-12-07 05:36","market":"us","language":"en","title":"Wall Street regains some ground with help from easing virus fears","url":"https://stock-news.laohu8.com/highlight/detail?id=2189686612","media":"Reuters","summary":"Dec 6  - Wall Street's major averages closed higher on Monday with economically sensitive sectors and travel-related stocks advancing solidly as investors were encouraged by some optimistic comments from a top U.S. official on the latest COVID-19 variant.Of Wall Street's three major averages, the Dow rose the most while industrials and consumer staples , up around 1.6%, were the S&P's strongest sectors followed by energy and utilities , up 1.5%. But declines in COVID-19 vaccine companies diminis","content":"<p>Dec 6 (Reuters) - Wall Street's major averages closed higher on Monday with economically sensitive sectors and travel-related stocks advancing solidly as investors were encouraged by some optimistic comments from a top U.S. official on the latest COVID-19 variant.</p>\n<p>Of Wall Street's three major averages, the Dow rose the most while industrials and consumer staples , up around 1.6%, were the S&amp;P's strongest sectors followed by energy and utilities , up 1.5%. But declines in COVID-19 vaccine companies diminished gains in the healthcare sector .</p>\n<p>While the Omicron COVID-19 variant has caused alarm and some new restrictions around the world, investors appeared to be reassured by Dr. Anthony Fauci, the top U.S. infectious disease official, who told CNN that \"thus far it does not look like there's a great degree of severity to it.\" However, he did say that more study is needed.</p>\n<p>\"People are less worried about the variant,\" said King Lip, chief investment strategist at Baker Avenue Asset Management in San Francisco.</p>\n<p>Lip also cited a boost from news that China's central bank would cut the amount of cash that banks must hold in reserve, potentially boosting overseas companies that sell products in China as well as China's economy.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 646.95 points, or 1.87%, to 35,227.03, the S&amp;P 500 gained 53.24 points, or 1.17%, to 4,591.67 and the Nasdaq Composite&nbsp;added 139.68 points, or 0.93%, to 15,225.15.</p>\n<p>The S&amp;P 500 Value Index&nbsp;rose 1.5%, outperforming its growth counterpart , which gained 0.9%.</p>\n<p>The economically sensitive Dow Jones Transportation index&nbsp;outperformed the broader market with a 2.3% gain while the small-cap Russell 2000&nbsp;climbed 2%.</p>\n<p>Wall Street's major indexes have been swinging wildly since Nov. 26 as investors digested news of the COVID-19 Omicron variant and then Federal Reserve Chair Jerome Powell's hawkish comments last week about a speedier tapering of government bond-buying to tackle surging inflation.</p>\n<p>The S&amp;P's finish on Monday was 2.3% below where it traded before investors started reacting to the Omicron virus.</p>\n<p>\"If today's strength in the blue chips can sort of sustain itself, that might give the rest of the market the ability to start to feel confident,\" said Robert Pavlik, senior portfolio manager at Dakota Wealth Management.</p>\n<p>Still, Goldman Sachs on Saturday cut its outlook for U.S. economic growth to 3.8% for 2022, citing risks and uncertainty around the emergence of Omicron. Investors had also been bracing for a potential hit to corporate earnings, particularly among retailers, restaurants and travel companies.</p>\n<p>The industrials sector's three biggest percentage gainers were airlines led by United Airlines 8.3% gain while the S&amp;P Airline's index&nbsp;closed up 5.5%.</p>\n<p>Other strong gainers in travel related stocks included Norwegian Cruise Line Holdings , which finished up 9.5%. Vacation rental company Airbnb&nbsp;added 8.5%.</p>\n<p>Big decliners included COVID-19 vaccine makers such as Moderna Inc&nbsp;, down 13.5%, and Pfizer, down 5%, as investors anticipated development of vaccines with protections specific to Omicron could take months.</p>\n<p>Nvidia&nbsp;closed down 2%. Investors have been worried about the outcome of regulatory scrutiny of its deal to buy British chip firm ARM Ltd.</p>\n<p>Kohl's Corp&nbsp;shares closed up 5.4% after hedge fund Engine Capital LP said it was pushing the department-store chain to consider a sale of the company or separate its e-commerce division to improve its lagging stock price.</p>\n<p>JJ Kinahan, chief market strategist at TD Ameritrade, said investors may be preparing for a Dec. 17 expiration of options and futures.</p>\n<p>\"You have a lot of firms that have a double mandate right now. You are trying to take off risk, expiration related, while the same time rebalancing your portfolio heading into 2022,\" he said.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.82-to-1 ratio; on Nasdaq, a 1.71-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 20 new 52-week highs and <a href=\"https://laohu8.com/S/AONE.U\">one</a> new low; the Nasdaq Composite recorded 28 new highs and 600 new lows.</p>\n<p>On U.S. exchanges, 11.96 billion shares changed hands compared with the 11.55 billion average for the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street regains some ground with help from easing virus fears</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street regains some ground with help from easing virus fears\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-07 05:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 6 (Reuters) - Wall Street's major averages closed higher on Monday with economically sensitive sectors and travel-related stocks advancing solidly as investors were encouraged by some optimistic comments from a top U.S. official on the latest COVID-19 variant.</p>\n<p>Of Wall Street's three major averages, the Dow rose the most while industrials and consumer staples , up around 1.6%, were the S&amp;P's strongest sectors followed by energy and utilities , up 1.5%. But declines in COVID-19 vaccine companies diminished gains in the healthcare sector .</p>\n<p>While the Omicron COVID-19 variant has caused alarm and some new restrictions around the world, investors appeared to be reassured by Dr. Anthony Fauci, the top U.S. infectious disease official, who told CNN that \"thus far it does not look like there's a great degree of severity to it.\" However, he did say that more study is needed.</p>\n<p>\"People are less worried about the variant,\" said King Lip, chief investment strategist at Baker Avenue Asset Management in San Francisco.</p>\n<p>Lip also cited a boost from news that China's central bank would cut the amount of cash that banks must hold in reserve, potentially boosting overseas companies that sell products in China as well as China's economy.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 646.95 points, or 1.87%, to 35,227.03, the S&amp;P 500 gained 53.24 points, or 1.17%, to 4,591.67 and the Nasdaq Composite&nbsp;added 139.68 points, or 0.93%, to 15,225.15.</p>\n<p>The S&amp;P 500 Value Index&nbsp;rose 1.5%, outperforming its growth counterpart , which gained 0.9%.</p>\n<p>The economically sensitive Dow Jones Transportation index&nbsp;outperformed the broader market with a 2.3% gain while the small-cap Russell 2000&nbsp;climbed 2%.</p>\n<p>Wall Street's major indexes have been swinging wildly since Nov. 26 as investors digested news of the COVID-19 Omicron variant and then Federal Reserve Chair Jerome Powell's hawkish comments last week about a speedier tapering of government bond-buying to tackle surging inflation.</p>\n<p>The S&amp;P's finish on Monday was 2.3% below where it traded before investors started reacting to the Omicron virus.</p>\n<p>\"If today's strength in the blue chips can sort of sustain itself, that might give the rest of the market the ability to start to feel confident,\" said Robert Pavlik, senior portfolio manager at Dakota Wealth Management.</p>\n<p>Still, Goldman Sachs on Saturday cut its outlook for U.S. economic growth to 3.8% for 2022, citing risks and uncertainty around the emergence of Omicron. Investors had also been bracing for a potential hit to corporate earnings, particularly among retailers, restaurants and travel companies.</p>\n<p>The industrials sector's three biggest percentage gainers were airlines led by United Airlines 8.3% gain while the S&amp;P Airline's index&nbsp;closed up 5.5%.</p>\n<p>Other strong gainers in travel related stocks included Norwegian Cruise Line Holdings , which finished up 9.5%. Vacation rental company Airbnb&nbsp;added 8.5%.</p>\n<p>Big decliners included COVID-19 vaccine makers such as Moderna Inc&nbsp;, down 13.5%, and Pfizer, down 5%, as investors anticipated development of vaccines with protections specific to Omicron could take months.</p>\n<p>Nvidia&nbsp;closed down 2%. Investors have been worried about the outcome of regulatory scrutiny of its deal to buy British chip firm ARM Ltd.</p>\n<p>Kohl's Corp&nbsp;shares closed up 5.4% after hedge fund Engine Capital LP said it was pushing the department-store chain to consider a sale of the company or separate its e-commerce division to improve its lagging stock price.</p>\n<p>JJ Kinahan, chief market strategist at TD Ameritrade, said investors may be preparing for a Dec. 17 expiration of options and futures.</p>\n<p>\"You have a lot of firms that have a double mandate right now. You are trying to take off risk, expiration related, while the same time rebalancing your portfolio heading into 2022,\" he said.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.82-to-1 ratio; on Nasdaq, a 1.71-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 20 new 52-week highs and <a href=\"https://laohu8.com/S/AONE.U\">one</a> new low; the Nasdaq Composite recorded 28 new highs and 600 new lows.</p>\n<p>On U.S. exchanges, 11.96 billion shares changed hands compared with the 11.55 billion average for the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QID":"纳指两倍做空ETF","DOG":"道指反向ETF","SDOW":"道指三倍做空ETF-ProShares","DDM":"道指两倍做多ETF",".DJI":"道琼斯","DXD":"道指两倍做空ETF",".IXIC":"NASDAQ Composite","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","QLD":"纳指两倍做多ETF",".SPX":"S&P 500 Index","UDOW":"道指三倍做多ETF-ProShares","SQQQ":"纳指三倍做空ETF","DJX":"1/100道琼斯","TQQQ":"纳指三倍做多ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189686612","content_text":"Dec 6 (Reuters) - Wall Street's major averages closed higher on Monday with economically sensitive sectors and travel-related stocks advancing solidly as investors were encouraged by some optimistic comments from a top U.S. official on the latest COVID-19 variant.\nOf Wall Street's three major averages, the Dow rose the most while industrials and consumer staples , up around 1.6%, were the S&P's strongest sectors followed by energy and utilities , up 1.5%. But declines in COVID-19 vaccine companies diminished gains in the healthcare sector .\nWhile the Omicron COVID-19 variant has caused alarm and some new restrictions around the world, investors appeared to be reassured by Dr. Anthony Fauci, the top U.S. infectious disease official, who told CNN that \"thus far it does not look like there's a great degree of severity to it.\" However, he did say that more study is needed.\n\"People are less worried about the variant,\" said King Lip, chief investment strategist at Baker Avenue Asset Management in San Francisco.\nLip also cited a boost from news that China's central bank would cut the amount of cash that banks must hold in reserve, potentially boosting overseas companies that sell products in China as well as China's economy.\nThe Dow Jones Industrial Average rose 646.95 points, or 1.87%, to 35,227.03, the S&P 500 gained 53.24 points, or 1.17%, to 4,591.67 and the Nasdaq Composite added 139.68 points, or 0.93%, to 15,225.15.\nThe S&P 500 Value Index rose 1.5%, outperforming its growth counterpart , which gained 0.9%.\nThe economically sensitive Dow Jones Transportation index outperformed the broader market with a 2.3% gain while the small-cap Russell 2000 climbed 2%.\nWall Street's major indexes have been swinging wildly since Nov. 26 as investors digested news of the COVID-19 Omicron variant and then Federal Reserve Chair Jerome Powell's hawkish comments last week about a speedier tapering of government bond-buying to tackle surging inflation.\nThe S&P's finish on Monday was 2.3% below where it traded before investors started reacting to the Omicron virus.\n\"If today's strength in the blue chips can sort of sustain itself, that might give the rest of the market the ability to start to feel confident,\" said Robert Pavlik, senior portfolio manager at Dakota Wealth Management.\nStill, Goldman Sachs on Saturday cut its outlook for U.S. economic growth to 3.8% for 2022, citing risks and uncertainty around the emergence of Omicron. Investors had also been bracing for a potential hit to corporate earnings, particularly among retailers, restaurants and travel companies.\nThe industrials sector's three biggest percentage gainers were airlines led by United Airlines 8.3% gain while the S&P Airline's index closed up 5.5%.\nOther strong gainers in travel related stocks included Norwegian Cruise Line Holdings , which finished up 9.5%. Vacation rental company Airbnb added 8.5%.\nBig decliners included COVID-19 vaccine makers such as Moderna Inc , down 13.5%, and Pfizer, down 5%, as investors anticipated development of vaccines with protections specific to Omicron could take months.\nNvidia closed down 2%. Investors have been worried about the outcome of regulatory scrutiny of its deal to buy British chip firm ARM Ltd.\nKohl's Corp shares closed up 5.4% after hedge fund Engine Capital LP said it was pushing the department-store chain to consider a sale of the company or separate its e-commerce division to improve its lagging stock price.\nJJ Kinahan, chief market strategist at TD Ameritrade, said investors may be preparing for a Dec. 17 expiration of options and futures.\n\"You have a lot of firms that have a double mandate right now. You are trying to take off risk, expiration related, while the same time rebalancing your portfolio heading into 2022,\" he said.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.82-to-1 ratio; on Nasdaq, a 1.71-to-1 ratio favored advancers.\nThe S&P 500 posted 20 new 52-week highs and one new low; the Nasdaq Composite recorded 28 new highs and 600 new lows.\nOn U.S. exchanges, 11.96 billion shares changed hands compared with the 11.55 billion average for the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608461315,"gmtCreate":1638780005960,"gmtModify":1638780006201,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584399073835367","authorIdStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/608461315","repostId":"1179313612","repostType":4,"repost":{"id":"1179313612","pubTimestamp":1638745398,"share":"https://www.laohu8.com/m/news/1179313612?lang=&edition=full","pubTime":"2021-12-06 07:03","market":"us","language":"en","title":"Game Stop, Toll Brothers, Costco, CVS, and Other Stocks to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1179313612","media":"Barrons","summary":"Meme stock darling GameStop headlines this week’s earnings report lineup. The videogame retailer rep","content":"<p>Meme stock darling <a href=\"https://laohu8.com/S/GME\">GameStop</a> headlines this week’s earnings report lineup. The videogame retailer reports results after the market closes on Wednesday. <a href=\"https://laohu8.com/S/AZO\">AutoZone</a>, Casey’s <a href=\"https://laohu8.com/S/BGC\">General</a> Stores, and <a href=\"https://laohu8.com/S/TOL\">Toll Brothers</a> report earnings on Tuesday, followed by <a href=\"https://laohu8.com/S/BF.A\">Brown-Forman</a> and <a href=\"https://laohu8.com/S/CPB\">Campbell Soup</a> on Wednesday. <a href=\"https://laohu8.com/S/AVGO\">Broadcom</a>, <a href=\"https://laohu8.com/S/COST\">Costco</a> Wholesale, and <a href=\"https://laohu8.com/S/HRL\">Hormel</a> Foods round things out on Thursday.</p>\n<p>On Monday, <a href=\"https://laohu8.com/S/UNP\">Union Pacific</a> will hold a conference call to discuss its climate action plan. <a href=\"https://laohu8.com/S/MCK\">McKesson</a> and <a href=\"https://laohu8.com/S/LUV\">Southwest Airlines</a> host their 2021 investor days on Wednesday, followed by <a href=\"https://laohu8.com/S/CVS\">CVS Health</a> and <a href=\"https://laohu8.com/S/TSN\">Tyson</a> Foods on Thursday.</p>\n<p>The Federal Reserve’s report on consumer credit data for October will be released on Tuesday. On Thursday, the U.S. Labor Department reports initial jobless claims for the week ending on Dec. 4.</p>\n<p>The Bureau of Labor Statistics releases the consumer price index for November on Friday. The consensus estimate is for a 6.7% year-over-year jump, half a percentage point more than in October. The core CPI, which excludes volatile food and energy prices, is expected to rise 4.8% versus 4.6% previously.</p>\n<p><b>Monday 12/6</b></p>\n<p>Union Pacific holds a conference call to discuss its climate action plan.</p>\n<p><b>Tuesday 12/7</b></p>\n<p>AutoZone, Casey’s General Stores, and Toll Brothers announce quarterly results.</p>\n<p>The Federal Reserve reports on consumer credit data for October. After falling slightly last year, total outstanding consumer debt has risen an average of $20 billion a month through September, and stands at a record $4.37 trillion.</p>\n<p><b>Wednesday 12/8</b></p>\n<p>The BLS releases the Job Openings and Labor Turnover Survey. Economists forecast 10.5 million job openings on the last business day of October, only 600,000 less than the record high of 11.1 million in July.</p>\n<p><a href=\"https://laohu8.com/S/BF.B\">Brown-Forman</a>, Campbell Soup, and GameStop report earnings.</p>\n<p>McKesson and <a href=\"https://laohu8.com/S/OKSB\">Southwest</a> Airlines host their 2021 investor days.</p>\n<p><a href=\"https://laohu8.com/S/EW\">Edwards Lifesciences</a> holds an investor conference in Irvine, Calif. The company will discuss its product pipeline as well as its financial outlook for 2022.</p>\n<p>The Bank of Canada announces its monetary-policy decision. The central bank is expected to keep its key short-term interest rate unchanged at 0.25%. At its late-October meeting, the bank ended its quantitative-easing program and signaled that its first interest-rate hike would be earlier in 2022 than had been expected.</p>\n<p><b>Thursday 12/9</b></p>\n<p>Broadcom, Costco Wholesale, and Hormel Foods hold conference calls to discuss quarterly results.</p>\n<p>CVS Health and Tyson Foods host their annual investor days.</p>\n<p>The Department of Labor reports initial jobless claims for the week ending on Dec. 4. Jobless claims averaged 238,750 in November, the lowest since the beginning of the pandemic, and just 24,750 more than in February of 2020.</p>\n<p><b>Friday 12/10</b></p>\n<p>Archer-Daniels-Midland holds its global investor day.</p>\n<p><a href=\"https://laohu8.com/S/CNC\">Centene</a> holds an investor meeting and will provide financial guidance for 2022.</p>\n<p>The Bureau of Labor Statistics releases the consumer price index for November. Consensus estimate is for a 6.7% year-over-year jump, half a percentage point more than in October. The core CPI, which excludes volatile food and energy prices, is expected to rise 4.8% versus 4.6% previously. October’s 6.2% increase was the hottest the CPI has run in more than 30 years, and this past week Federal Reserve Chairman Jerome <a href=\"https://laohu8.com/S/POWL\">Powell</a> finally ditched “transitory” when discussing inflation before the Senate Banking Committee.</p>\n<p>The University of Michigan releases its Consumer Sentiment index for December. Economists forecast a 66 reading, slightly less than the November data.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Game Stop, Toll Brothers, Costco, CVS, and Other Stocks to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGame Stop, Toll Brothers, Costco, CVS, and Other Stocks to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 07:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/game-stop-toll-brothers-costco-cvs-and-other-stocks-to-watch-this-week-51638734413?mod=barrons-on-marketwatch><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Meme stock darling GameStop headlines this week’s earnings report lineup. The videogame retailer reports results after the market closes on Wednesday. AutoZone, Casey’s General Stores, and Toll ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/game-stop-toll-brothers-costco-cvs-and-other-stocks-to-watch-this-week-51638734413?mod=barrons-on-marketwatch\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4088":"住宅建筑","GME":"游戏驿站","TOL":"托尔兄弟","COST":"好市多","CVS":"西维斯健康"},"source_url":"https://www.marketwatch.com/articles/game-stop-toll-brothers-costco-cvs-and-other-stocks-to-watch-this-week-51638734413?mod=barrons-on-marketwatch","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1179313612","content_text":"Meme stock darling GameStop headlines this week’s earnings report lineup. The videogame retailer reports results after the market closes on Wednesday. AutoZone, Casey’s General Stores, and Toll Brothers report earnings on Tuesday, followed by Brown-Forman and Campbell Soup on Wednesday. Broadcom, Costco Wholesale, and Hormel Foods round things out on Thursday.\nOn Monday, Union Pacific will hold a conference call to discuss its climate action plan. McKesson and Southwest Airlines host their 2021 investor days on Wednesday, followed by CVS Health and Tyson Foods on Thursday.\nThe Federal Reserve’s report on consumer credit data for October will be released on Tuesday. On Thursday, the U.S. Labor Department reports initial jobless claims for the week ending on Dec. 4.\nThe Bureau of Labor Statistics releases the consumer price index for November on Friday. The consensus estimate is for a 6.7% year-over-year jump, half a percentage point more than in October. The core CPI, which excludes volatile food and energy prices, is expected to rise 4.8% versus 4.6% previously.\nMonday 12/6\nUnion Pacific holds a conference call to discuss its climate action plan.\nTuesday 12/7\nAutoZone, Casey’s General Stores, and Toll Brothers announce quarterly results.\nThe Federal Reserve reports on consumer credit data for October. After falling slightly last year, total outstanding consumer debt has risen an average of $20 billion a month through September, and stands at a record $4.37 trillion.\nWednesday 12/8\nThe BLS releases the Job Openings and Labor Turnover Survey. Economists forecast 10.5 million job openings on the last business day of October, only 600,000 less than the record high of 11.1 million in July.\nBrown-Forman, Campbell Soup, and GameStop report earnings.\nMcKesson and Southwest Airlines host their 2021 investor days.\nEdwards Lifesciences holds an investor conference in Irvine, Calif. The company will discuss its product pipeline as well as its financial outlook for 2022.\nThe Bank of Canada announces its monetary-policy decision. The central bank is expected to keep its key short-term interest rate unchanged at 0.25%. At its late-October meeting, the bank ended its quantitative-easing program and signaled that its first interest-rate hike would be earlier in 2022 than had been expected.\nThursday 12/9\nBroadcom, Costco Wholesale, and Hormel Foods hold conference calls to discuss quarterly results.\nCVS Health and Tyson Foods host their annual investor days.\nThe Department of Labor reports initial jobless claims for the week ending on Dec. 4. Jobless claims averaged 238,750 in November, the lowest since the beginning of the pandemic, and just 24,750 more than in February of 2020.\nFriday 12/10\nArcher-Daniels-Midland holds its global investor day.\nCentene holds an investor meeting and will provide financial guidance for 2022.\nThe Bureau of Labor Statistics releases the consumer price index for November. Consensus estimate is for a 6.7% year-over-year jump, half a percentage point more than in October. The core CPI, which excludes volatile food and energy prices, is expected to rise 4.8% versus 4.6% previously. October’s 6.2% increase was the hottest the CPI has run in more than 30 years, and this past week Federal Reserve Chairman Jerome Powell finally ditched “transitory” when discussing inflation before the Senate Banking Committee.\nThe University of Michigan releases its Consumer Sentiment index for December. Economists forecast a 66 reading, slightly less than the November data.","news_type":1},"isVote":1,"tweetType":1,"viewCount":507,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":115031568,"gmtCreate":1622939970854,"gmtModify":1634096840763,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Pls comment and like thanks","listText":"Pls comment and like thanks","text":"Pls comment and like thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/115031568","repostId":"1106312903","repostType":4,"repost":{"id":"1106312903","pubTimestamp":1622855773,"share":"https://www.laohu8.com/m/news/1106312903?lang=&edition=full","pubTime":"2021-06-05 09:16","market":"us","language":"en","title":"U.S. IPO Week Ahead: Digital Payments, Mental Health Services, And More In A Diverse 8 IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1106312903","media":"Renaissance Capital","summary":"Summary\n\nEight IPOs are currently slated to raise $3.7 billion, featuring digital payments, mental h","content":"<p><b>Summary</b></p>\n<ul>\n <li>Eight IPOs are currently slated to raise $3.7 billion, featuring digital payments, mental health services, and more.</li>\n <li>Payments platform Marqeta plans to raise $1.0 billion at a $12.4 billion market cap.</li>\n <li>Chinese online recruitment platform Kanzhun plans to raise $864 million at an $8.2 billion market cap.</li>\n</ul>\n<p>Eight IPOs are currently slated to raise $3.7 billion, featuring digital payments, mental health services, and more.</p>\n<p>Payments platform&nbsp;<b>Marqeta</b>(MQ) plans to raise $1.0 billion at a $12.4 billion market cap. The company's platform allows businesses to launch and manage their own card programs, issue cards to their customers or end users, and authorize and settle transactions. Marqeta is fast growing and counts names like Affirm (AFRM) and DoorDash (DASH) among its customers.</p>\n<p>Chinese online recruitment platform&nbsp;<b>Kanzhun</b>(BZ) plans to raise $864 million at an $8.2 billion market cap. Kanzhun's core product, BOSS Zhipin, is a mobile-native platform that promotes direct chats between job seekers and enterprise clients. The company claims it was the largest online recruitment platform in China by MAUs in 2020.</p>\n<p>Mental health services provider&nbsp;<b>LifeStance Health</b>(LFST) plans to raise $640 million at a $6.1 billion market cap. LifeStance states that it has built one of the nation's largest outpatient mental health platforms, employing over 3,300 licensed mental health clinicians across 73 MSAs in 27 states as of March 31, 2021. The company has demonstrated growth, though EBIT turned negative in the 1Q21.</p>\n<p>Israel’s&nbsp;<b>monday.com</b>(MNDY) plans to raise $490 million at a $6.8 billion market cap. monday.com allows organizations to easily build software applications and work management tools that fit their needs. As of March 31, 2021, it served nearly 128,000 customers across over 200 industries in more than 190 countries. Salesforce and Zoom plan to invest a combined $150 million in a concurrent private placement.</p>\n<p>BPO vendor&nbsp;<b>TaskUs</b>(TASK) plans to raise $304 million at a $2.5 billion market cap. TaskUs is a digital business services outsourcer, providing digital customer experience services, content security services, and artificial intelligence operations. Profitable with strong growth, the company had over 100 clients as of December 31, 2020.</p>\n<p>Data-driven marketing platform&nbsp;<b>Zeta Global</b>(ZETA) plans to raise $250 million at a $2.1 billion market cap. The company’s Zeta Marketing Platform uses identity data to target, connect, and engage consumers across email, social media, web, chat, connected TV, video, and other channels. Zeta is profitable and serves more than 1,000 customers, delivering roughly 500 million ad impressions in 2020.</p>\n<p>Online luxury goods marketplace&nbsp;<b>1stDibs</b>(DIBS) plans to raise $112 million at a $773 million market cap. 1stDibs connects buyers and sellers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. In 2020, the marketplace had more than 58,000 buyers who had made a purchase in the past year, with an average aggregate purchase per year of over $5,500.</p>\n<p>Chinese online tutoring platform&nbsp;<b>Zhangmen Education</b>(ZME) plans to raise $43 million at a $1.9 billion market cap. Zhangmen Education states that it has been the largest online K-12 tutoring service provider in China by revenue since 2017, claiming a 32% market share in 2020.</p>\n<p><img src=\"https://static.tigerbbs.com/d771f02e44d9d489ff772f1577280332\" tg-width=\"945\" tg-height=\"666\"></p>\n<p>Street research is expected for six companies, and lock-up periods will be expiring for up to 11 companies.</p>\n<p><b>IPO Market Snapshot</b></p>\n<p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 6/3/21, the Renaissance IPO Index was down 6.0% year-to-date, while the S&amp;P 500 was up 11.6%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Zoom Video (ZM) and Uber (UBER). The Renaissance International IPO Index was down 1.1% year-to-date, while the ACWX was up 10.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Nexi and EQT Partners.</p>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. IPO Week Ahead: Digital Payments, Mental Health Services, And More In A Diverse 8 IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. IPO Week Ahead: Digital Payments, Mental Health Services, And More In A Diverse 8 IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-05 09:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/82421/US-IPO-Week-Ahead-Digital-payments-mental-health-services-and-more-in-a-div><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nEight IPOs are currently slated to raise $3.7 billion, featuring digital payments, mental health services, and more.\nPayments platform Marqeta plans to raise $1.0 billion at a $12.4 billion ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/82421/US-IPO-Week-Ahead-Digital-payments-mental-health-services-and-more-in-a-div\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index","MNDY":"Monday.com Ltd.","ZETA":"Zeta Global Holdings Corp.","MQ":"Marqeta, Inc.","LFST":"LifeStance Health Group, Inc.","DIBS":"1stdibs.com Inc.","ZME":"掌门教育","BZ":"BOSS直聘",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","TASK":"TaskUs Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/82421/US-IPO-Week-Ahead-Digital-payments-mental-health-services-and-more-in-a-div","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106312903","content_text":"Summary\n\nEight IPOs are currently slated to raise $3.7 billion, featuring digital payments, mental health services, and more.\nPayments platform Marqeta plans to raise $1.0 billion at a $12.4 billion market cap.\nChinese online recruitment platform Kanzhun plans to raise $864 million at an $8.2 billion market cap.\n\nEight IPOs are currently slated to raise $3.7 billion, featuring digital payments, mental health services, and more.\nPayments platform Marqeta(MQ) plans to raise $1.0 billion at a $12.4 billion market cap. The company's platform allows businesses to launch and manage their own card programs, issue cards to their customers or end users, and authorize and settle transactions. Marqeta is fast growing and counts names like Affirm (AFRM) and DoorDash (DASH) among its customers.\nChinese online recruitment platform Kanzhun(BZ) plans to raise $864 million at an $8.2 billion market cap. Kanzhun's core product, BOSS Zhipin, is a mobile-native platform that promotes direct chats between job seekers and enterprise clients. The company claims it was the largest online recruitment platform in China by MAUs in 2020.\nMental health services provider LifeStance Health(LFST) plans to raise $640 million at a $6.1 billion market cap. LifeStance states that it has built one of the nation's largest outpatient mental health platforms, employing over 3,300 licensed mental health clinicians across 73 MSAs in 27 states as of March 31, 2021. The company has demonstrated growth, though EBIT turned negative in the 1Q21.\nIsrael’s monday.com(MNDY) plans to raise $490 million at a $6.8 billion market cap. monday.com allows organizations to easily build software applications and work management tools that fit their needs. As of March 31, 2021, it served nearly 128,000 customers across over 200 industries in more than 190 countries. Salesforce and Zoom plan to invest a combined $150 million in a concurrent private placement.\nBPO vendor TaskUs(TASK) plans to raise $304 million at a $2.5 billion market cap. TaskUs is a digital business services outsourcer, providing digital customer experience services, content security services, and artificial intelligence operations. Profitable with strong growth, the company had over 100 clients as of December 31, 2020.\nData-driven marketing platform Zeta Global(ZETA) plans to raise $250 million at a $2.1 billion market cap. The company’s Zeta Marketing Platform uses identity data to target, connect, and engage consumers across email, social media, web, chat, connected TV, video, and other channels. Zeta is profitable and serves more than 1,000 customers, delivering roughly 500 million ad impressions in 2020.\nOnline luxury goods marketplace 1stDibs(DIBS) plans to raise $112 million at a $773 million market cap. 1stDibs connects buyers and sellers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. In 2020, the marketplace had more than 58,000 buyers who had made a purchase in the past year, with an average aggregate purchase per year of over $5,500.\nChinese online tutoring platform Zhangmen Education(ZME) plans to raise $43 million at a $1.9 billion market cap. Zhangmen Education states that it has been the largest online K-12 tutoring service provider in China by revenue since 2017, claiming a 32% market share in 2020.\n\nStreet research is expected for six companies, and lock-up periods will be expiring for up to 11 companies.\nIPO Market Snapshot\nThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 6/3/21, the Renaissance IPO Index was down 6.0% year-to-date, while the S&P 500 was up 11.6%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Zoom Video (ZM) and Uber (UBER). The Renaissance International IPO Index was down 1.1% year-to-date, while the ACWX was up 10.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Nexi and EQT Partners.","news_type":1},"isVote":1,"tweetType":1,"viewCount":86,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184729092,"gmtCreate":1623725992516,"gmtModify":1634029496079,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Pls comment thank you!","listText":"Pls comment thank you!","text":"Pls comment thank you!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/184729092","repostId":"1175897310","repostType":4,"repost":{"id":"1175897310","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623725513,"share":"https://www.laohu8.com/m/news/1175897310?lang=&edition=full","pubTime":"2021-06-15 10:51","market":"us","language":"en","title":"IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=1175897310","media":"Benzinga","summary":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is ","content":"<p>This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.</p>\n<p><b>AMTD Digital:</b>Asian digital solutions platform&nbsp;<b>AMTD Digital</b>(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.</p>\n<p><b>Molecular Partners:</b>Clinical stage biotechnology company&nbsp;<b>Molecular Partners</b>(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;<b>Novartis</b>(NYSE:NVS) in 2020,<b>Amgen Inc</b>(NASDAQ:AMGN) in 2018 and&nbsp;<b>AbbVie Inc</b>(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.</p>\n<p><b>WalkMe:</b>With a mission to change the way humans interact with technology,<b>WalkMe</b>(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.</p>\n<p>WalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.</p>\n<p><b>Convey Holding:</b>Health care company&nbsp;<b>Convey Holding</b>(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.</p>\n<p><b>Angel Oak Mortgage:</b>Real estate finance company&nbsp;<b>Angel Oak Mortgage</b>(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.</p>\n<p><b>Lyell Immunopharma:</b>Seeking to disrupt the T-cell reprogramming market,<b>Lyell ImmunoPharma</b>(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered with<b>GlaxoSmithKline</b>(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.</p>\n<p>GlaxoSmithKline owns 14% of Lyell and&nbsp;<b>Bristol-MyersSquibb</b>(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.</p>\n<p><b>Verve Therapeutics:</b>Genetic medicine company<b>Verve Therapeutics</b>(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.</p>\n<p><b>Atai Life Sciences:</b>Backedby&nbsp;<b>Palantir Technologies</b>(NYSE:PLTR) and&nbsp;<b>Paypal Holdings</b>(NASDAQ:PYPL) founder Peter Thiel,<b>Atai Life Sciences</b>(NASDAQ:ATAI) could be one of the high profile IPOs of the week.</p>\n<p>The company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.</p>\n<p><b>AiHui Shou International:</b>Pre-owned consumer electronics reseller&nbsp;<b>AiHuiShou International</b>(NYSE: RERE)seeksto give a second life to all idle goods.</p>\n<p>The company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.<b>JD.com</b>(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 10:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.</p>\n<p><b>AMTD Digital:</b>Asian digital solutions platform&nbsp;<b>AMTD Digital</b>(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.</p>\n<p><b>Molecular Partners:</b>Clinical stage biotechnology company&nbsp;<b>Molecular Partners</b>(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;<b>Novartis</b>(NYSE:NVS) in 2020,<b>Amgen Inc</b>(NASDAQ:AMGN) in 2018 and&nbsp;<b>AbbVie Inc</b>(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.</p>\n<p><b>WalkMe:</b>With a mission to change the way humans interact with technology,<b>WalkMe</b>(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.</p>\n<p>WalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.</p>\n<p><b>Convey Holding:</b>Health care company&nbsp;<b>Convey Holding</b>(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.</p>\n<p><b>Angel Oak Mortgage:</b>Real estate finance company&nbsp;<b>Angel Oak Mortgage</b>(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.</p>\n<p><b>Lyell Immunopharma:</b>Seeking to disrupt the T-cell reprogramming market,<b>Lyell ImmunoPharma</b>(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered with<b>GlaxoSmithKline</b>(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.</p>\n<p>GlaxoSmithKline owns 14% of Lyell and&nbsp;<b>Bristol-MyersSquibb</b>(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.</p>\n<p><b>Verve Therapeutics:</b>Genetic medicine company<b>Verve Therapeutics</b>(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.</p>\n<p><b>Atai Life Sciences:</b>Backedby&nbsp;<b>Palantir Technologies</b>(NYSE:PLTR) and&nbsp;<b>Paypal Holdings</b>(NASDAQ:PYPL) founder Peter Thiel,<b>Atai Life Sciences</b>(NASDAQ:ATAI) could be one of the high profile IPOs of the week.</p>\n<p>The company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.</p>\n<p><b>AiHui Shou International:</b>Pre-owned consumer electronics reseller&nbsp;<b>AiHuiShou International</b>(NYSE: RERE)seeksto give a second life to all idle goods.</p>\n<p>The company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.<b>JD.com</b>(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LYEL":"Lyell Immunopharma, Inc.","MOLN":"Molecular Partners AG","AOMR":"ANGEL OAK MORTGAGE REIT INC","WKME":"WalkMe Ltd.","NVS":"诺华","RERE":"万物新生","ATAI":"ATAI Life Sciences B.V.*","HKD":"尚乘数科"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175897310","content_text":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform AMTD Digital(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company Angel Oak Mortgage(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby Palantir Technologies(NYSE:PLTR) and Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","news_type":1},"isVote":1,"tweetType":1,"viewCount":177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124404039,"gmtCreate":1624776677321,"gmtModify":1633948695189,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/124404039","repostId":"2146090006","repostType":4,"repost":{"id":"2146090006","pubTimestamp":1624755315,"share":"https://www.laohu8.com/m/news/2146090006?lang=&edition=full","pubTime":"2021-06-27 08:55","market":"us","language":"en","title":"5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2146090006","media":"Motley Fool","summary":"These growth and value stocks are begging to be bought by investors.","content":"<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.</p>\n<p>Although Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1077c8372814d2b8150e933b4c608005\" tg-width=\"700\" tg-height=\"466\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>Even though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in <b>Amazon</b> (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.</p>\n<p>As most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.</p>\n<p>But it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Pharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>One reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with <b>Pfizer</b>, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.</p>\n<p>Another reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b152e369d7c967dcbc926192ee888c1\" tg-width=\"700\" tg-height=\"531\"><span>Image source: Getty Images.</span></p>\n<h2>Mastercard</h2>\n<p>Everyone seems to be looking for the smartest recovery play from the pandemic. Payment processor <b>Mastercard</b> (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.</p>\n<p>Mastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.</p>\n<p>Investors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e4e1a1fe028efa4c966b66ef2cd466f5\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>If you have an appetite for turnaround plays, brand-name and generic-drug developer <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.</p>\n<p>While there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.</p>\n<p>Schultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/44a30c4dfd6886a29e22d3c6558c3e56\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>Lastly, bank stock <b>Bank of America</b> (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.</p>\n<p>For much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.</p>\n<p>At the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-27 08:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.B":"伯克希尔B","TEVA":"梯瓦制药","AMZN":"亚马逊","BMY":"施贵宝","BAC":"美国银行","MA":"万事达","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146090006","content_text":"When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.\nAlthough Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nEven though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in Amazon (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.\nAs most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.\nBut it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.\nImage source: Getty Images.\nBristol Myers Squibb\nPharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than Bristol Myers Squibb (NYSE:BMY).\nOne reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with Pfizer, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.\nAnother reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.\nImage source: Getty Images.\nMastercard\nEveryone seems to be looking for the smartest recovery play from the pandemic. Payment processor Mastercard (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.\nMastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.\nInvestors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nIf you have an appetite for turnaround plays, brand-name and generic-drug developer Teva Pharmaceutical Industries (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.\nWhile there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.\nSchultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.\nImage source: Getty Images.\nBank of America\nLastly, bank stock Bank of America (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.\nFor much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.\nAt the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.","news_type":1},"isVote":1,"tweetType":1,"viewCount":72,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":110619639,"gmtCreate":1622448171221,"gmtModify":1634101404244,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Pls like and comment","listText":"Pls like and comment","text":"Pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/110619639","repostId":"2139648773","repostType":4,"isVote":1,"tweetType":1,"viewCount":341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":605345611,"gmtCreate":1639122001547,"gmtModify":1639122065526,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/605345611","repostId":"2190964556","repostType":4,"repost":{"id":"2190964556","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639090919,"share":"https://www.laohu8.com/m/news/2190964556?lang=&edition=full","pubTime":"2021-12-10 07:01","market":"us","language":"en","title":"Wall St closes lower ahead of inflation data, Fed meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2190964556","media":"Reuters","summary":"Wall Street closed lower on Thursday as investors banked some profits after three straight days of g","content":"<p>Wall Street closed lower on Thursday as investors banked some profits after three straight days of gains and turned their focus toward upcoming inflation data and how it might influence the Federal Reserve's meeting next week.</p>\n<p>The Nasdaq was down more sharply than the S&amp;P 500 while the Dow was virtually flat, ending down less than 1 point.</p>\n<p>Investors were in a waiting game ahead of U.S. consumer prices index inflation data due Friday morning. A higher-than-expected reading would strengthen the case for a policy tightening decision at the U.S. central bank's meeting.</p>\n<p>In the first three days of the week, the Nasdaq rallied 4.7%, the S&amp;P advanced 3.6% and the Dow gained 3.4% as fears abated about the latest coronavirus variant Omicron.</p>\n<p>\"We had a rip roaring rally. There's still nervous people out there,\" said Dennis Dick, head of markets structure, proprietary trader at Bright Trading LLC in Las Vegas.</p>\n<p>\"We'd a Omicron relief rally but the underlying problem still remains, that the Fed's taking the punchbowl away.\"</p>\n<p>Joe Quinlan, chief market strategist for the CIO office of Bank of America, said investors may be taking profits and pausing buying after the three days of gains.</p>\n<p>\"Also there may be a little risk-off trade ahead of the CPI number on Friday,\" he said. \"If it comes in hotter than expected it really shines the light and the focus on the Fed meeting. The pressure would build on the Fed for a faster tapering.\"</p>\n<p>Fed Chair Powell signaled last week that the meeting would include a discussion about a faster tapering of bond-buying.</p>\n<p>\"It would reaffirm in many people's minds that the Fed is behind the curve,\" said Quinlan.</p>\n<p>If the inflation number implies a need to hike rates faster, this \"would put pressure on technology and give a bid to cyclicals\" he said.</p>\n<p>\"You'd want to buy the companies that could pass on these higher costs to consumers. That undermines the growth story. You want to own more cyclicals and value than growth,\" said Quinlan.</p>\n<p>A Reuters poll of economists predicted the Fed would raise rates by 25 basis points to 0.25-0.50% in the third quarter of next year. However, most saw the risk that a hike comes even sooner.</p>\n<p>The Dow Jones Industrial Average fell 0.06 points to 35,754.69, the S&amp;P 500 lost 33.76 points, or 0.72%, to 4,667.45 and the Nasdaq Composite dropped 269.62 points, or 1.71%, to 15,517.37.</p>\n<p>Nine of the 11 major S&amp;P sectors declined, with consumer discretionary down 1.7%, losing the most and real estate , down 1.4%, and information technology&nbsp;falling 1%, showing the next biggest losses.</p>\n<p>The only sector gainers were healthcare up 0.2% and consumer staples which clung to a 0.06% advance.</p>\n<p>Healthcare was boosted by a CVS Health Corp share gain of 4.5% after the drugstore operator raised its 2021 profit forecast.</p>\n<p>In consumer staples, heavyweight electric car maker Tesla&nbsp;was the biggest percentage decliner, falling 6%.</p>\n<p>Markets have seesawed since late November when the Omicron variant was discovered. Investors worried it could upend a global recovery at a time of surging inflation with Fed commentary exacerbating volatility.</p>\n<p>Wall Street's main indexes were supported this week by an update showing Pfizer and BioNTech's vaccine offered some protection against the Omicron variant.</p>\n<p>Data showed initial claims for state unemployment benefits tumbled 43,000 last week to 184,000, the lowest level in more than 52 years.</p>\n<p>GameStop Corp fell 10% after the video game retailer popular among retail investors said it was issued a subpoena by the U.S. securities regulator back in August for documents on an investigation into its share trading activity.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 3.03-to-1 ratio; on Nasdaq, a 3.05-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 23 new 52-week highs and 1 new lows; the Nasdaq Composite recorded 34 new highs and 68 new lows.</p>\n<p>On U.S. exchanges 9.75 billion shares changed hands compared with the 11.41 billion average for the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St closes lower ahead of inflation data, Fed meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St closes lower ahead of inflation data, Fed meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-10 07:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Wall Street closed lower on Thursday as investors banked some profits after three straight days of gains and turned their focus toward upcoming inflation data and how it might influence the Federal Reserve's meeting next week.</p>\n<p>The Nasdaq was down more sharply than the S&amp;P 500 while the Dow was virtually flat, ending down less than 1 point.</p>\n<p>Investors were in a waiting game ahead of U.S. consumer prices index inflation data due Friday morning. A higher-than-expected reading would strengthen the case for a policy tightening decision at the U.S. central bank's meeting.</p>\n<p>In the first three days of the week, the Nasdaq rallied 4.7%, the S&amp;P advanced 3.6% and the Dow gained 3.4% as fears abated about the latest coronavirus variant Omicron.</p>\n<p>\"We had a rip roaring rally. There's still nervous people out there,\" said Dennis Dick, head of markets structure, proprietary trader at Bright Trading LLC in Las Vegas.</p>\n<p>\"We'd a Omicron relief rally but the underlying problem still remains, that the Fed's taking the punchbowl away.\"</p>\n<p>Joe Quinlan, chief market strategist for the CIO office of Bank of America, said investors may be taking profits and pausing buying after the three days of gains.</p>\n<p>\"Also there may be a little risk-off trade ahead of the CPI number on Friday,\" he said. \"If it comes in hotter than expected it really shines the light and the focus on the Fed meeting. The pressure would build on the Fed for a faster tapering.\"</p>\n<p>Fed Chair Powell signaled last week that the meeting would include a discussion about a faster tapering of bond-buying.</p>\n<p>\"It would reaffirm in many people's minds that the Fed is behind the curve,\" said Quinlan.</p>\n<p>If the inflation number implies a need to hike rates faster, this \"would put pressure on technology and give a bid to cyclicals\" he said.</p>\n<p>\"You'd want to buy the companies that could pass on these higher costs to consumers. That undermines the growth story. You want to own more cyclicals and value than growth,\" said Quinlan.</p>\n<p>A Reuters poll of economists predicted the Fed would raise rates by 25 basis points to 0.25-0.50% in the third quarter of next year. However, most saw the risk that a hike comes even sooner.</p>\n<p>The Dow Jones Industrial Average fell 0.06 points to 35,754.69, the S&amp;P 500 lost 33.76 points, or 0.72%, to 4,667.45 and the Nasdaq Composite dropped 269.62 points, or 1.71%, to 15,517.37.</p>\n<p>Nine of the 11 major S&amp;P sectors declined, with consumer discretionary down 1.7%, losing the most and real estate , down 1.4%, and information technology&nbsp;falling 1%, showing the next biggest losses.</p>\n<p>The only sector gainers were healthcare up 0.2% and consumer staples which clung to a 0.06% advance.</p>\n<p>Healthcare was boosted by a CVS Health Corp share gain of 4.5% after the drugstore operator raised its 2021 profit forecast.</p>\n<p>In consumer staples, heavyweight electric car maker Tesla&nbsp;was the biggest percentage decliner, falling 6%.</p>\n<p>Markets have seesawed since late November when the Omicron variant was discovered. Investors worried it could upend a global recovery at a time of surging inflation with Fed commentary exacerbating volatility.</p>\n<p>Wall Street's main indexes were supported this week by an update showing Pfizer and BioNTech's vaccine offered some protection against the Omicron variant.</p>\n<p>Data showed initial claims for state unemployment benefits tumbled 43,000 last week to 184,000, the lowest level in more than 52 years.</p>\n<p>GameStop Corp fell 10% after the video game retailer popular among retail investors said it was issued a subpoena by the U.S. securities regulator back in August for documents on an investigation into its share trading activity.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 3.03-to-1 ratio; on Nasdaq, a 3.05-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 23 new 52-week highs and 1 new lows; the Nasdaq Composite recorded 34 new highs and 68 new lows.</p>\n<p>On U.S. exchanges 9.75 billion shares changed hands compared with the 11.41 billion average for the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QLD":"纳指两倍做多ETF","BK4504":"桥水持仓","TQQQ":"纳指三倍做多ETF","BK4099":"汽车制造商","BK4548":"巴美列捷福持仓","SDOW":"道指三倍做空ETF-ProShares","DJX":"1/100道琼斯","PSQ":"纳指反向ETF","TSLA":"特斯拉","QQQ":"纳指100ETF","UDOW":"道指三倍做多ETF-ProShares","PFE":"辉瑞","DXD":"道指两倍做空ETF","BK4534":"瑞士信贷持仓","BK4555":"新能源车","CVS":"西维斯健康","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4196":"保健护理服务","QID":"纳指两倍做空ETF","DDM":"道指两倍做多ETF","CPI":"IQ Real Return ETF","BK4527":"明星科技股",".DJI":"道琼斯","BK4550":"红杉资本持仓","SQQQ":"纳指三倍做空ETF",".IXIC":"NASDAQ Composite","BK4076":"电脑与电子产品零售","GME":"游戏驿站","DOG":"道指反向ETF",".SPX":"S&P 500 Index","BK4551":"寇图资本持仓","BK4547":"WSB热门概念"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190964556","content_text":"Wall Street closed lower on Thursday as investors banked some profits after three straight days of gains and turned their focus toward upcoming inflation data and how it might influence the Federal Reserve's meeting next week.\nThe Nasdaq was down more sharply than the S&P 500 while the Dow was virtually flat, ending down less than 1 point.\nInvestors were in a waiting game ahead of U.S. consumer prices index inflation data due Friday morning. A higher-than-expected reading would strengthen the case for a policy tightening decision at the U.S. central bank's meeting.\nIn the first three days of the week, the Nasdaq rallied 4.7%, the S&P advanced 3.6% and the Dow gained 3.4% as fears abated about the latest coronavirus variant Omicron.\n\"We had a rip roaring rally. There's still nervous people out there,\" said Dennis Dick, head of markets structure, proprietary trader at Bright Trading LLC in Las Vegas.\n\"We'd a Omicron relief rally but the underlying problem still remains, that the Fed's taking the punchbowl away.\"\nJoe Quinlan, chief market strategist for the CIO office of Bank of America, said investors may be taking profits and pausing buying after the three days of gains.\n\"Also there may be a little risk-off trade ahead of the CPI number on Friday,\" he said. \"If it comes in hotter than expected it really shines the light and the focus on the Fed meeting. The pressure would build on the Fed for a faster tapering.\"\nFed Chair Powell signaled last week that the meeting would include a discussion about a faster tapering of bond-buying.\n\"It would reaffirm in many people's minds that the Fed is behind the curve,\" said Quinlan.\nIf the inflation number implies a need to hike rates faster, this \"would put pressure on technology and give a bid to cyclicals\" he said.\n\"You'd want to buy the companies that could pass on these higher costs to consumers. That undermines the growth story. You want to own more cyclicals and value than growth,\" said Quinlan.\nA Reuters poll of economists predicted the Fed would raise rates by 25 basis points to 0.25-0.50% in the third quarter of next year. However, most saw the risk that a hike comes even sooner.\nThe Dow Jones Industrial Average fell 0.06 points to 35,754.69, the S&P 500 lost 33.76 points, or 0.72%, to 4,667.45 and the Nasdaq Composite dropped 269.62 points, or 1.71%, to 15,517.37.\nNine of the 11 major S&P sectors declined, with consumer discretionary down 1.7%, losing the most and real estate , down 1.4%, and information technology falling 1%, showing the next biggest losses.\nThe only sector gainers were healthcare up 0.2% and consumer staples which clung to a 0.06% advance.\nHealthcare was boosted by a CVS Health Corp share gain of 4.5% after the drugstore operator raised its 2021 profit forecast.\nIn consumer staples, heavyweight electric car maker Tesla was the biggest percentage decliner, falling 6%.\nMarkets have seesawed since late November when the Omicron variant was discovered. Investors worried it could upend a global recovery at a time of surging inflation with Fed commentary exacerbating volatility.\nWall Street's main indexes were supported this week by an update showing Pfizer and BioNTech's vaccine offered some protection against the Omicron variant.\nData showed initial claims for state unemployment benefits tumbled 43,000 last week to 184,000, the lowest level in more than 52 years.\nGameStop Corp fell 10% after the video game retailer popular among retail investors said it was issued a subpoena by the U.S. securities regulator back in August for documents on an investigation into its share trading activity.\nDeclining issues outnumbered advancing ones on the NYSE by a 3.03-to-1 ratio; on Nasdaq, a 3.05-to-1 ratio favored decliners.\nThe S&P 500 posted 23 new 52-week highs and 1 new lows; the Nasdaq Composite recorded 34 new highs and 68 new lows.\nOn U.S. exchanges 9.75 billion shares changed hands compared with the 11.41 billion average for the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":578,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872013591,"gmtCreate":1637374195480,"gmtModify":1637374195780,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/872013591","repostId":"2184842262","repostType":4,"repost":{"id":"2184842262","pubTimestamp":1637359018,"share":"https://www.laohu8.com/m/news/2184842262?lang=&edition=full","pubTime":"2021-11-20 05:56","market":"us","language":"en","title":"Nasdaq ends atop 16,000 mark for the first time on tech strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2184842262","media":"Reuters","summary":"(Reuters) - The Nasdaq Composite Index closed above 16,000 points for the first time on Friday, in i","content":"<p>(Reuters) - The Nasdaq Composite Index closed above 16,000 points for the first time on Friday, in its second-straight record finish powered by technology stocks, while pandemic jitters sent the Dow to its fourth losing session in the last five.</p>\n<p>Both the Nasdaq and S&amp;P 500 index scored a winning week, up 1.2% and 0.3% respectively, after last week's declines snapped a five-week run of higher finishes.</p>\n<p>The Dow Jones Industrial Average's second-successive weekly loss - this one of 1.4% - wiped out the last of its November gains, extending the index's drop from a Nov. 8 record high to 2.3%.</p>\n<p>Friday's fall was caused by banking, energy and airline stocks slumping on fears that European countries, battling a resurgence of COVID-19 cases, could follow Austria in moving towards a full lockdown.</p>\n<p>Banking stocks fell 1.6%, tracking a drop in Treasury yields as investors snapped up safe-haven bonds. The S&amp;P energy index dropped 3.9%, the worst performing sector, as crude prices fell on demand implications.</p>\n<p>Carriers including Delta Air Lines, United Airlines and American Airlines, and cruiseliners Norwegian Cruise Line and Carnival Corp all dropped between 0.6% and 2.8%.</p>\n<p>\"It's a normal time to take risk off. And in this case, there's just so much liquidity that the market doesn't go down - just people take risk off by going into safe havens,\" said Jay Hatfield, chief executive of Infrastructure Capital Management in New York.</p>\n<p>Falling yields and safe-haven demand supported major technology stocks, which in turn lifted the Nasdaq.</p>\n<p>FAANG stocks, which have largely persevered through economic shocks since 2020, traded broadly higher. Netflix Inc gained along with other stay-at-home stocks.</p>\n<p>Chipmaker Nvidia Corp rose 4.1% to its third straight closing high, and the Philadelphia semiconductor index , up 0.3%, hit its third record closing high in four.</p>\n<p>The Dow Jones Industrial Average fell 268.97 points, or 0.75%, to 35,601.98; the S&amp;P 500 lost 6.58 points, or 0.14%, at 4,697.96; and the Nasdaq Composite added 63.73 points, or 0.4%, to 16,057.44.</p>\n<p>The S&amp;P 500 gyrated on Friday before slipping into negative territory, after a week in which retailers pushed it to a record finish the previous day.</p>\n<p>The S&amp;P consumer discretionary sector rose 0.3% to a closing peak for a second day in a row, after breaking its lifetime intraday high on Friday. This follows strong retail earnings this week and positive signs for holiday shopping.</p>\n<p>Lowe's Companies rose 0.9% to its third successive record close after reporting third-quarter results on Wednesday. Etsy Inc, which posted earnings earlier this month, achieved the same closing feat after finishing up 1.4%.</p>\n<p>\"Out of the Q3 earnings, one of the trends we have seen is the resounding strength of the U.S. consumer,\" said Jessica Bemer, portfolio manager at Easterly Investment Partners.</p>\n<p>\"We've heard it all through this week from retailers talking about the consumer coming back into the store, enjoying the shopping experience and getting ready for the holidays. It makes sense but it was really validated during earnings season.\"</p>\n<p>Profit-taking in names which gained earlier in the week led to drops of between 2.9% and 8.8% in Macy's Inc, Kohls Corp and Gap Inc.</p>\n<p>The information technology segment, up 0.8%, was the best performer on the S&amp;P 500.</p>\n<p>It was buoyed by Intuit Inc, which jumped 10.1% as brokerages lifted their price targets on the income tax software company after it beat quarterly estimates and raised forecasts.</p>\n<p>Volume on U.S. exchanges was 10.68 billion shares, compared with the 11.12 billion average for the full session over the last 20 trading days.</p>\n<p>The S&amp;P 500 posted 45 new 52-week highs and nine new lows; the Nasdaq Composite recorded 100 new highs and 309 new lows.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq ends atop 16,000 mark for the first time on tech strength</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq ends atop 16,000 mark for the first time on tech strength\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-20 05:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/us-stocks-nasdaq-ends-atop-215658565.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - The Nasdaq Composite Index closed above 16,000 points for the first time on Friday, in its second-straight record finish powered by technology stocks, while pandemic jitters sent the Dow ...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-nasdaq-ends-atop-215658565.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COMP":"Compass, Inc.",".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://finance.yahoo.com/news/us-stocks-nasdaq-ends-atop-215658565.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2184842262","content_text":"(Reuters) - The Nasdaq Composite Index closed above 16,000 points for the first time on Friday, in its second-straight record finish powered by technology stocks, while pandemic jitters sent the Dow to its fourth losing session in the last five.\nBoth the Nasdaq and S&P 500 index scored a winning week, up 1.2% and 0.3% respectively, after last week's declines snapped a five-week run of higher finishes.\nThe Dow Jones Industrial Average's second-successive weekly loss - this one of 1.4% - wiped out the last of its November gains, extending the index's drop from a Nov. 8 record high to 2.3%.\nFriday's fall was caused by banking, energy and airline stocks slumping on fears that European countries, battling a resurgence of COVID-19 cases, could follow Austria in moving towards a full lockdown.\nBanking stocks fell 1.6%, tracking a drop in Treasury yields as investors snapped up safe-haven bonds. The S&P energy index dropped 3.9%, the worst performing sector, as crude prices fell on demand implications.\nCarriers including Delta Air Lines, United Airlines and American Airlines, and cruiseliners Norwegian Cruise Line and Carnival Corp all dropped between 0.6% and 2.8%.\n\"It's a normal time to take risk off. And in this case, there's just so much liquidity that the market doesn't go down - just people take risk off by going into safe havens,\" said Jay Hatfield, chief executive of Infrastructure Capital Management in New York.\nFalling yields and safe-haven demand supported major technology stocks, which in turn lifted the Nasdaq.\nFAANG stocks, which have largely persevered through economic shocks since 2020, traded broadly higher. Netflix Inc gained along with other stay-at-home stocks.\nChipmaker Nvidia Corp rose 4.1% to its third straight closing high, and the Philadelphia semiconductor index , up 0.3%, hit its third record closing high in four.\nThe Dow Jones Industrial Average fell 268.97 points, or 0.75%, to 35,601.98; the S&P 500 lost 6.58 points, or 0.14%, at 4,697.96; and the Nasdaq Composite added 63.73 points, or 0.4%, to 16,057.44.\nThe S&P 500 gyrated on Friday before slipping into negative territory, after a week in which retailers pushed it to a record finish the previous day.\nThe S&P consumer discretionary sector rose 0.3% to a closing peak for a second day in a row, after breaking its lifetime intraday high on Friday. This follows strong retail earnings this week and positive signs for holiday shopping.\nLowe's Companies rose 0.9% to its third successive record close after reporting third-quarter results on Wednesday. Etsy Inc, which posted earnings earlier this month, achieved the same closing feat after finishing up 1.4%.\n\"Out of the Q3 earnings, one of the trends we have seen is the resounding strength of the U.S. consumer,\" said Jessica Bemer, portfolio manager at Easterly Investment Partners.\n\"We've heard it all through this week from retailers talking about the consumer coming back into the store, enjoying the shopping experience and getting ready for the holidays. It makes sense but it was really validated during earnings season.\"\nProfit-taking in names which gained earlier in the week led to drops of between 2.9% and 8.8% in Macy's Inc, Kohls Corp and Gap Inc.\nThe information technology segment, up 0.8%, was the best performer on the S&P 500.\nIt was buoyed by Intuit Inc, which jumped 10.1% as brokerages lifted their price targets on the income tax software company after it beat quarterly estimates and raised forecasts.\nVolume on U.S. exchanges was 10.68 billion shares, compared with the 11.12 billion average for the full session over the last 20 trading days.\nThe S&P 500 posted 45 new 52-week highs and nine new lows; the Nasdaq Composite recorded 100 new highs and 309 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":130,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848511766,"gmtCreate":1636011791509,"gmtModify":1636012085571,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/848511766","repostId":"1109940019","repostType":4,"repost":{"id":"1109940019","pubTimestamp":1636011412,"share":"https://www.laohu8.com/m/news/1109940019?lang=&edition=full","pubTime":"2021-11-04 15:36","market":"us","language":"en","title":"Why a Fed rate hike could be just the medicine stocks need to keep this bull market going","url":"https://stock-news.laohu8.com/highlight/detail?id=1109940019","media":"MarketWatch","summary":"Stock market reacts in unusual ways to hikes in the Fed funds rate \niStockphoto\n\nHow should stock ma","content":"<p>Stock market reacts in unusual ways to hikes in the Fed funds rate </p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/98c464a358115dc8c8dfc1b078414b4a\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>iStockphoto</span></p>\n<p></p>\n<p>How should stock market investors react when the U.S. Federal Reserve begins to raise the Federal Funds rate? That question, in one form or another, is being asked by almost all investors these days. While no one knows for sure when the Fed’s rate hike cycle will begin, it could happen soon —perhaps by the end of the year. With the Fed funds rate near zero and the U.S. economy growing, the question is when, not if.</p>\n<p>Conventional wisdom dictates that rate increases are bad news. Higher rates mean that stocks face stiffer competition from bonds. It also means that stocks are worth less, according to standard discounted cash flow analysis: Higher rates mean that the present value of stocks’ future earnings and dividends are lower.</p>\n<p>Yet it’s surprisingly difficult to support this conventional wisdom with historical data. In fact, the S&amp;P 500&nbsp;has performed better in the wake of Fed decisions to raise the Fed funds rate than in the wake of rate cuts, on average.</p>\n<p>I reached this conclusion upon analyzing all rate hike increases and decreases announced by the Federal Reserve’s Open Market Committee (FOMC) dating back to 1990. For each rate change decision I calculated the S&amp;P 500’s total return from the date of the increase, either over the subsequent 12 months or until the date of the FOMC’s next rate change decision, whichever came first. The results are summarized in the table below.</p>\n<p><img src=\"https://static.tigerbbs.com/8ae1ad34f281733852d0ac5a95f0cc2f\" tg-width=\"700\" tg-height=\"471\" width=\"100%\" height=\"auto\"></p>\n<p></p>\n<p>If other things were equal, these results would suggest that investors actually prefer higher rates. But, as is so often the case, things are not equal. For example, as Eric Swanson told me in an interview, the Fed raises rates when it worries that the economy may be overheating. Swanson is a finance professor at the University of California, Irvine. Since the stock market typically does well when the economy is firing on all cylinders, it’s not particularly surprising that the stock market will do well, on average, during a rate-hike cycle.</p>\n<p>For similar reasons, it’s not surprising that the stock market will struggle during a rate-cut cycle. That’s because the FOMC will cut the Fed funds rate when it is worried that the economy is in danger of contracting. For a recent example of that, just think back to the waterfall decline in February and March of 2020 that was precipitated by the COVID-19 pandemic.</p>\n<p>There are two other big reasons why the stock market doesn’t react to rate hikes in the way conventional wisdom would suggest. The first is that the Federal Reserve in recent years has become increasingly transparent, telegraphing to the markets well in advance about when it may change the Fed funds rate. This means that the stock market will have had plenty of time to react by the time a rate hike actually occurs.</p>\n<p>This certainly has been the case this year, for example. For a number of months now, the Fed has explicitly announced its intention to begin tapering its monetary stimulus. In addition, the Fed circulates a “dot plot” after each rate-setting meeting showing FOMC members’ projections of where the Fed funds rate will be in coming months.</p>\n<p>Advisers often say: “Buy the rumor, sell the news.” This appears to apply here, making it difficult to measure the stock market’s reaction to higher rates. What appears to be the poor performance during a rate-cutting cycle might in fact be anticipation of the beginning of a rate-hike cycle.</p>\n<p>The other reason the stock market doesn’t always react in predictable ways to rate hike decisions: The Fed in recent years has increasingly relied on large-scale asset purchases in addition to changing the Fed funds rate —otherwise known as quantitative easing (QE).</p>\n<p>Indeed, according to research from UC Irvine’s Swanson, QE appears to have just as much impact on the stock market as cutting the Fed funds rate used to have in the decades before any of us had ever heard of QE. The study, “Measuring the Effects of Federal Reserve Forward Guidance and Asset Purchases on Financial Markets,” appeared in the March 2021 issue of the <i>Journal of Monetary Economics</i>. In fact, Swanson reports that, in a zero-Fed-funds world, QE may have even more impact on the stock market than rate changes.</p>\n<p>The bottom line? It’s not the case that a Fed funds rate hike is good news. But, at the same time, there is no easy, straightforward or mechanical way in which you can use changes to the Fed funds rate to time the stock market.</p>\n<p></p>\n<p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why a Fed rate hike could be just the medicine stocks need to keep this bull market going</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy a Fed rate hike could be just the medicine stocks need to keep this bull market going\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-04 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/why-a-fed-rate-hike-could-be-just-the-medicine-stocks-need-to-keep-this-bull-market-going-11635955739?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stock market reacts in unusual ways to hikes in the Fed funds rate \niStockphoto\n\nHow should stock market investors react when the U.S. Federal Reserve begins to raise the Federal Funds rate? That ...</p>\n\n<a href=\"https://www.marketwatch.com/story/why-a-fed-rate-hike-could-be-just-the-medicine-stocks-need-to-keep-this-bull-market-going-11635955739?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.marketwatch.com/story/why-a-fed-rate-hike-could-be-just-the-medicine-stocks-need-to-keep-this-bull-market-going-11635955739?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109940019","content_text":"Stock market reacts in unusual ways to hikes in the Fed funds rate \niStockphoto\n\nHow should stock market investors react when the U.S. Federal Reserve begins to raise the Federal Funds rate? That question, in one form or another, is being asked by almost all investors these days. While no one knows for sure when the Fed’s rate hike cycle will begin, it could happen soon —perhaps by the end of the year. With the Fed funds rate near zero and the U.S. economy growing, the question is when, not if.\nConventional wisdom dictates that rate increases are bad news. Higher rates mean that stocks face stiffer competition from bonds. It also means that stocks are worth less, according to standard discounted cash flow analysis: Higher rates mean that the present value of stocks’ future earnings and dividends are lower.\nYet it’s surprisingly difficult to support this conventional wisdom with historical data. In fact, the S&P 500 has performed better in the wake of Fed decisions to raise the Fed funds rate than in the wake of rate cuts, on average.\nI reached this conclusion upon analyzing all rate hike increases and decreases announced by the Federal Reserve’s Open Market Committee (FOMC) dating back to 1990. For each rate change decision I calculated the S&P 500’s total return from the date of the increase, either over the subsequent 12 months or until the date of the FOMC’s next rate change decision, whichever came first. The results are summarized in the table below.\n\n\nIf other things were equal, these results would suggest that investors actually prefer higher rates. But, as is so often the case, things are not equal. For example, as Eric Swanson told me in an interview, the Fed raises rates when it worries that the economy may be overheating. Swanson is a finance professor at the University of California, Irvine. Since the stock market typically does well when the economy is firing on all cylinders, it’s not particularly surprising that the stock market will do well, on average, during a rate-hike cycle.\nFor similar reasons, it’s not surprising that the stock market will struggle during a rate-cut cycle. That’s because the FOMC will cut the Fed funds rate when it is worried that the economy is in danger of contracting. For a recent example of that, just think back to the waterfall decline in February and March of 2020 that was precipitated by the COVID-19 pandemic.\nThere are two other big reasons why the stock market doesn’t react to rate hikes in the way conventional wisdom would suggest. The first is that the Federal Reserve in recent years has become increasingly transparent, telegraphing to the markets well in advance about when it may change the Fed funds rate. This means that the stock market will have had plenty of time to react by the time a rate hike actually occurs.\nThis certainly has been the case this year, for example. For a number of months now, the Fed has explicitly announced its intention to begin tapering its monetary stimulus. In addition, the Fed circulates a “dot plot” after each rate-setting meeting showing FOMC members’ projections of where the Fed funds rate will be in coming months.\nAdvisers often say: “Buy the rumor, sell the news.” This appears to apply here, making it difficult to measure the stock market’s reaction to higher rates. What appears to be the poor performance during a rate-cutting cycle might in fact be anticipation of the beginning of a rate-hike cycle.\nThe other reason the stock market doesn’t always react in predictable ways to rate hike decisions: The Fed in recent years has increasingly relied on large-scale asset purchases in addition to changing the Fed funds rate —otherwise known as quantitative easing (QE).\nIndeed, according to research from UC Irvine’s Swanson, QE appears to have just as much impact on the stock market as cutting the Fed funds rate used to have in the decades before any of us had ever heard of QE. The study, “Measuring the Effects of Federal Reserve Forward Guidance and Asset Purchases on Financial Markets,” appeared in the March 2021 issue of the Journal of Monetary Economics. In fact, Swanson reports that, in a zero-Fed-funds world, QE may have even more impact on the stock market than rate changes.\nThe bottom line? It’s not the case that a Fed funds rate hike is good news. But, at the same time, there is no easy, straightforward or mechanical way in which you can use changes to the Fed funds rate to time the stock market.","news_type":1},"isVote":1,"tweetType":1,"viewCount":181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843288557,"gmtCreate":1635832451804,"gmtModify":1635832451903,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/843288557","repostId":"2180209403","repostType":4,"repost":{"id":"2180209403","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1635798424,"share":"https://www.laohu8.com/m/news/2180209403?lang=&edition=full","pubTime":"2021-11-02 04:27","market":"us","language":"en","title":"Wall Street hits records as Tesla surges; focus on Fed meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2180209403","media":"Reuters","summary":"Nov 1 (Reuters) - Wall Street's main indexes notched record closing highs on Monday as Tesla shares ","content":"<p>Nov 1 (Reuters) - Wall Street's main indexes notched record closing highs on Monday as Tesla shares surged and the energy sector gained while investors looked ahead to a major Federal Reserve meeting later in the week.</p>\n<p>The Dow Jones Industrial Average eclipsed 36,000 points for the first time ever during intraday trading, ending just shy of that level.</p>\n<p>Accommodative monetary policy has been <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the key supports for the stock market, with the benchmark S&amp;P 500 rising 22.8% so far this year.</p>\n<p>The Federal Reserve on Wednesday is expected to approve plans to scale back its $120 billion monthly bond-buying program put in place to help the economy during the coronavirus pandemic, while investors will also be focused on commentary about interest rates and how sustained the recent surge in inflation is.</p>\n<p>\"This (meeting) is going to be a relatively big deal,\" said Paul Nolte, portfolio manager at Kingsview Investment Management in Chicago. \"We are expecting to hear the glide path for tapering the bond purchases.\"</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 94.28 points, or 0.26%, to 35,913.84, the S&amp;P 500&nbsp;gained 8.29 points, or 0.18%, to 4,613.67 and the Nasdaq Composite&nbsp;added 97.53 points, or 0.63%, to 15,595.92.</p>\n<p>Tesla shares jumped 8.5%, helping lift the S&amp;P 500 consumer discretionary sector&nbsp;about 1.5%.</p>\n<p>Shares of the electric car maker have charged higher since the company's market value crossed $1 trillion last week.</p>\n<p>Among S&amp;P 500 sectors, energy led the way, rising 1.6%, while the communications services group dropped 0.7%.</p>\n<p>The small-cap Russell 2000 index was a standout, rising 2.7% for its biggest daily percentage gain since late August.</p>\n<p>A survey on Monday showed U.S. manufacturing activity slowed in October, with all industries reporting record-long lead times for raw materials, indicating that stretched supply chains continued to constrain economic activity early in the fourth quarter.</p>\n<p>With over half of S&amp;P 500 companies having reported, third-quarter earnings are expected to have climbed 39%, according to Refinitiv IBES.</p>\n<p>\"There continues to be positive sentiment around earnings despite some high-profile misses,\" said Kristina Hooper, chief global market strategist at investment management firm Invesco.</p>\n<p>In company news, Harley-Davidson Inc shares jumped 9.1% after the European Union removed retaliatory tariffs on U.S. products, including whiskey, power boats and company's motorcycles.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.84-to-1 ratio; on Nasdaq, a 3.05-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 46 new 52-week highs and 2 new lows; the Nasdaq Composite recorded 208 new highs and 39 new lows.</p>\n<p>About 10.5 billion shares changed hands in U.S. exchanges, compared with the 10.3 billion daily average over the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street hits records as Tesla surges; focus on Fed meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street hits records as Tesla surges; focus on Fed meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-11-02 04:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nov 1 (Reuters) - Wall Street's main indexes notched record closing highs on Monday as Tesla shares surged and the energy sector gained while investors looked ahead to a major Federal Reserve meeting later in the week.</p>\n<p>The Dow Jones Industrial Average eclipsed 36,000 points for the first time ever during intraday trading, ending just shy of that level.</p>\n<p>Accommodative monetary policy has been <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the key supports for the stock market, with the benchmark S&amp;P 500 rising 22.8% so far this year.</p>\n<p>The Federal Reserve on Wednesday is expected to approve plans to scale back its $120 billion monthly bond-buying program put in place to help the economy during the coronavirus pandemic, while investors will also be focused on commentary about interest rates and how sustained the recent surge in inflation is.</p>\n<p>\"This (meeting) is going to be a relatively big deal,\" said Paul Nolte, portfolio manager at Kingsview Investment Management in Chicago. \"We are expecting to hear the glide path for tapering the bond purchases.\"</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 94.28 points, or 0.26%, to 35,913.84, the S&amp;P 500&nbsp;gained 8.29 points, or 0.18%, to 4,613.67 and the Nasdaq Composite&nbsp;added 97.53 points, or 0.63%, to 15,595.92.</p>\n<p>Tesla shares jumped 8.5%, helping lift the S&amp;P 500 consumer discretionary sector&nbsp;about 1.5%.</p>\n<p>Shares of the electric car maker have charged higher since the company's market value crossed $1 trillion last week.</p>\n<p>Among S&amp;P 500 sectors, energy led the way, rising 1.6%, while the communications services group dropped 0.7%.</p>\n<p>The small-cap Russell 2000 index was a standout, rising 2.7% for its biggest daily percentage gain since late August.</p>\n<p>A survey on Monday showed U.S. manufacturing activity slowed in October, with all industries reporting record-long lead times for raw materials, indicating that stretched supply chains continued to constrain economic activity early in the fourth quarter.</p>\n<p>With over half of S&amp;P 500 companies having reported, third-quarter earnings are expected to have climbed 39%, according to Refinitiv IBES.</p>\n<p>\"There continues to be positive sentiment around earnings despite some high-profile misses,\" said Kristina Hooper, chief global market strategist at investment management firm Invesco.</p>\n<p>In company news, Harley-Davidson Inc shares jumped 9.1% after the European Union removed retaliatory tariffs on U.S. products, including whiskey, power boats and company's motorcycles.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.84-to-1 ratio; on Nasdaq, a 3.05-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 46 new 52-week highs and 2 new lows; the Nasdaq Composite recorded 208 new highs and 39 new lows.</p>\n<p>About 10.5 billion shares changed hands in U.S. exchanges, compared with the 10.3 billion daily average over the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2180209403","content_text":"Nov 1 (Reuters) - Wall Street's main indexes notched record closing highs on Monday as Tesla shares surged and the energy sector gained while investors looked ahead to a major Federal Reserve meeting later in the week.\nThe Dow Jones Industrial Average eclipsed 36,000 points for the first time ever during intraday trading, ending just shy of that level.\nAccommodative monetary policy has been one of the key supports for the stock market, with the benchmark S&P 500 rising 22.8% so far this year.\nThe Federal Reserve on Wednesday is expected to approve plans to scale back its $120 billion monthly bond-buying program put in place to help the economy during the coronavirus pandemic, while investors will also be focused on commentary about interest rates and how sustained the recent surge in inflation is.\n\"This (meeting) is going to be a relatively big deal,\" said Paul Nolte, portfolio manager at Kingsview Investment Management in Chicago. \"We are expecting to hear the glide path for tapering the bond purchases.\"\nThe Dow Jones Industrial Average rose 94.28 points, or 0.26%, to 35,913.84, the S&P 500 gained 8.29 points, or 0.18%, to 4,613.67 and the Nasdaq Composite added 97.53 points, or 0.63%, to 15,595.92.\nTesla shares jumped 8.5%, helping lift the S&P 500 consumer discretionary sector about 1.5%.\nShares of the electric car maker have charged higher since the company's market value crossed $1 trillion last week.\nAmong S&P 500 sectors, energy led the way, rising 1.6%, while the communications services group dropped 0.7%.\nThe small-cap Russell 2000 index was a standout, rising 2.7% for its biggest daily percentage gain since late August.\nA survey on Monday showed U.S. manufacturing activity slowed in October, with all industries reporting record-long lead times for raw materials, indicating that stretched supply chains continued to constrain economic activity early in the fourth quarter.\nWith over half of S&P 500 companies having reported, third-quarter earnings are expected to have climbed 39%, according to Refinitiv IBES.\n\"There continues to be positive sentiment around earnings despite some high-profile misses,\" said Kristina Hooper, chief global market strategist at investment management firm Invesco.\nIn company news, Harley-Davidson Inc shares jumped 9.1% after the European Union removed retaliatory tariffs on U.S. products, including whiskey, power boats and company's motorcycles.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.84-to-1 ratio; on Nasdaq, a 3.05-to-1 ratio favored advancers.\nThe S&P 500 posted 46 new 52-week highs and 2 new lows; the Nasdaq Composite recorded 208 new highs and 39 new lows.\nAbout 10.5 billion shares changed hands in U.S. exchanges, compared with the 10.3 billion daily average over the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":113611036,"gmtCreate":1622609557625,"gmtModify":1634099952450,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Pls like and comment","listText":"Pls like and comment","text":"Pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/113611036","repostId":"1106176005","repostType":4,"repost":{"id":"1106176005","pubTimestamp":1622588821,"share":"https://www.laohu8.com/m/news/1106176005?lang=&edition=full","pubTime":"2021-06-02 07:07","market":"us","language":"en","title":"S&P 500 dips, as healthcare weighs; Dow ends higher","url":"https://stock-news.laohu8.com/highlight/detail?id=1106176005","media":"Reuters","summary":"The S&P 500dipped on Tuesday, with declines in healthcare and tech shares countered by energy and financial gains, as investors weighed the latest U.S. economic data for signs of a rebound and rising inflation.The S&P 500 financial sectorhit a record high, while expected growth in fuel demand boosted oil prices and helped lift the energy sector3.9%, its biggest $one$-day gain in nearly four months. The heavyweight tech sectorfell while the healthcare sectorwas dragged down by a weak profit forec","content":"<p>The S&amp;P 500(.SPX)dipped on Tuesday, with declines in healthcare and tech shares countered by energy and financial gains, as investors weighed the latest U.S. economic data for signs of a rebound and rising inflation.</p><p>The S&amp;P 500 financial sector(.SPSY)hit a record high, while expected growth in fuel demand boosted oil prices and helped lift the energy sector(.SPNY)3.9%, its biggest <a href=\"https://laohu8.com/S/AONE\">one</a>-day gain in nearly four months. The heavyweight tech sector(.SPLRCT)fell while the healthcare sector(.SPXHC)was dragged down by a weak profit forecast from <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories</a>(ABT.N).</p><p>Data showed U.S.manufacturing activity pickedup in May as pent-up demand in a reopening economy boosted orders. But unfinished work piled up because of shortages of raw materials and labor.</p><p>\"People came back from a holiday weekend convinced that the economy is recovering nicely and that any inflation that we might be seeing in labor and other costs is temporary,\" Peter Tuz, president of <a href=\"https://laohu8.com/S/CCF\">Chase</a> Investment Counsel in Charlottesville, Virginia.</p><p>The Dow Jones Industrial Average(.DJI)rose 45.86 points, or 0.13%, to 34,575.31; the S&amp;P 500(.SPX)lost 2.07 points, or 0.05%, at 4,202.04; and the <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> Composite(.IXIC)dropped 12.26 points, or 0.09%, to 13,736.48.</p><p>Along with sharp gains for financials and energy, the small-cap Russell 2000(.RUT)rose 1.1% on Tuesday, underscoring strength for segments of the stock market expected to do particularly well in an expanding economy.</p><p>While the S&amp;P 500 remains less than 1% of its record high after four straight months of gains, investors are worried about whether rising inflation could hit equity prices.</p><p>\"We have supply chain issues, delays, price increases, pricing pressures in general, we have got employers saying they have got difficulty sourcing labor,\" said Kristina Hooper, chief global market strategist at <a href=\"https://laohu8.com/S/IVZ\">Invesco</a> in <a href=\"https://laohu8.com/S/NWY\">New York</a>.</p><p>\"So this is a microcosm of what we are already hearing about and seeing in the overall economy and it's just a reminder that inflation remains a concern.\"</p><p>A Wall St. sign is seen near the <a href=\"https://laohu8.com/S/NYRT\">New York</a> Stock Exchange (NYSE) in <a href=\"https://laohu8.com/S/NGD\">New</a> York <a href=\"https://laohu8.com/S/CHCO\">City</a>, U.S., May 4, 2021. REUTERS/Brendan McDermid/File Photo</p><p>Stock markets on Friday brushed off a surge inkey inflation readingsfor April following reassurances from Federal Reserve officials that the central bank’s ultra-loose monetary policy would remain in place.</p><p>Minneapolis Federal Reserve Bank President Neel Kashkari and Fed Vice Chair for supervision Randal Quarles on Tuesday reiterated the view that higher prices would be transitory.</p><p>This week's focus will be on a raft of economic data, culminating with U.S. payrolls due on Friday.</p><p>Abbott Labs shares fell 9.3% after the company cut itsfull-year 2021 profit forecast, citing expectations for a sharp decline in revenue from its COVID-19 tests as more Americans get vaccinated. Shares of other test makers also fell.</p><p>Cloudera Inc(CLDR.N)shares jumped 23.9% after private equity firms KKR &amp; Co(KKR.N)and Clayton Dubilier &amp; Rice LLCagreed to take the data analytics firm private.</p><p>A group of“meme stocks” extended gainsfrom the previous week, with shares of <a href=\"https://laohu8.com/S/AMC\">AMC Entertainment</a> Holdings Inc(AMC.N)up 22.7% after the movie theater chain said it sold $230 million of its stock.</p><p>Advancing issues outnumbered decliners on the NYSE by a 2.54-to-1 ratio; on <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a>, a 1.79-to-1 ratio favored advancers.</p><p>The S&amp;P 500 posted 73 new 52-week highs and no new lows; the Nasdaq Composite recorded 168 new highs and 25 new lows.</p><p>About 10.7 billion shares changed hands in U.S. exchanges, compared with the 10.5 billion daily average over the last 20 sessions.</p><p><b>Here are company's financial statements：</b></p><p><a href=\"https://laohu8.com/NW/1184181912\" target=\"_blank\"><b>Zoom reports blowout earnings but warns of a coming slowdown</b></a></p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 dips, as healthcare weighs; Dow ends higher</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 dips, as healthcare weighs; Dow ends higher\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-02 07:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/sp-500-dips-healthcare-weighs-dow-ends-higher-2021-06-01/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500(.SPX)dipped on Tuesday, with declines in healthcare and tech shares countered by energy and financial gains, as investors weighed the latest U.S. economic data for signs of a rebound and ...</p>\n\n<a href=\"https://www.reuters.com/business/sp-500-dips-healthcare-weighs-dow-ends-higher-2021-06-01/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","OEX":"标普100",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","SPY":"标普500ETF","IVV":"标普500指数ETF","SDS":"两倍做空标普500ETF","OEF":"标普100指数ETF-iShares","SPXU":"三倍做空标普500ETF","SH":"标普500反向ETF","UPRO":"三倍做多标普500ETF","SSO":"两倍做多标普500ETF"},"source_url":"https://www.reuters.com/business/sp-500-dips-healthcare-weighs-dow-ends-higher-2021-06-01/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106176005","content_text":"The S&P 500(.SPX)dipped on Tuesday, with declines in healthcare and tech shares countered by energy and financial gains, as investors weighed the latest U.S. economic data for signs of a rebound and rising inflation.The S&P 500 financial sector(.SPSY)hit a record high, while expected growth in fuel demand boosted oil prices and helped lift the energy sector(.SPNY)3.9%, its biggest one-day gain in nearly four months. The heavyweight tech sector(.SPLRCT)fell while the healthcare sector(.SPXHC)was dragged down by a weak profit forecast from Abbott Laboratories(ABT.N).Data showed U.S.manufacturing activity pickedup in May as pent-up demand in a reopening economy boosted orders. But unfinished work piled up because of shortages of raw materials and labor.\"People came back from a holiday weekend convinced that the economy is recovering nicely and that any inflation that we might be seeing in labor and other costs is temporary,\" Peter Tuz, president of Chase Investment Counsel in Charlottesville, Virginia.The Dow Jones Industrial Average(.DJI)rose 45.86 points, or 0.13%, to 34,575.31; the S&P 500(.SPX)lost 2.07 points, or 0.05%, at 4,202.04; and the Nasdaq Composite(.IXIC)dropped 12.26 points, or 0.09%, to 13,736.48.Along with sharp gains for financials and energy, the small-cap Russell 2000(.RUT)rose 1.1% on Tuesday, underscoring strength for segments of the stock market expected to do particularly well in an expanding economy.While the S&P 500 remains less than 1% of its record high after four straight months of gains, investors are worried about whether rising inflation could hit equity prices.\"We have supply chain issues, delays, price increases, pricing pressures in general, we have got employers saying they have got difficulty sourcing labor,\" said Kristina Hooper, chief global market strategist at Invesco in New York.\"So this is a microcosm of what we are already hearing about and seeing in the overall economy and it's just a reminder that inflation remains a concern.\"A Wall St. sign is seen near the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2021. REUTERS/Brendan McDermid/File PhotoStock markets on Friday brushed off a surge inkey inflation readingsfor April following reassurances from Federal Reserve officials that the central bank’s ultra-loose monetary policy would remain in place.Minneapolis Federal Reserve Bank President Neel Kashkari and Fed Vice Chair for supervision Randal Quarles on Tuesday reiterated the view that higher prices would be transitory.This week's focus will be on a raft of economic data, culminating with U.S. payrolls due on Friday.Abbott Labs shares fell 9.3% after the company cut itsfull-year 2021 profit forecast, citing expectations for a sharp decline in revenue from its COVID-19 tests as more Americans get vaccinated. Shares of other test makers also fell.Cloudera Inc(CLDR.N)shares jumped 23.9% after private equity firms KKR & Co(KKR.N)and Clayton Dubilier & Rice LLCagreed to take the data analytics firm private.A group of“meme stocks” extended gainsfrom the previous week, with shares of AMC Entertainment Holdings Inc(AMC.N)up 22.7% after the movie theater chain said it sold $230 million of its stock.Advancing issues outnumbered decliners on the NYSE by a 2.54-to-1 ratio; on Nasdaq, a 1.79-to-1 ratio favored advancers.The S&P 500 posted 73 new 52-week highs and no new lows; the Nasdaq Composite recorded 168 new highs and 25 new lows.About 10.7 billion shares changed hands in U.S. exchanges, compared with the 10.5 billion daily average over the last 20 sessions.Here are company's financial statements：Zoom reports blowout earnings but warns of a coming slowdown","news_type":1},"isVote":1,"tweetType":1,"viewCount":193,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":134383160,"gmtCreate":1622208154850,"gmtModify":1634182855146,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Pls comment and like","listText":"Pls comment and like","text":"Pls comment and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/134383160","repostId":"1117074228","repostType":4,"isVote":1,"tweetType":1,"viewCount":254,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":868195204,"gmtCreate":1632618072308,"gmtModify":1632652150356,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/868195204","repostId":"2170861444","repostType":4,"isVote":1,"tweetType":1,"viewCount":101,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":884395526,"gmtCreate":1631853965665,"gmtModify":1631890097883,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/884395526","repostId":"1105376345","repostType":4,"repost":{"id":"1105376345","pubTimestamp":1631833833,"share":"https://www.laohu8.com/m/news/1105376345?lang=&edition=full","pubTime":"2021-09-17 07:10","market":"us","language":"en","title":"S&P ends modestly lower as rising Treasury yields offset robust retail data","url":"https://stock-news.laohu8.com/highlight/detail?id=1105376345","media":"Reuters","summary":"NEW YORK (Reuters) - The S&P 500 ended slightly down on Thursday, paring losses in late trading afte","content":"<p>NEW YORK (Reuters) - The S&amp;P 500 ended slightly down on Thursday, paring losses in late trading after unexpectedly strong retail sales data underscored the strength of the U.S. economic recovery.</p>\n<p>The three major indexes spent much of the day in negative territory as rising U.S. Treasury yields pressured market-leading tech stocks, and the rising dollar weighed on exporters.</p>\n<p>Amazon.com Inc, buoyed by solid online sales in the Commerce Department’s report, helped push the Nasdaq into positive territory.</p>\n<p>“Looking at today, clearly we had positive news from retail sales and it looks as if the massive slowdown in the economy is not materializing as a lot of people expected,” said Ryan Detrick, senior market strategist at LPL Financial in Charlotte, North Carolina.</p>\n<p>“It’s a nice reminder that the economy is still taking two steps forward for each step back even amid the COVID concerns,” Detrick added.</p>\n<p>Economically sensitive transports and microchips were among the outperformers.</p>\n<p>Data released before the opening bell showed an unexpected bump in retail sales as shoppers weathered Hurricane Ida and the COVID Delta variant, evidence of resilience in the consumer, who contributes about 70% to U.S. economic growth.</p>\n<p>“Once again, it shows the U.S. consumer continues to spend and continues to help this economy grow,” Detrick said.</p>\n<p>The Dow Jones Industrial Average fell 63.07 points, or 0.18%, to 34,751.32; the S&amp;P 500 lost 6.95 points, or 0.16%, at 4,473.75; and the Nasdaq Composite added 20.40 points, or 0.13%, at 15,181.92.</p>\n<p>Eight of the 11 major sectors in the S&amp;P 500 ended lower, with materials suffering the largest percentage drop.</p>\n<p>The consumer discretionary spending sector posted the biggest gain, with Amazon.com doing the heavy lifting.</p>\n<p>Apparel company Gap Inc gained 1.6%. Online marketplace Etsy Inc and luxury accessory company Tapestry Inc rose 3.1% and 1.9%, respectively.</p>\n<p>Ford Motor Co rose 1.4% after it announced plans to boost production of its F-150 electric pickup model.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.27-to-1 ratio; on Nasdaq, a 1.06-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted nine new 52-week highs and one new low; the Nasdaq Composite recorded 82 new highs and 94 new lows.</p>\n<p>Volume on U.S. exchanges was 9.37 billion shares, compared with the 9.44 billion average over the last 20 trading days.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P ends modestly lower as rising Treasury yields offset robust retail data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P ends modestly lower as rising Treasury yields offset robust retail data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-17 07:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/usa-stocks/us-stocks-sp-ends-modestly-lower-as-rising-treasury-yields-offset-robust-retail-data-idUSL1N2QI2MB><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - The S&P 500 ended slightly down on Thursday, paring losses in late trading after unexpectedly strong retail sales data underscored the strength of the U.S. economic recovery.\nThe ...</p>\n\n<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-sp-ends-modestly-lower-as-rising-treasury-yields-offset-robust-retail-data-idUSL1N2QI2MB\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-sp-ends-modestly-lower-as-rising-treasury-yields-offset-robust-retail-data-idUSL1N2QI2MB","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105376345","content_text":"NEW YORK (Reuters) - The S&P 500 ended slightly down on Thursday, paring losses in late trading after unexpectedly strong retail sales data underscored the strength of the U.S. economic recovery.\nThe three major indexes spent much of the day in negative territory as rising U.S. Treasury yields pressured market-leading tech stocks, and the rising dollar weighed on exporters.\nAmazon.com Inc, buoyed by solid online sales in the Commerce Department’s report, helped push the Nasdaq into positive territory.\n“Looking at today, clearly we had positive news from retail sales and it looks as if the massive slowdown in the economy is not materializing as a lot of people expected,” said Ryan Detrick, senior market strategist at LPL Financial in Charlotte, North Carolina.\n“It’s a nice reminder that the economy is still taking two steps forward for each step back even amid the COVID concerns,” Detrick added.\nEconomically sensitive transports and microchips were among the outperformers.\nData released before the opening bell showed an unexpected bump in retail sales as shoppers weathered Hurricane Ida and the COVID Delta variant, evidence of resilience in the consumer, who contributes about 70% to U.S. economic growth.\n“Once again, it shows the U.S. consumer continues to spend and continues to help this economy grow,” Detrick said.\nThe Dow Jones Industrial Average fell 63.07 points, or 0.18%, to 34,751.32; the S&P 500 lost 6.95 points, or 0.16%, at 4,473.75; and the Nasdaq Composite added 20.40 points, or 0.13%, at 15,181.92.\nEight of the 11 major sectors in the S&P 500 ended lower, with materials suffering the largest percentage drop.\nThe consumer discretionary spending sector posted the biggest gain, with Amazon.com doing the heavy lifting.\nApparel company Gap Inc gained 1.6%. Online marketplace Etsy Inc and luxury accessory company Tapestry Inc rose 3.1% and 1.9%, respectively.\nFord Motor Co rose 1.4% after it announced plans to boost production of its F-150 electric pickup model.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.27-to-1 ratio; on Nasdaq, a 1.06-to-1 ratio favored advancers.\nThe S&P 500 posted nine new 52-week highs and one new low; the Nasdaq Composite recorded 82 new highs and 94 new lows.\nVolume on U.S. exchanges was 9.37 billion shares, compared with the 9.44 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":35,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804554404,"gmtCreate":1627967348108,"gmtModify":1631892690930,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/804554404","repostId":"1177462457","repostType":4,"repost":{"id":"1177462457","pubTimestamp":1627962300,"share":"https://www.laohu8.com/m/news/1177462457?lang=&edition=full","pubTime":"2021-08-03 11:45","market":"us","language":"en","title":"Tesla Stock Is Rallying Again. Thank China.","url":"https://stock-news.laohu8.com/highlight/detail?id=1177462457","media":"Barrons","summary":"Tesla stock looks like it is breaking out, with a hefty gain despite a lack of substantial news. The","content":"<p>Tesla stock looks like it is breaking out, with a hefty gain despite a lack of substantial news. The likeliest reason is developments in China.</p>\n<p>Shares have been on a tear. Last week, despite a 2% decline after the electric-car company reported its earnings on Tuesday, Tesla (ticker: TSLA) shares rose 6.8% from $643.38, closing the week at $687.20.</p>\n<p>The results were better than expected, with the company setting new records for operating profit and bottom-line income, so that news may have helped the stock even if the positive reaction was delayed.News&nbsp;from&nbsp;Ford Motor(F) may have helped Tesla stock even more.</p>\n<p>Wednesday evening, Ford raised its forecast for operating profits for the full year—a sign that the shortage of&nbsp;semiconductors&nbsp;that constrained global auto production in the first half of 2021 is abating.</p>\n<p>But that was all last week’s news, and Tesla shares were up another 3% on Monday. The&nbsp;S&amp;P 500&nbsp;and&nbsp;Dow Jones Industrial Average&nbsp;were down 0.2% and 0.3%, respectively.</p>\n<p>Investors may be feeling bullish about&nbsp;China’s electric-vehicle&nbsp;market.NIO(NIO),XPeng(XPEV) and&nbsp;Li Auto(LI) all reported their&nbsp;July&nbsp;deliveries recently. All were at about 8,000 units for the month, but XPeng and Li reported records, NIO was just short of its monthly record.</p>\n<p>Those numbers are another sign that Chinese EV demand is hot. And China is the world’s largest market for new cars.</p>\n<p>XPeng shares were up 7.1% on Monday, while Li stock rose 0.9%. NIO shares were up 2.6%.</p>\n<p>Optimism about Tesla’s driver-assistance software might also be adding to the rally. Tesla recently released new versions of its autonomous-driving software. Now, videos are popping up on&nbsp;Twitter(TWTR) and YouTube showing Tesla vehicles driving themselves successfully.</p>\n<p>The videos, of course, are only a sampling. And Tesla’s software still requires drivers to be engaged at all times. True self-driving cars are still down the road.</p>\n<p>Tesla stock closed 2020 at $705.67. At current levels of around $710, the shares are up about 2% year to date. Closing above $700 would be a good sign for the stock. Shares haven’t closed above $700 since May, when investors were worrying about the chip shortage and the pace of growth in China’s EV industry.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Stock Is Rallying Again. Thank China.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Stock Is Rallying Again. Thank China.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-03 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/tesla-stock-ev-china-li-xpeng-nio-51627923717?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla stock looks like it is breaking out, with a hefty gain despite a lack of substantial news. The likeliest reason is developments in China.\nShares have been on a tear. Last week, despite a 2% ...</p>\n\n<a href=\"https://www.barrons.com/articles/tesla-stock-ev-china-li-xpeng-nio-51627923717?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.barrons.com/articles/tesla-stock-ev-china-li-xpeng-nio-51627923717?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177462457","content_text":"Tesla stock looks like it is breaking out, with a hefty gain despite a lack of substantial news. The likeliest reason is developments in China.\nShares have been on a tear. Last week, despite a 2% decline after the electric-car company reported its earnings on Tuesday, Tesla (ticker: TSLA) shares rose 6.8% from $643.38, closing the week at $687.20.\nThe results were better than expected, with the company setting new records for operating profit and bottom-line income, so that news may have helped the stock even if the positive reaction was delayed.News from Ford Motor(F) may have helped Tesla stock even more.\nWednesday evening, Ford raised its forecast for operating profits for the full year—a sign that the shortage of semiconductors that constrained global auto production in the first half of 2021 is abating.\nBut that was all last week’s news, and Tesla shares were up another 3% on Monday. The S&P 500 and Dow Jones Industrial Average were down 0.2% and 0.3%, respectively.\nInvestors may be feeling bullish about China’s electric-vehicle market.NIO(NIO),XPeng(XPEV) and Li Auto(LI) all reported their July deliveries recently. All were at about 8,000 units for the month, but XPeng and Li reported records, NIO was just short of its monthly record.\nThose numbers are another sign that Chinese EV demand is hot. And China is the world’s largest market for new cars.\nXPeng shares were up 7.1% on Monday, while Li stock rose 0.9%. NIO shares were up 2.6%.\nOptimism about Tesla’s driver-assistance software might also be adding to the rally. Tesla recently released new versions of its autonomous-driving software. Now, videos are popping up on Twitter(TWTR) and YouTube showing Tesla vehicles driving themselves successfully.\nThe videos, of course, are only a sampling. And Tesla’s software still requires drivers to be engaged at all times. True self-driving cars are still down the road.\nTesla stock closed 2020 at $705.67. At current levels of around $710, the shares are up about 2% year to date. Closing above $700 would be a good sign for the stock. Shares haven’t closed above $700 since May, when investors were worrying about the chip shortage and the pace of growth in China’s EV industry.","news_type":1},"isVote":1,"tweetType":1,"viewCount":53,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":607593319,"gmtCreate":1639557284217,"gmtModify":1639557284489,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/607593319","repostId":"1107549050","repostType":4,"repost":{"id":"1107549050","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639552499,"share":"https://www.laohu8.com/m/news/1107549050?lang=&edition=full","pubTime":"2021-12-15 15:14","market":"us","language":"en","title":"Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=1107549050","media":"Tiger Newspress","summary":"Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and c","content":"<p><b>Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation</b></p>\n<ul>\n <li>Positive booster data show that neutralizing antibodies increased across all primary vaccines received (mRNA or adenovirus) in a 9- to 43-fold range and for all age groups tested, with a good safety and tolerability profile</li>\n <li>Phase 3 trial continues to accrue number of events needed for analysis as populations around the world are increasingly exposed to COVID-19 variants; results expected in Q1, 2022</li>\n <li>Companies intend to file booster data with regulatory authorities following the Phase 3 results</li>\n</ul>\n<p>Sanofi and GSK announced today that a single booster dose of their recombinant adjuvanted COVID-19 vaccine candidate delivered consistently strong immune responses. Preliminary results from the VAT0002 clinical trial investigating the safety and immunogenicity of the booster showed neutralizing antibodies increased 9- to 43-fold regardless of the primary vaccine received (AstraZeneca, Johnson &amp; Johnson, Moderna, Pfizer/BioNTech) and for all age groups tested. The booster was well tolerated, with a safety profile similar to currently approved COVID-19 vaccines. This is the most comprehensive booster trial to date to explore boosting across different vaccine technologies used for primary vaccination.</p>\n<p>The ongoing global Phase 3 trial, VAT0008, includes regular reviews by an independent Data Safety Monitoring Board (DSMB). During its last review, the DSMB identified no safety concerns and recommended the trial to continue into early 2022 to accrue more data.</p>\n<p>Regulatory authorities require Phase 3 efficacy to be demonstrated in “naive” populations, i.e. participants who have never been infected by the COVID-19 virus (seronegative). The Phase 3 trial recruited most participants in Q3 2021, coinciding with a significant increase in the number of people infected by the COVID-19 virus globally due to the Delta variant. To provide the necessary data to regulatory authorities for the booster vaccine submission, the trial will continue to accrue the number of events needed for analysis, with results expected in Q1, 2022.</p>\n<p><i>“These preliminary data show we have a strong booster candidate, whatever primary vaccine you have received.”</i>said Thomas Triomphe, Executive Vice President, Sanofi Pasteur.<i>“This is consistent with our efforts to provide relevantresponses to evolving public health needs. While pursuing a phase 3 trial is a challenge in a quickly shifting pandemic environment, we look forward to seeing the results to support submissions of our booster vaccine as quickly as possible.”</i></p>\n<p>Roger Connor, President of GSK Vaccines, added<i>: “As the pandemic threat continues with the current dominant Delta variant and Omicron rapidly gaining ground, booster vaccines will continue to be needed to help protect people over time. The initial booster data are promising, and we await the phase III results to determine the next steps on making protein-based adjuvanted COVID-19 vaccines available.\"</i></p>\n<p>In parallel, Sanofi continues its contribution to global public health needs with the manufacturing of up to half a billion doses from BioNTech/Pfizer, Moderna, and Johnson &amp; Johnson vaccines.</p>\n<p><b>About the booster trial (VAT0002)</b></p>\n<p>The VAT0002 extension trial is the most comprehensive heterologous booster trial conducted to date. In the first cohort of this trial, the four most-widely approved COVID-19 primary vaccines using mRNA and adenovirus vector technologies were boosted with the Sanofi/GSK protein-based adjuvanted vaccine candidate after full primary vaccination to assess its safety profile and immunogenicity.</p>\n<p>Participants in the first cohort (n=521) had previously been vaccinated with the approved dosing schedule of an authorized COVID-19 mRNA vaccine (Moderna, Pfizer/BioNTech,) or adenovirus vector vaccine (AstraZeneca, Johnson &amp; Johnson,). This preliminary analysis includes data from trial participants who received one 5µg booster dose of the adjuvanted recombinant protein vaccine targeting the D614 parent virus, between four and ten months after a complete primary vaccination schedule.</p>\n<p>The trial is ongoing across sites in multiple countries, including the U.S., France, and the UK. To address the emergence of COVID-19 variants of concern, additional trial cohorts are assessing the boosting potential of monovalent and bivalent vaccine formulations also containing the Beta (B.1.351) variant. More data from this trial are expected during the first half of 2022. The Omicron variant was not circulating during the trial. Using sera from booster trial participants, testing is underway to establish the ability of the vaccine candidate to cross-neutralize against Omicron.</p>\n<p><b>About the Phase 3 efficacy trial (VAT0008)</b></p>\n<p>The primary endpoint of this ongoing Phase 3, randomized, double-blind, placebo-controlled trial is the prevention of symptomatic COVID-19 in SARS-CoV-2 naïve adults, with secondary endpoints of preventing severe COVID-19 disease and infection. Stage one of the trial is assessing the efficacy of a vaccine formulation containing the spike protein against the original D614 (parent) virus in more than 10,000 participants &gt;18 years of age, randomized to receive two doses of 10µg vaccine or placebo at day 1 and day 22 across sites in the US, Asia, Africa and Latin America. A second stage in the trial is evaluating a second bivalent formulation, adding the spike protein of the B.1.351 (Beta) variant.</p>\n<p>These efforts are supported by federal funds from the Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services in collaboration with the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense under Contract # W15QKN-16-9-1002.</p>\n<p><b>About the Sanofi and GSK collaboration</b></p>\n<p>In the collaboration between the two companies, Sanofi provides its recombinant antigen and GSK contributes its pandemic adjuvant, both established vaccine platforms that have proven successful against influenza.</p>\n<p><b>About GSK</b></p>\n<p>GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GSK is the leading manufacturer of vaccines globally.</p>\n<p><b>About Sanofi</b></p>\n<p>Sanofi is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. It prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. It stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.</p>\n<p>With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-15 15:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation</b></p>\n<ul>\n <li>Positive booster data show that neutralizing antibodies increased across all primary vaccines received (mRNA or adenovirus) in a 9- to 43-fold range and for all age groups tested, with a good safety and tolerability profile</li>\n <li>Phase 3 trial continues to accrue number of events needed for analysis as populations around the world are increasingly exposed to COVID-19 variants; results expected in Q1, 2022</li>\n <li>Companies intend to file booster data with regulatory authorities following the Phase 3 results</li>\n</ul>\n<p>Sanofi and GSK announced today that a single booster dose of their recombinant adjuvanted COVID-19 vaccine candidate delivered consistently strong immune responses. Preliminary results from the VAT0002 clinical trial investigating the safety and immunogenicity of the booster showed neutralizing antibodies increased 9- to 43-fold regardless of the primary vaccine received (AstraZeneca, Johnson &amp; Johnson, Moderna, Pfizer/BioNTech) and for all age groups tested. The booster was well tolerated, with a safety profile similar to currently approved COVID-19 vaccines. This is the most comprehensive booster trial to date to explore boosting across different vaccine technologies used for primary vaccination.</p>\n<p>The ongoing global Phase 3 trial, VAT0008, includes regular reviews by an independent Data Safety Monitoring Board (DSMB). During its last review, the DSMB identified no safety concerns and recommended the trial to continue into early 2022 to accrue more data.</p>\n<p>Regulatory authorities require Phase 3 efficacy to be demonstrated in “naive” populations, i.e. participants who have never been infected by the COVID-19 virus (seronegative). The Phase 3 trial recruited most participants in Q3 2021, coinciding with a significant increase in the number of people infected by the COVID-19 virus globally due to the Delta variant. To provide the necessary data to regulatory authorities for the booster vaccine submission, the trial will continue to accrue the number of events needed for analysis, with results expected in Q1, 2022.</p>\n<p><i>“These preliminary data show we have a strong booster candidate, whatever primary vaccine you have received.”</i>said Thomas Triomphe, Executive Vice President, Sanofi Pasteur.<i>“This is consistent with our efforts to provide relevantresponses to evolving public health needs. While pursuing a phase 3 trial is a challenge in a quickly shifting pandemic environment, we look forward to seeing the results to support submissions of our booster vaccine as quickly as possible.”</i></p>\n<p>Roger Connor, President of GSK Vaccines, added<i>: “As the pandemic threat continues with the current dominant Delta variant and Omicron rapidly gaining ground, booster vaccines will continue to be needed to help protect people over time. The initial booster data are promising, and we await the phase III results to determine the next steps on making protein-based adjuvanted COVID-19 vaccines available.\"</i></p>\n<p>In parallel, Sanofi continues its contribution to global public health needs with the manufacturing of up to half a billion doses from BioNTech/Pfizer, Moderna, and Johnson &amp; Johnson vaccines.</p>\n<p><b>About the booster trial (VAT0002)</b></p>\n<p>The VAT0002 extension trial is the most comprehensive heterologous booster trial conducted to date. In the first cohort of this trial, the four most-widely approved COVID-19 primary vaccines using mRNA and adenovirus vector technologies were boosted with the Sanofi/GSK protein-based adjuvanted vaccine candidate after full primary vaccination to assess its safety profile and immunogenicity.</p>\n<p>Participants in the first cohort (n=521) had previously been vaccinated with the approved dosing schedule of an authorized COVID-19 mRNA vaccine (Moderna, Pfizer/BioNTech,) or adenovirus vector vaccine (AstraZeneca, Johnson &amp; Johnson,). This preliminary analysis includes data from trial participants who received one 5µg booster dose of the adjuvanted recombinant protein vaccine targeting the D614 parent virus, between four and ten months after a complete primary vaccination schedule.</p>\n<p>The trial is ongoing across sites in multiple countries, including the U.S., France, and the UK. To address the emergence of COVID-19 variants of concern, additional trial cohorts are assessing the boosting potential of monovalent and bivalent vaccine formulations also containing the Beta (B.1.351) variant. More data from this trial are expected during the first half of 2022. The Omicron variant was not circulating during the trial. Using sera from booster trial participants, testing is underway to establish the ability of the vaccine candidate to cross-neutralize against Omicron.</p>\n<p><b>About the Phase 3 efficacy trial (VAT0008)</b></p>\n<p>The primary endpoint of this ongoing Phase 3, randomized, double-blind, placebo-controlled trial is the prevention of symptomatic COVID-19 in SARS-CoV-2 naïve adults, with secondary endpoints of preventing severe COVID-19 disease and infection. Stage one of the trial is assessing the efficacy of a vaccine formulation containing the spike protein against the original D614 (parent) virus in more than 10,000 participants &gt;18 years of age, randomized to receive two doses of 10µg vaccine or placebo at day 1 and day 22 across sites in the US, Asia, Africa and Latin America. A second stage in the trial is evaluating a second bivalent formulation, adding the spike protein of the B.1.351 (Beta) variant.</p>\n<p>These efforts are supported by federal funds from the Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services in collaboration with the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense under Contract # W15QKN-16-9-1002.</p>\n<p><b>About the Sanofi and GSK collaboration</b></p>\n<p>In the collaboration between the two companies, Sanofi provides its recombinant antigen and GSK contributes its pandemic adjuvant, both established vaccine platforms that have proven successful against influenza.</p>\n<p><b>About GSK</b></p>\n<p>GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GSK is the leading manufacturer of vaccines globally.</p>\n<p><b>About Sanofi</b></p>\n<p>Sanofi is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. It prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. It stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.</p>\n<p>With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNY":"赛诺菲安万特","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107549050","content_text":"Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation\n\nPositive booster data show that neutralizing antibodies increased across all primary vaccines received (mRNA or adenovirus) in a 9- to 43-fold range and for all age groups tested, with a good safety and tolerability profile\nPhase 3 trial continues to accrue number of events needed for analysis as populations around the world are increasingly exposed to COVID-19 variants; results expected in Q1, 2022\nCompanies intend to file booster data with regulatory authorities following the Phase 3 results\n\nSanofi and GSK announced today that a single booster dose of their recombinant adjuvanted COVID-19 vaccine candidate delivered consistently strong immune responses. Preliminary results from the VAT0002 clinical trial investigating the safety and immunogenicity of the booster showed neutralizing antibodies increased 9- to 43-fold regardless of the primary vaccine received (AstraZeneca, Johnson & Johnson, Moderna, Pfizer/BioNTech) and for all age groups tested. The booster was well tolerated, with a safety profile similar to currently approved COVID-19 vaccines. This is the most comprehensive booster trial to date to explore boosting across different vaccine technologies used for primary vaccination.\nThe ongoing global Phase 3 trial, VAT0008, includes regular reviews by an independent Data Safety Monitoring Board (DSMB). During its last review, the DSMB identified no safety concerns and recommended the trial to continue into early 2022 to accrue more data.\nRegulatory authorities require Phase 3 efficacy to be demonstrated in “naive” populations, i.e. participants who have never been infected by the COVID-19 virus (seronegative). The Phase 3 trial recruited most participants in Q3 2021, coinciding with a significant increase in the number of people infected by the COVID-19 virus globally due to the Delta variant. To provide the necessary data to regulatory authorities for the booster vaccine submission, the trial will continue to accrue the number of events needed for analysis, with results expected in Q1, 2022.\n“These preliminary data show we have a strong booster candidate, whatever primary vaccine you have received.”said Thomas Triomphe, Executive Vice President, Sanofi Pasteur.“This is consistent with our efforts to provide relevantresponses to evolving public health needs. While pursuing a phase 3 trial is a challenge in a quickly shifting pandemic environment, we look forward to seeing the results to support submissions of our booster vaccine as quickly as possible.”\nRoger Connor, President of GSK Vaccines, added: “As the pandemic threat continues with the current dominant Delta variant and Omicron rapidly gaining ground, booster vaccines will continue to be needed to help protect people over time. The initial booster data are promising, and we await the phase III results to determine the next steps on making protein-based adjuvanted COVID-19 vaccines available.\"\nIn parallel, Sanofi continues its contribution to global public health needs with the manufacturing of up to half a billion doses from BioNTech/Pfizer, Moderna, and Johnson & Johnson vaccines.\nAbout the booster trial (VAT0002)\nThe VAT0002 extension trial is the most comprehensive heterologous booster trial conducted to date. In the first cohort of this trial, the four most-widely approved COVID-19 primary vaccines using mRNA and adenovirus vector technologies were boosted with the Sanofi/GSK protein-based adjuvanted vaccine candidate after full primary vaccination to assess its safety profile and immunogenicity.\nParticipants in the first cohort (n=521) had previously been vaccinated with the approved dosing schedule of an authorized COVID-19 mRNA vaccine (Moderna, Pfizer/BioNTech,) or adenovirus vector vaccine (AstraZeneca, Johnson & Johnson,). This preliminary analysis includes data from trial participants who received one 5µg booster dose of the adjuvanted recombinant protein vaccine targeting the D614 parent virus, between four and ten months after a complete primary vaccination schedule.\nThe trial is ongoing across sites in multiple countries, including the U.S., France, and the UK. To address the emergence of COVID-19 variants of concern, additional trial cohorts are assessing the boosting potential of monovalent and bivalent vaccine formulations also containing the Beta (B.1.351) variant. More data from this trial are expected during the first half of 2022. The Omicron variant was not circulating during the trial. Using sera from booster trial participants, testing is underway to establish the ability of the vaccine candidate to cross-neutralize against Omicron.\nAbout the Phase 3 efficacy trial (VAT0008)\nThe primary endpoint of this ongoing Phase 3, randomized, double-blind, placebo-controlled trial is the prevention of symptomatic COVID-19 in SARS-CoV-2 naïve adults, with secondary endpoints of preventing severe COVID-19 disease and infection. Stage one of the trial is assessing the efficacy of a vaccine formulation containing the spike protein against the original D614 (parent) virus in more than 10,000 participants >18 years of age, randomized to receive two doses of 10µg vaccine or placebo at day 1 and day 22 across sites in the US, Asia, Africa and Latin America. A second stage in the trial is evaluating a second bivalent formulation, adding the spike protein of the B.1.351 (Beta) variant.\nThese efforts are supported by federal funds from the Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services in collaboration with the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense under Contract # W15QKN-16-9-1002.\nAbout the Sanofi and GSK collaboration\nIn the collaboration between the two companies, Sanofi provides its recombinant antigen and GSK contributes its pandemic adjuvant, both established vaccine platforms that have proven successful against influenza.\nAbout GSK\nGSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GSK is the leading manufacturer of vaccines globally.\nAbout Sanofi\nSanofi is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. It prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. It stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.\nWith more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.","news_type":1},"isVote":1,"tweetType":1,"viewCount":371,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600940569,"gmtCreate":1638060114771,"gmtModify":1638060114882,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/600940569","repostId":"2186340224","repostType":4,"repost":{"id":"2186340224","pubTimestamp":1638059445,"share":"https://www.laohu8.com/m/news/2186340224?lang=&edition=full","pubTime":"2021-11-28 08:30","market":"us","language":"en","title":"Got $5,000? These 2 Stocks Could Be Bargain Buys in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2186340224","media":"Motley Fool","summary":"Both of these businesses could be in much better shape a year from now.","content":"<p>Investing in stocks that are falling can be tough to do; nobody wants to look at their portfolio and see red. But if you're investing for the long haul, you know that short-term trends could subside, and this year's sell-off stock could be next year's top performer.</p>\n<p>That's exactly what I think of with&nbsp;<a href=\"https://laohu8.com/S/AZN\"><b>AstraZeneca&nbsp;</b></a> and&nbsp;<a href=\"https://laohu8.com/S/BYND\"><b>Beyond Meat&nbsp;</b></a>. Both of these stocks have been falling recently, but heading into next year, things could look a lot better. If you can afford to invest $5,000 into these stocks, here's why you should consider doing so.</p>\n<h4><b>1. AstraZeneca</b></h4>\n<p>Shares of COVID-19 vaccine-maker AstraZeneca are down 5% over the past three months, while the <b>S&amp;P 500</b> has soared by more than 5%. The company released its third-quarter results on Nov. 12, which disappointed investors as it fell short of earnings expectations. The stock sank more than 6% on the day.</p>\n<p>But next year, things could look much different. Up until now, AstraZeneca hasn't been trying to make a profit from its COVID-19 vaccine. But now that the pandemic is turning into more of an endemic, the company is going to focus on turning a profit on the vaccine on any new orders.</p>\n<p>That means an increase in price. The company has been selling its vaccine for just a few dollars per dose, well below what other COVID-19 vaccine makers are charging countries.</p>\n<p>For the period ending Sept. 30, the company's COVID-19 vaccine generated over $1 billion in revenue. Meanwhile, rival vaccine-maker <b>Moderna</b> reported $4.8 billion in product sales for the same period, and <b>Pfizer</b>'s COVID-19 vaccine generated $13 billion in revenue, also during the same interval.</p>\n<p>While it's unclear just how much higher AstraZeneca's COVID-19-related revenue may climb on an increase in the vaccine's price, its top line is likely to get a boost next year nonetheless. Plus, it completed the acquisition of healthcare-company Alexion Pharmaceuticals in July, which has already started contributing to AstraZeneca's financials this past quarter to the tune of $1.3 billion in new revenue. Alexion's focus on rare diseases expands AstraZeneca's product mix and can set it up for some great gains over the long term.</p>\n<p>Although AstraZeneca incurred a net loss of $1.7 billion this past quarter, that's largely due to the acquisition of Alexion, as its operations are typically profitable. (In each of the previous four quarters, AstraZeneca has reported a profit margin of at least 6%.)</p>\n<p>As it integrates Alexion into its business and eliminates inefficiencies and redundancies, the company's financials will improve. That, combined with the additional revenue from the new business plus an increase in COVID-19 sales, could set the stock up for a terrific performance in 2022.</p>\n<h4><b>2. Beyond Meat</b></h4>\n<p>Beyond Meat's stock has been falling fast as it's down 36% in just three months. What was looking like it might be a promising year for the company amid reopenings has stalled due to the delta variant causing a spike in COVID-19 cases.</p>\n<p>The company had a bad earnings report and the stock has become a better buy in November. Although sales of $106.4 million for the period ending Oct. 2 rose 13% year over year, the company disappointed investors with a net loss of $54.8 million that was more than double the $19.3 million loss it reported in the same period in 2020. Beyond Meat doesn't project a picture of getting much better in the final quarter of the year, as it expects net revenue to fall within a range of just $85 million to $110 million.</p>\n<p>There's no shortage of bearishness surrounding Beyond Meat right now. But heading into next year, a lot can change. What's important is that the company has some great growth opportunities in place.</p>\n<p>Beyond's sales were up 13% this past quarter, but that was driven primarily by growth in the international markets, where revenue more than doubled to $38.9 million. In the U.S. market, sales of $67.5 million declined by 14%.</p>\n<p>However, if supply-chain issues resolve next year and COVID-19 case numbers come down as people receive booster shots, there's reason to believe that the U.S. numbers could strengthen with a return to normalcy in the economy. And fast-food restaurant <b>McDonald's</b> recently launched its McPlant burger (which features a Beyond Meat patty) in multiple U.S. cities. If successful, that could also lead to some improved financials for Beyond in 2022.</p>\n<p>Although the growth stock is beaten up today, a year from now, today's price could look like a bargain.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $5,000? These 2 Stocks Could Be Bargain Buys in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $5,000? These 2 Stocks Could Be Bargain Buys in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-28 08:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/27/these-2-stocks-could-be-bargain-buys-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in stocks that are falling can be tough to do; nobody wants to look at their portfolio and see red. But if you're investing for the long haul, you know that short-term trends could subside, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/27/these-2-stocks-could-be-bargain-buys-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","AZN":"阿斯利康"},"source_url":"https://www.fool.com/investing/2021/11/27/these-2-stocks-could-be-bargain-buys-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186340224","content_text":"Investing in stocks that are falling can be tough to do; nobody wants to look at their portfolio and see red. But if you're investing for the long haul, you know that short-term trends could subside, and this year's sell-off stock could be next year's top performer.\nThat's exactly what I think of with AstraZeneca  and Beyond Meat . Both of these stocks have been falling recently, but heading into next year, things could look a lot better. If you can afford to invest $5,000 into these stocks, here's why you should consider doing so.\n1. AstraZeneca\nShares of COVID-19 vaccine-maker AstraZeneca are down 5% over the past three months, while the S&P 500 has soared by more than 5%. The company released its third-quarter results on Nov. 12, which disappointed investors as it fell short of earnings expectations. The stock sank more than 6% on the day.\nBut next year, things could look much different. Up until now, AstraZeneca hasn't been trying to make a profit from its COVID-19 vaccine. But now that the pandemic is turning into more of an endemic, the company is going to focus on turning a profit on the vaccine on any new orders.\nThat means an increase in price. The company has been selling its vaccine for just a few dollars per dose, well below what other COVID-19 vaccine makers are charging countries.\nFor the period ending Sept. 30, the company's COVID-19 vaccine generated over $1 billion in revenue. Meanwhile, rival vaccine-maker Moderna reported $4.8 billion in product sales for the same period, and Pfizer's COVID-19 vaccine generated $13 billion in revenue, also during the same interval.\nWhile it's unclear just how much higher AstraZeneca's COVID-19-related revenue may climb on an increase in the vaccine's price, its top line is likely to get a boost next year nonetheless. Plus, it completed the acquisition of healthcare-company Alexion Pharmaceuticals in July, which has already started contributing to AstraZeneca's financials this past quarter to the tune of $1.3 billion in new revenue. Alexion's focus on rare diseases expands AstraZeneca's product mix and can set it up for some great gains over the long term.\nAlthough AstraZeneca incurred a net loss of $1.7 billion this past quarter, that's largely due to the acquisition of Alexion, as its operations are typically profitable. (In each of the previous four quarters, AstraZeneca has reported a profit margin of at least 6%.)\nAs it integrates Alexion into its business and eliminates inefficiencies and redundancies, the company's financials will improve. That, combined with the additional revenue from the new business plus an increase in COVID-19 sales, could set the stock up for a terrific performance in 2022.\n2. Beyond Meat\nBeyond Meat's stock has been falling fast as it's down 36% in just three months. What was looking like it might be a promising year for the company amid reopenings has stalled due to the delta variant causing a spike in COVID-19 cases.\nThe company had a bad earnings report and the stock has become a better buy in November. Although sales of $106.4 million for the period ending Oct. 2 rose 13% year over year, the company disappointed investors with a net loss of $54.8 million that was more than double the $19.3 million loss it reported in the same period in 2020. Beyond Meat doesn't project a picture of getting much better in the final quarter of the year, as it expects net revenue to fall within a range of just $85 million to $110 million.\nThere's no shortage of bearishness surrounding Beyond Meat right now. But heading into next year, a lot can change. What's important is that the company has some great growth opportunities in place.\nBeyond's sales were up 13% this past quarter, but that was driven primarily by growth in the international markets, where revenue more than doubled to $38.9 million. In the U.S. market, sales of $67.5 million declined by 14%.\nHowever, if supply-chain issues resolve next year and COVID-19 case numbers come down as people receive booster shots, there's reason to believe that the U.S. numbers could strengthen with a return to normalcy in the economy. And fast-food restaurant McDonald's recently launched its McPlant burger (which features a Beyond Meat patty) in multiple U.S. cities. If successful, that could also lead to some improved financials for Beyond in 2022.\nAlthough the growth stock is beaten up today, a year from now, today's price could look like a bargain.","news_type":1},"isVote":1,"tweetType":1,"viewCount":119,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875895445,"gmtCreate":1637630370938,"gmtModify":1637630371080,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875895445","repostId":"2185306806","repostType":4,"repost":{"id":"2185306806","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1637620044,"share":"https://www.laohu8.com/m/news/2185306806?lang=&edition=full","pubTime":"2021-11-23 06:27","market":"us","language":"en","title":"Nasdaq and S&P 500 end down after hitting record highs","url":"https://stock-news.laohu8.com/highlight/detail?id=2185306806","media":"Reuters","summary":"* Apple hits record high, JPM sees iPhone supply improving. Nov 22  - The S&P 500 ended lower and the Nasdaq tumbled deep into negative territory on Monday after both earlier hit record highs following the announcement of a second term for Federal Reserve Chair Jerome Powell.The Dow Jones Industrial Average ended slightly higher.Climbing Treasury yields kept tech stocks broadly lower, with holdouts including Microsoft and Apple, which many investors view as relatively safe, giving up gains late ","content":"<p>* Financials rally on rate hike expectations</p>\n<p>* Higher Treasury yields pressure tech stocks</p>\n<p>* Apple hits record high, JPM sees iPhone supply improving</p>\n<p>Nov 22 (Reuters) - The S&amp;P 500 ended lower and the Nasdaq tumbled deep into negative territory on Monday after both earlier hit record highs following the announcement of a second term for Federal Reserve Chair Jerome Powell.</p>\n<p>The Dow Jones Industrial Average ended slightly higher.</p>\n<p>Climbing Treasury yields kept tech stocks broadly lower, with holdouts including Microsoft and Apple, which many investors view as relatively safe, giving up gains late in the session.</p>\n<p>Apple ended up 0.3%, its highest closing level ever, after rising over 3% earlier in the day. JPMorgan flagged possible improvements to the supply of the iPhone 13 in coming months.</p>\n<p>Microsoft ended down almost 1% after earlier rising almost 2%.</p>\n<p>\"The market is nervous. We know we have Powell, but that doesn't help with the inflation issue,\" said Dennis Dick, a trader at Bright Trading LLC. \"Under the hood, growth tech got hit all day, and then all of tech got hit at the end.\"</p>\n<p>Powell's nomination was welcomed by many investors hoping for no big changes in the Fed as it guides the economy through a recovery from the pandemic. The central bank is set to herald a return to pre-pandemic policy by end-2022.</p>\n<p>Fed Governor Lael Brainard, who was the other top candidate for the job, will be vice chair, the White House said.</p>\n<p>\"Markets like predictability. ... While Brainard may have been a fine choice, the markets would not know what to expect from her even though the general consensus was that it meant lower rates for longer,\" said Randy Frederick, managing director of trading and derivatives at Charles Schwab in Austin, Texas.</p>\n<p>The S&amp;P 500 banks index rallied 2%, tracking a surge in Treasury yields as investors priced in policy tightening by the first half of 2022. Wells Fargo &amp; Co rose over 3% and was among the strongest major Wall Street banks.</p>\n<p>Futures contracts tied to the Fed's policy rate indicated that money markets are now expecting the U.S. central bank to raise interest rates by 25 basis points by next June versus a previous estimate of July.</p>\n<p>The Dow Jones Industrial Average rose 0.05% to end at 35,619.25 points, while the S&amp;P 500 lost 0.32% to 4,682.94.</p>\n<p>The Nasdaq Composite dropped 1.26% to 15,854.76.</p>\n<p>The S&amp;P 500 value index climbed 0.6%, strongly outperforming the S&amp;P 500 growth index's 1% dip.</p>\n<p>In extended trade, <a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications fell 3% after the video-conferencing company posted quarterly revenue that beat expectations.</p>\n<p>Investors were awaiting a slew of economic data this week, including IHS business activity readings, personal consumption expenditure, and minutes of the Fed's latest meeting.</p>\n<p>In Monday's session, Amazon fell 2.8% and Alphabet declined 1.8%, both weighing heavily on the Nasdaq.</p>\n<p>Tesla Inc gained 1.7% after CEO Elon Musk tweeted that the Model S Plaid will \"probably\" be coming to China around March. The stock has almost recovered from a steep selloff earlier this month that started after Musk polled <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> users about whether he should sell some of his shares in the electric car maker.</p>\n<p>Activision Blizzard slipped 0.3% after a media report that the video game publisher's chief executive, Bobby Kotick, would consider leaving if he could not quickly address concerns about company culture.</p>\n<p>The S&amp;P 500 has now gained about 25% in 2021, while the Nasdaq is up 23%.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.28-to-1 ratio; on Nasdaq, a 1.76-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 52 new 52-week highs and 11 new lows; the Nasdaq Composite recorded 138 new highs and 507 new lows.</p>\n<p>Volume on U.S. exchanges was 11.6 billion shares, compared with the 11.1 billion average for the full session over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq and S&P 500 end down after hitting record highs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq and S&P 500 end down after hitting record highs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-11-23 06:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Financials rally on rate hike expectations</p>\n<p>* Higher Treasury yields pressure tech stocks</p>\n<p>* Apple hits record high, JPM sees iPhone supply improving</p>\n<p>Nov 22 (Reuters) - The S&amp;P 500 ended lower and the Nasdaq tumbled deep into negative territory on Monday after both earlier hit record highs following the announcement of a second term for Federal Reserve Chair Jerome Powell.</p>\n<p>The Dow Jones Industrial Average ended slightly higher.</p>\n<p>Climbing Treasury yields kept tech stocks broadly lower, with holdouts including Microsoft and Apple, which many investors view as relatively safe, giving up gains late in the session.</p>\n<p>Apple ended up 0.3%, its highest closing level ever, after rising over 3% earlier in the day. JPMorgan flagged possible improvements to the supply of the iPhone 13 in coming months.</p>\n<p>Microsoft ended down almost 1% after earlier rising almost 2%.</p>\n<p>\"The market is nervous. We know we have Powell, but that doesn't help with the inflation issue,\" said Dennis Dick, a trader at Bright Trading LLC. \"Under the hood, growth tech got hit all day, and then all of tech got hit at the end.\"</p>\n<p>Powell's nomination was welcomed by many investors hoping for no big changes in the Fed as it guides the economy through a recovery from the pandemic. The central bank is set to herald a return to pre-pandemic policy by end-2022.</p>\n<p>Fed Governor Lael Brainard, who was the other top candidate for the job, will be vice chair, the White House said.</p>\n<p>\"Markets like predictability. ... While Brainard may have been a fine choice, the markets would not know what to expect from her even though the general consensus was that it meant lower rates for longer,\" said Randy Frederick, managing director of trading and derivatives at Charles Schwab in Austin, Texas.</p>\n<p>The S&amp;P 500 banks index rallied 2%, tracking a surge in Treasury yields as investors priced in policy tightening by the first half of 2022. Wells Fargo &amp; Co rose over 3% and was among the strongest major Wall Street banks.</p>\n<p>Futures contracts tied to the Fed's policy rate indicated that money markets are now expecting the U.S. central bank to raise interest rates by 25 basis points by next June versus a previous estimate of July.</p>\n<p>The Dow Jones Industrial Average rose 0.05% to end at 35,619.25 points, while the S&amp;P 500 lost 0.32% to 4,682.94.</p>\n<p>The Nasdaq Composite dropped 1.26% to 15,854.76.</p>\n<p>The S&amp;P 500 value index climbed 0.6%, strongly outperforming the S&amp;P 500 growth index's 1% dip.</p>\n<p>In extended trade, <a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications fell 3% after the video-conferencing company posted quarterly revenue that beat expectations.</p>\n<p>Investors were awaiting a slew of economic data this week, including IHS business activity readings, personal consumption expenditure, and minutes of the Fed's latest meeting.</p>\n<p>In Monday's session, Amazon fell 2.8% and Alphabet declined 1.8%, both weighing heavily on the Nasdaq.</p>\n<p>Tesla Inc gained 1.7% after CEO Elon Musk tweeted that the Model S Plaid will \"probably\" be coming to China around March. The stock has almost recovered from a steep selloff earlier this month that started after Musk polled <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> users about whether he should sell some of his shares in the electric car maker.</p>\n<p>Activision Blizzard slipped 0.3% after a media report that the video game publisher's chief executive, Bobby Kotick, would consider leaving if he could not quickly address concerns about company culture.</p>\n<p>The S&amp;P 500 has now gained about 25% in 2021, while the Nasdaq is up 23%.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.28-to-1 ratio; on Nasdaq, a 1.76-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 52 new 52-week highs and 11 new lows; the Nasdaq Composite recorded 138 new highs and 507 new lows.</p>\n<p>Volume on U.S. exchanges was 11.6 billion shares, compared with the 11.1 billion average for the full session over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","OEF":"标普100指数ETF-iShares","SDS":"两倍做空标普500ETF","UPRO":"三倍做多标普500ETF",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","IVV":"标普500指数ETF","BK4534":"瑞士信贷持仓",".DJI":"道琼斯","SH":"标普500反向ETF","SSO":"两倍做多标普500ETF","BK4559":"巴菲特持仓","SPXU":"三倍做空标普500ETF","AAPL":"苹果","BK4550":"红杉资本持仓","MSFT":"微软","SPY":"标普500ETF","ZM":"Zoom","BK4504":"桥水持仓","OEX":"标普100","COMP":"Compass, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185306806","content_text":"* Financials rally on rate hike expectations\n* Higher Treasury yields pressure tech stocks\n* Apple hits record high, JPM sees iPhone supply improving\nNov 22 (Reuters) - The S&P 500 ended lower and the Nasdaq tumbled deep into negative territory on Monday after both earlier hit record highs following the announcement of a second term for Federal Reserve Chair Jerome Powell.\nThe Dow Jones Industrial Average ended slightly higher.\nClimbing Treasury yields kept tech stocks broadly lower, with holdouts including Microsoft and Apple, which many investors view as relatively safe, giving up gains late in the session.\nApple ended up 0.3%, its highest closing level ever, after rising over 3% earlier in the day. JPMorgan flagged possible improvements to the supply of the iPhone 13 in coming months.\nMicrosoft ended down almost 1% after earlier rising almost 2%.\n\"The market is nervous. We know we have Powell, but that doesn't help with the inflation issue,\" said Dennis Dick, a trader at Bright Trading LLC. \"Under the hood, growth tech got hit all day, and then all of tech got hit at the end.\"\nPowell's nomination was welcomed by many investors hoping for no big changes in the Fed as it guides the economy through a recovery from the pandemic. The central bank is set to herald a return to pre-pandemic policy by end-2022.\nFed Governor Lael Brainard, who was the other top candidate for the job, will be vice chair, the White House said.\n\"Markets like predictability. ... While Brainard may have been a fine choice, the markets would not know what to expect from her even though the general consensus was that it meant lower rates for longer,\" said Randy Frederick, managing director of trading and derivatives at Charles Schwab in Austin, Texas.\nThe S&P 500 banks index rallied 2%, tracking a surge in Treasury yields as investors priced in policy tightening by the first half of 2022. Wells Fargo & Co rose over 3% and was among the strongest major Wall Street banks.\nFutures contracts tied to the Fed's policy rate indicated that money markets are now expecting the U.S. central bank to raise interest rates by 25 basis points by next June versus a previous estimate of July.\nThe Dow Jones Industrial Average rose 0.05% to end at 35,619.25 points, while the S&P 500 lost 0.32% to 4,682.94.\nThe Nasdaq Composite dropped 1.26% to 15,854.76.\nThe S&P 500 value index climbed 0.6%, strongly outperforming the S&P 500 growth index's 1% dip.\nIn extended trade, Zoom Video Communications fell 3% after the video-conferencing company posted quarterly revenue that beat expectations.\nInvestors were awaiting a slew of economic data this week, including IHS business activity readings, personal consumption expenditure, and minutes of the Fed's latest meeting.\nIn Monday's session, Amazon fell 2.8% and Alphabet declined 1.8%, both weighing heavily on the Nasdaq.\nTesla Inc gained 1.7% after CEO Elon Musk tweeted that the Model S Plaid will \"probably\" be coming to China around March. The stock has almost recovered from a steep selloff earlier this month that started after Musk polled Twitter users about whether he should sell some of his shares in the electric car maker.\nActivision Blizzard slipped 0.3% after a media report that the video game publisher's chief executive, Bobby Kotick, would consider leaving if he could not quickly address concerns about company culture.\nThe S&P 500 has now gained about 25% in 2021, while the Nasdaq is up 23%.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.28-to-1 ratio; on Nasdaq, a 1.76-to-1 ratio favored decliners.\nThe S&P 500 posted 52 new 52-week highs and 11 new lows; the Nasdaq Composite recorded 138 new highs and 507 new lows.\nVolume on U.S. exchanges was 11.6 billion shares, compared with the 11.1 billion average for the full session over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":117,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":834985817,"gmtCreate":1629767098239,"gmtModify":1631890281300,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/834985817","repostId":"2161777891","repostType":4,"repost":{"id":"2161777891","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1629750559,"share":"https://www.laohu8.com/m/news/2161777891?lang=&edition=full","pubTime":"2021-08-24 04:29","market":"us","language":"en","title":"Wall St gains, Nasdaq notches record closing high on full vaccine approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2161777891","media":"Reuters","summary":"NEW YORK, Aug 23 (Reuters) - Wall Street rallied on Monday, and the Nasdaq reached an all-time closi","content":"<p>NEW YORK, Aug 23 (Reuters) - Wall Street rallied on Monday, and the Nasdaq reached an all-time closing high as sentiment was boosted by full FDA approval of a COVID-19 vaccine and market participants looked ahead to the Jackson Hole Symposium expected to convene later this week.</p>\n<p>All three major U.S. stock indexes ended the session sharply higher, with the S&amp;P 500 in the session's final minutes just failing to hold what would have been a record-high close.</p>\n<p>Surging crude prices, driven by expected demand growth, putting energy shares&nbsp;out front.</p>\n<p>\"This has been the script all along,\" said Peter Cardillo, chief market economist at Spartan Capital Securities in New York. \"We make new highs, pull back, and then we’re off to the races again.\"</p>\n<p>\"That tells me the fundamentals are in place,\" Cardillo added. \"There’s worries out there, but it’s hard to keep this market down.\"</p>\n<p>The U.S. Food and Drug Administration (FDA) granted full approval to the COVID-19 vaccine developed by Pfizer Inc&nbsp;and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;in a move that could accelerate inoculations in the United States.</p>\n<p>\"Full approval means that there’s most likely going to be more mandates, more companies will mandate that you have to get the vaccine in order to get back to the office,\" Cardillo said. \"I don’t think this will get all the doubters vaccinated but this news today will probably drive (the vaccinated rate) closer to 75%.\"</p>\n<p>Pfizer and U.S.-listed shares of BioNTech advanced 2.5% and 9.6%, respectively.</p>\n<p>Rival Moderna Inc&nbsp;gained 7.5%.</p>\n<p>Spiking COVID-19 infections caused by the highly contagious Delta variant have fueled concerns over a protracted recovery from the global health crisis.</p>\n<p>For an interactive graphic on worldwide vaccine deployment and access, click here</p>\n<p>Data released on Monday painted a \"Goldilocks\" portrait of an economic recovery headed in the right direction, but not enough to warrant a change in the Federal Reserve's dovish monetary policy, which helped feed investor risk appetite.</p>\n<p>Market participants look to the Jackson Hole Symposium, due to convene in Wyoming later this week. The comments of Fed Chairman Jerome Powell will be closely parsed for clues regarding the central bank's policy-tightening timeline.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 215.63 points, or 0.61%, to 35,335.71, the S&amp;P 500&nbsp;gained 37.86 points, or 0.85%, to 4,479.53 and the Nasdaq Composite&nbsp;added 227.99 points, or 1.55%, to 14,942.65.</p>\n<p>Of the 11 major sectors in the S&amp;P 500, seven ended the session green, with energy enjoying its best day in nearly two months.</p>\n<p>Exxon Mobil Corp&nbsp;and Chevron Corp&nbsp;gained 4.1% and 2.6%, respectively.</p>\n<p>U.S.-listed shares of Trillium Therapeutics Inc&nbsp;soared 188.8% after Pfizer agreed to buy the cancer drug developer in a $2.26 billion deal.</p>\n<p>General Motors Co fell 1.3% following its announcement that it would take a $1 billion hit to expand the recall of its Chevrolet Bolt electric vehicles.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.46-to-1 ratio; on Nasdaq, a 2.81-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 57 new 52-week highs and 1 new low; the Nasdaq Composite recorded 108 new highs and 54 new lows.</p>\n<p>Volume on U.S. exchanges was 8.63 billion shares, compared with the 9.15 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St gains, Nasdaq notches record closing high on full vaccine approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St gains, Nasdaq notches record closing high on full vaccine approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-24 04:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, Aug 23 (Reuters) - Wall Street rallied on Monday, and the Nasdaq reached an all-time closing high as sentiment was boosted by full FDA approval of a COVID-19 vaccine and market participants looked ahead to the Jackson Hole Symposium expected to convene later this week.</p>\n<p>All three major U.S. stock indexes ended the session sharply higher, with the S&amp;P 500 in the session's final minutes just failing to hold what would have been a record-high close.</p>\n<p>Surging crude prices, driven by expected demand growth, putting energy shares&nbsp;out front.</p>\n<p>\"This has been the script all along,\" said Peter Cardillo, chief market economist at Spartan Capital Securities in New York. \"We make new highs, pull back, and then we’re off to the races again.\"</p>\n<p>\"That tells me the fundamentals are in place,\" Cardillo added. \"There’s worries out there, but it’s hard to keep this market down.\"</p>\n<p>The U.S. Food and Drug Administration (FDA) granted full approval to the COVID-19 vaccine developed by Pfizer Inc&nbsp;and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;in a move that could accelerate inoculations in the United States.</p>\n<p>\"Full approval means that there’s most likely going to be more mandates, more companies will mandate that you have to get the vaccine in order to get back to the office,\" Cardillo said. \"I don’t think this will get all the doubters vaccinated but this news today will probably drive (the vaccinated rate) closer to 75%.\"</p>\n<p>Pfizer and U.S.-listed shares of BioNTech advanced 2.5% and 9.6%, respectively.</p>\n<p>Rival Moderna Inc&nbsp;gained 7.5%.</p>\n<p>Spiking COVID-19 infections caused by the highly contagious Delta variant have fueled concerns over a protracted recovery from the global health crisis.</p>\n<p>For an interactive graphic on worldwide vaccine deployment and access, click here</p>\n<p>Data released on Monday painted a \"Goldilocks\" portrait of an economic recovery headed in the right direction, but not enough to warrant a change in the Federal Reserve's dovish monetary policy, which helped feed investor risk appetite.</p>\n<p>Market participants look to the Jackson Hole Symposium, due to convene in Wyoming later this week. The comments of Fed Chairman Jerome Powell will be closely parsed for clues regarding the central bank's policy-tightening timeline.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 215.63 points, or 0.61%, to 35,335.71, the S&amp;P 500&nbsp;gained 37.86 points, or 0.85%, to 4,479.53 and the Nasdaq Composite&nbsp;added 227.99 points, or 1.55%, to 14,942.65.</p>\n<p>Of the 11 major sectors in the S&amp;P 500, seven ended the session green, with energy enjoying its best day in nearly two months.</p>\n<p>Exxon Mobil Corp&nbsp;and Chevron Corp&nbsp;gained 4.1% and 2.6%, respectively.</p>\n<p>U.S.-listed shares of Trillium Therapeutics Inc&nbsp;soared 188.8% after Pfizer agreed to buy the cancer drug developer in a $2.26 billion deal.</p>\n<p>General Motors Co fell 1.3% following its announcement that it would take a $1 billion hit to expand the recall of its Chevrolet Bolt electric vehicles.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.46-to-1 ratio; on Nasdaq, a 2.81-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 57 new 52-week highs and 1 new low; the Nasdaq Composite recorded 108 new highs and 54 new lows.</p>\n<p>Volume on U.S. exchanges was 8.63 billion shares, compared with the 9.15 billion average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite","PFE":"辉瑞",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161777891","content_text":"NEW YORK, Aug 23 (Reuters) - Wall Street rallied on Monday, and the Nasdaq reached an all-time closing high as sentiment was boosted by full FDA approval of a COVID-19 vaccine and market participants looked ahead to the Jackson Hole Symposium expected to convene later this week.\nAll three major U.S. stock indexes ended the session sharply higher, with the S&P 500 in the session's final minutes just failing to hold what would have been a record-high close.\nSurging crude prices, driven by expected demand growth, putting energy shares out front.\n\"This has been the script all along,\" said Peter Cardillo, chief market economist at Spartan Capital Securities in New York. \"We make new highs, pull back, and then we’re off to the races again.\"\n\"That tells me the fundamentals are in place,\" Cardillo added. \"There’s worries out there, but it’s hard to keep this market down.\"\nThe U.S. Food and Drug Administration (FDA) granted full approval to the COVID-19 vaccine developed by Pfizer Inc and BioNTech SE in a move that could accelerate inoculations in the United States.\n\"Full approval means that there’s most likely going to be more mandates, more companies will mandate that you have to get the vaccine in order to get back to the office,\" Cardillo said. \"I don’t think this will get all the doubters vaccinated but this news today will probably drive (the vaccinated rate) closer to 75%.\"\nPfizer and U.S.-listed shares of BioNTech advanced 2.5% and 9.6%, respectively.\nRival Moderna Inc gained 7.5%.\nSpiking COVID-19 infections caused by the highly contagious Delta variant have fueled concerns over a protracted recovery from the global health crisis.\nFor an interactive graphic on worldwide vaccine deployment and access, click here\nData released on Monday painted a \"Goldilocks\" portrait of an economic recovery headed in the right direction, but not enough to warrant a change in the Federal Reserve's dovish monetary policy, which helped feed investor risk appetite.\nMarket participants look to the Jackson Hole Symposium, due to convene in Wyoming later this week. The comments of Fed Chairman Jerome Powell will be closely parsed for clues regarding the central bank's policy-tightening timeline.\nThe Dow Jones Industrial Average rose 215.63 points, or 0.61%, to 35,335.71, the S&P 500 gained 37.86 points, or 0.85%, to 4,479.53 and the Nasdaq Composite added 227.99 points, or 1.55%, to 14,942.65.\nOf the 11 major sectors in the S&P 500, seven ended the session green, with energy enjoying its best day in nearly two months.\nExxon Mobil Corp and Chevron Corp gained 4.1% and 2.6%, respectively.\nU.S.-listed shares of Trillium Therapeutics Inc soared 188.8% after Pfizer agreed to buy the cancer drug developer in a $2.26 billion deal.\nGeneral Motors Co fell 1.3% following its announcement that it would take a $1 billion hit to expand the recall of its Chevrolet Bolt electric vehicles.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.46-to-1 ratio; on Nasdaq, a 2.81-to-1 ratio favored advancers.\nThe S&P 500 posted 57 new 52-week highs and 1 new low; the Nasdaq Composite recorded 108 new highs and 54 new lows.\nVolume on U.S. exchanges was 8.63 billion shares, compared with the 9.15 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":573,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165863990,"gmtCreate":1624116772110,"gmtModify":1634010558583,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Pls comment and like thanks","listText":"Pls comment and like thanks","text":"Pls comment and like thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":2,"link":"https://laohu8.com/post/165863990","repostId":"1113942445","repostType":4,"isVote":1,"tweetType":1,"viewCount":61,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166518774,"gmtCreate":1624017129398,"gmtModify":1634024080160,"author":{"id":"3584399073835367","authorId":"3584399073835367","name":"fluttershy","avatar":"https://static.tigerbbs.com/6f46bdced4d22227b740f71de9a6295b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584399073835367","idStr":"3584399073835367"},"themes":[],"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":1,"link":"https://laohu8.com/post/166518774","repostId":"1133025835","repostType":4,"repost":{"id":"1133025835","pubTimestamp":1624015886,"share":"https://www.laohu8.com/m/news/1133025835?lang=&edition=full","pubTime":"2021-06-18 19:31","market":"us","language":"en","title":"Piper Sandler upgrades Biogen, says Alzheimer's drug demand will be strong despite controversy","url":"https://stock-news.laohu8.com/highlight/detail?id=1133025835","media":"cnbc","summary":"The demand outlook for Biogen’s new Alzheimer’s drug appears strong despite lingering concerns about","content":"<div>\n<p>The demand outlook for Biogen’s new Alzheimer’s drug appears strong despite lingering concerns about the new treatment, and that should push the company’s stock higher, according to Piper Sandler.\nThe...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/18/piper-sandler-upgrades-biogen-says-alzheimers-drug-demand-will-be-strong-despite-controversy.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Piper Sandler upgrades Biogen, says Alzheimer's drug demand will be strong despite controversy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPiper Sandler upgrades Biogen, says Alzheimer's drug demand will be strong despite controversy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 19:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/18/piper-sandler-upgrades-biogen-says-alzheimers-drug-demand-will-be-strong-despite-controversy.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The demand outlook for Biogen’s new Alzheimer’s drug appears strong despite lingering concerns about the new treatment, and that should push the company’s stock higher, according to Piper Sandler.\nThe...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/18/piper-sandler-upgrades-biogen-says-alzheimers-drug-demand-will-be-strong-despite-controversy.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.cnbc.com/2021/06/18/piper-sandler-upgrades-biogen-says-alzheimers-drug-demand-will-be-strong-despite-controversy.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1133025835","content_text":"The demand outlook for Biogen’s new Alzheimer’s drug appears strong despite lingering concerns about the new treatment, and that should push the company’s stock higher, according to Piper Sandler.\nThe Food and Drug Administration’s approval of Aduhelm has been controversial, with multiple members of an FDA advisory committeeresigning in protestover the decision. There are concerns about the effectiveness of the treatment.\nPiper Sandler analyst Christopher Raymond said in a note to clients on Friday that he shared some of those concerns but that Aduhelm would still be a winner for Biogen’s business. Raymond upgraded the stock to overweight from neutral.\n“Despite our misgivings regarding FDA’s handling of the Aduhelm approval, we find two new data points too positive to ignore, and thus believe the path of least resistance on this stock is decidedly higher,” the note said.\nThose positive data points include a survey that shows strong demand and expected uptake for the drug, despite concerns about its effectiveness, and an expectation that Medicare and Medicaid will not significantly limit the available patient base for reimbursement, Piper Sandler said.\n“Combining this with what we see as a low-probability but still completely free call option that Biogen wins on appeal with the Tecfidera IP case, we think the stock is likely to go higher in the near term,” the note said.\nThe firm hiked its price target to $450 from $384, representing upside of 17% from where the stock closed on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":72,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}